12th World Congress on Inflammation

2015 Boston

August 8 – 12, 2015
Boston, Massachusetts, USA

Seaport Hotel and World Trade Center

Program

inflammation2015.org

IAIS INTERNATIONAL ASSOCIATION of INFLAMMATION SOCIETIES

Inflammation Research Association

The IAIS and IRA gratefully acknowledge the following outstanding sponsors for their generous support of the 12th World Congress on Inflammation:

PLATINUM LEVEL

novo nordisk®

GOLD LEVEL

abbvie

Biogen

Celgene

CTI
Centers for Therapeutic Innovation
A Pfizer-supported collaboration

gsk do more feel better live longer

The IAIS and IRA gratefully acknowledge the following outstanding sponsors for their generous support of the 12th World Congress on Inflammation:

SILVER LEVEL

AMGEN®

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

ARRAY BIOPHARMA

MedImmune
A member of the AstraZeneca Group

european respiratory society every breath counts

Genentech
A Member of the Roche Group

Ora, Inc.

HOTEL KEY CARDS SPONSORSHIP

HistoTox Labs

DOWNLOAD THE WCI 2015 MOBILE APP

via iPhone/iPad and Android native apps or via Blackberry, Windows Phone, and your desktop through the mobile web.

To access the WCI 2015 mobile app online, visit ***http://ddut.ch/wci2015***

Visit Us @ Booth #757

Dosing Animals with Test Compounds?

We can help… Research Diets will add your compound to diets for safe, effective, non- invasive dosing.
Come talk to our Scientists at the exhibit.



Studying the Effect of High- Fat Diets in Lab Animals?

We can help… Research Diets formulates and produces custom purified diets for specific research purposes.
We have formulated dozens of high fat diets with varying types and levels of fat.
Come talk to our Scientists about a formula for you next study.

OpenSource DIETS®

Report ▶ Repeat ▶ Revise™

Custom open formula purified diets for lab animals



RESEARCH DIETS INC.™

www.ResearchDiets.com

New Brunswick, NJ USA 732.247.2390

What you get

- Current
- Clinical
- Definitive

Where you get it

THE JOURNAL

To subscribe: visit jrheum.org online or send in your completed coupon below

Rates for 2015 calendar year
USA/INTERNATIONAL

	Print + Online	Online Only
INDIVIDUALS:	$350 US	$285 US
INSTITUTIONAL:		
- Multisite#	On request	On request
- Multiuser (IP ranges)	$1025 US	$975 US
- Basic (up to 4 users)	$550 US	$500 US
TRAINEES+	$215 US	$150 US+
Airmail (ADD)	$100 US	

For terms of access visit jrheum.org
+Supervisor certification required below.

NAME OF SUPERVISOR: _____

SUPERVISOR SIGNATURE: _____

SUPERVISOR TELEPHONE: _____

Please enter my 2015 subscription to **The Journal of Rheumatology**

Name (please print) _____

Address _____

City _____ State/Province _____

Country _____ Zip/Postal Code _____

Contact E-mail _____

Amount Enclosed $ _____ Bill Me _____

Telephone Number _____ Fax Number _____

VISA/MasterCard Number _____ Expiration Date _____

Signature _____ CVV _____

Mail completed form to: The Journal of Rheumatology
365 Bloor Street East, Suite 901
Toronto, Ontario Canada M4W 3L4

Phone: (416) 967-5155
Fax: (416) 967-7556
E-mail: subscriptions@jrheum.com

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2015 will be charged an additional $5 per back issue. Back issues: 3 years including current year are available if in stock. Single copies are available at $30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January Issue. PRIVACY POLICY: For details of our privacy policy, visit our website at www.jrheum.org.

A new safety tool to allow removal of cryogenic racks from freezers without getting burned.

Available through Princeton Cryotech:
www.princetoncryotech.com/
1-800-232-2796
Whitehouse, NJ

Manufactured by:
Buckstone Technologies
Holland, PA
Cryohook@comcast.net
267-795-8731

Special Event: **Patient Perspectives**



Sunday 0800 – 0900
Patient Perspectives on Psoriatic Arthritis

Monday 0800 – 0900
Patient Perspectives:
Unmet Medical Need – Inflammatory Bowel Disease

Tuesday 0800 – 0900
Patient Perspectives:
Unmet Medical Need – Lupus

Career/ Networking Events

Monday 1230 – 1400
Smooth Transitions – Top 10 List: Things Scientists Ask about Moving Out of Academia
Boxed lunch will be served.
Pre-registration is required.

Monday 1830 – 2000
Not Networking 101 – Building Relationships for Success
Refreshments served.
Advance registration required.

Poster Tours

The WCI 2015 Organizing Committee has arranged six (6) poster tours to promote scientific interaction and networking activities during the evening poster sessions and mixers. For these tours, senior/established scientists will lead a group of investigators around to select posters promoting discussions on the significance of the work and prompting introductions, interaction and input from members of the tour group. The set of posters selected by the "tour guides" will have some unifying theme and will likely focus on elements of inflammation research not highlighted at the symposia. Take the opportunity to participate in this activity. It is a great way to meet fellow attendees with common interests. Poster tour sign-up sheets with information on the tour guides and topics will be posted in the Exhibit Hall. Space is limited so sign-up early.

Job Board

The WCI Job Board is available to help job seekers connect with prospective employers, and will be located just inside the entrance to the Exhibit Hall. Whether you are looking to see what's out there or ready to take your next step, stop by during the meeting to peruse the postings and find out more information…you might be inspired!

Welcome letter from Congress Co-Chairs

Welcome to the 12th World Congress on Inflammation! We invite you to participate in one of the most exciting scientific meetings in the field of inflammation research to be held over the next four days, August 8-12, 2015, at the Seaport Hotel and World Trade Center in Boston, MA.

This meeting is organized by the Inflammation Research Association (**www.inflammationresearch.org**) under the auspices of the International Association of Inflammation Societies (**www.inflammationsocieties.org**), a global organization that represents scientists from many national inflammation societies across the globe. The chief goal of the IAIS is to facilitate the organization of scientific training and meetings where scientists from diverse backgrounds report on and discuss the latest innovative topics in inflammation research, ranging from basic molecular and cellular research through translational medicine, to application and experiences with anti-inflammatory agents in the clinic.

In keeping with our Congress Theme ***"Harnessing Patterns of Inflammation in Pursuit of Novel Therapeutics,"*** our scientific sessions will encompass key inflammatory processes across multiple organ systems, featuring science from the gene to the clinic. Our international audience will include researchers from government, academic, clinical and industrial laboratories. Our goal is to bring a large group of scientists from different backgrounds together to hear and discuss the newest and most innovative science so as to develop better drugs for patients. There is a growing realization that the inflammatory response lies at the root of many pathologies across organ systems. This four-day international meeting will begin with an in-depth look at the unmet medical need in one of 3 selected diseases, IBD, OA or Lupus, all chosen because of the high degree of research being conducted currently in these areas. This will be accompanied by a patient presentation providing their personal insights to their disease and treatment journeys with recommendations for treatment improvements. This will set the tone for the rest of the day, progressing into Prominent Keynote lectures, morning and afternoon Major Symposia and Mini-symposia comprised of abstract submissions, covering the latest and most exciting scientific discoveries. In addition, there will be daily poster sessions with poster tours and a competition for best poster in a number of categories. Lunch and Learn sessions and highlighted presentations will all take place in the large, well-appointed Exhibit Hall. All coffee breaks and the late afternoon cocktail hour during the official Poster Viewing hours, will also be held in the Exhibit Hall to facilitate scientific interactions and networking.

Please join this exciting and pioneering Congress, and mingle with the world's finest and most innovative and committed Inflammation Researchers!
Sincerely,

Lisa Marshall and Arpita Maiti
Congress Co-Chairs

Welcome Letter from Congress President

Dear Colleagues,

On behalf of the organizing committee of WCI, it is a great pleasure to invite you to join us in Boston for the 12th World Congress on Inflammation, which will take place from August 8-12 2015.

In the 19th century, our forebears made the seminal observation that injury or infection elicited stereotypical "patterns" of responses from the affected organism. We now know that "inflammation," as we now call it, is not limited to host defense but is also fundamental to the pathogenesis of many cardiovascular, metabolic, neurodegenerative and other diseases. This has greatly increased the scope of our discipline and today, interest in the nature of the inflammatory process and its control, has never been keener.

To review the most exciting new findings in this field, we have invited top researchers from around the world to present and to discuss their latest data and ideas about inflammation, its pathology, pharmacology and resolution.

Having viewed the final program, I can only say that I am very excited by the quality of the science at this conference and I do hope that you will join us for what looks like being a most rewarding event.

With warmest wishes,

Rod Flower, Congress President

Welcome Letter from the IAIS President

Dear Colleagues,

It is with great pleasure I welcome you to the 12th World Congress on Inflammation, August 8th-12th, 2015. This Congress is organized by the Inflammation Research Association (IRA), under the auspices of the International Association of Inflammation Societies (IAIS). The key objective of the IAIS is to foster cooperation between national inflammation society members for the purpose of organizing high quality international scientific meetings and/or teaching courses, focusing on inflammation. We also encourage new investigators to participate in these Congresses, both in scientific competition and through networking opportunities. The World Congress initiated in Vienna in 1993 and continued most recently with Copenhagen 2007, Tokyo 2009, Paris 2011 and Natal 2013.

The World Congress on Inflammation comes to Boston providing you with an excellent opportunity to interact with academic, clinical and industrial colleagues and discuss numerous topics covering the theme "Harnessing Patterns of Inflammation in the Pursuit of Novel Therapeutics". Inflammation is now being more widely recognized as impacting on many more pathologies than was previously appreciated and in fact the top selling therapeutics overall are mostly anti-inflammatory agents. The current high costs and regulatory challenges of drug development demand innovative changes in the way we develop medicines. The patterns/pathways within the inflammatory response provide a common thread and need to be understood if we are to develop novel therapeutics for many conditions with unmet medical need. The excellent scientific program with its breadth from basic science through to clinical research will contribute to this understanding.

We look forward to your active and productive participation.

John Hamilton, IAIS President

Welcome Letter from the IRA President

Dear WCI Attendees,

As President of the Inflammation Research Association it is my pleasure to welcome you to the 12th World Congress of Inflammation taking place in the beautiful city of Boston. The meeting organizers have assembled a superior agenda rich in a mixture of both industrial and academic scientific presentations reflecting the long history of the Inflammation Research Association and the IAIS in bringing together both basic and applied research scientists investigating in inflammatory mechanisms in grievous disease. I also want to especially welcome the many international inflammation research societies representing nine countries. This is a great opportunity for inflammation-minded scientists to mingle, share science, network and make new friends. Please enjoy what I know will be an outstanding WCI meeting and take time to visit the scientific posters and vendors too and of course enjoy the rich history of the Boston area. Welcome!

Joel Tocker, IRA President

Table of Contents

Congress Committees

Congress President
Rod Flower, UK

Congress Co-Chairs
Lisa Marshall, USA
Arpita Maiti, USA

International Scientific Advisory Board
Anthony Coyle, USA
Leslie J. Crofford, USA
Eugen Faist, Germany
Elisabeth Peen, Denmark
Fiona Powrie, UK
Charles Serhan, USA
Arlene H. Sharpe, USA

Local Scientific Committee
Lisa Schopf, Chair, USA
Andrew Glasebrook, USA
Liwu Li, USA
Alison O'Mahony, USA
Caralee Schaefer, USA
Stephen A. Stimpson, USA
Joel Tocker, USA
Thomas Wynn, USA
Edward Yurkow, USA

Abstracts and Poster Committee
Edward Yurkow, Chair, USA
Lauren Aleksunes, USA
Kent Barbay, USA
Alison Budelsky, USA
Subba Chintalacharuvu, USA
Heather Deutsch, USA
Karen Duffy, USA
Paul W. Fisher, USA
Catherine Healy, USA
Brian Jones, USA
Kevin Kreutter, USA
Erik Lubberts, Netherlands
Ravi Malaviya, USA
Carl L. Manthey, USA
Christine McCauley, USA
Michael McQueney, USA
Beverley Moore, USA
Lynne Murray, UK
Tatiana Ort, USA
Holly Raymond, USA
Lani San Mateo, USA
Pitchumani Sivakumar, USA
Mary Ryan, USA
Joshua Wertheimer, USA

Advertising Committee
Alison O'Mahony, Chair, USA
Heather Jones, USA
Doug Morgan, USA
Miranda Hanson-Baseler, USA

New Investigators Award Committee
John Somerville, Chair, USA
Ian Adcock, UK
Brydon Bennett, USA
Doug Morgan, USA
Beverley Moore, USA
Ann Welton, USA

Outstanding Scientist Award Committee
John Hamilton, Co-Chair, Australia
Graham Wallace, Co-Chair, UK
Nathalie Vergnolle, France
Stephen A. Stimpson, USA

Women in Inflammation Science Award Committee
Ellen Berg, Chair, USA
Leslie J. Crofford, USA
Rod Flower, UK
Graham Wallace, UK

Career Development and Networking Committee
Caralee Schaefer, USA
Larry Burgess, USA
Tineke Meijers, Canada
Sharlene Velichko, USA

Social Activities Committee
Doreen Gallagher, Chair, USA

Scientific Program Committee

Ian Adcock, UK
Ellen Berg, USA
Yasmine Belkaid, USA
Maria Belvisi, UK
Kate Blease, USA
Jason Brenchley, USA
Larry Burgess, USA
Liudmila Buryachkovskaya, Russia
Rachel Caspi, USA
Ernest Choy, UK
Leon Collis, USA
Anthony Coyle, USA
Leslie Crofford, USA
Salvatore Cuzzocrea, Italy
James Ellis, USA
Kate Fitzgerald, USA
Rod Flower, UK
Marc Gavin, USA
Claire Gelfman, USA
Andrew Glasebrook, USA
David Glass, USA
Emma Guttman-Yassky, USA
Jenny Gumperz, USA
Jennifer Hamilton, USA
Mark Hogarth, Australia
Stephen Holdsworth, Australia
David Howat, UK
David Huss, USA
Heather Jones, USA
Raj Kamath, USA
Jeff Karp, USA
Iain Kilty, USA
Paul Kirkham, UK
Liwu Li, USA
Peter Libby, USA
Nikita Lomakin, Russia
Alberto Mantovani, Italy
Anthony Marotta, Canada
Jason McDougall, Canada
Jane Mitchell, UK
James Mobley, USA
Kathryn Moore, USA
Ikuo Morita, Japan
Lynne Murray, UK
Lisa Olson, USA
Alison O'Mahony, USA
Luke O'Neill, Ireland
Tatiana Ort, USA
John Parkinson, USA
Robert Philibert, USA
Vijay Rathinam, USA
Simeon Ramsey, USA
Carlo Riccardi, Italy
Eric Sasso, USA
Caralee Schaefer, USA
Robert Schaub, USA
Lisa Schopf, USA
Charles Serhan, USA
Arlene Sharpe, USA
Gary Sims, UK
Mustapha Si-Tahar, France
Anthony Slavin, USA
Pejman Soroosh, USA
Avi Spira, USA
Hergen Spits, Netherlands
Thaddeus Stappenbeck, USA
Chris Stevenson, UK
Stephen A. Stimpson, USA
Tetsuya Taga, Japan
Mauro Teixeira, Brazil
Nathalie Vergnolle, France
John Wallace, Canada
Cara Williams, USA
Li Chun Wang, USA
Thomas Wynn, USA
Tim Zheng, USA

WCI 2015 Congress Management

FASEB Office of Scientific Meetings and Conferences
9650 Rockville Pike
Bethesda, MD 20814
Tel: 301-634-7010
Email: **Inflammation2015@faseb.org**

Roya Jaseb, Senior Meeting Manager
Ying Zhu, Meetings Coordinator
Janet Kearney, Exhibit Manager
Joni Friedman, Exhibits Coordinator
Sherri-Gae Scott, Grants Proposal Manager
Josie Leftwich, Registrar

IAIS Executive Committee & IRA Officers and Board Members

IAIS Executive Committee

John Hamilton, President
Stephen A. Stimpson, Vice-President
Graham R. Wallace, Treasurer
Nathalie Vergnolle, Secretary
Kouji Matsushima, Past-President
Boris Vargaftig, Chair, Brazil 2013 World Congress on Inflammation
Lisa Marshall, Chair, Boston 2015 World Congress on Inflammation
Ian Adcock, Chair, London 2017 World Congress on Inflammation
Ian Ahnfelt-Rønne, Chair, Corporate Advisory Group

IAIS Steering Committee

(Executive Committee plus two representatives from each member society)

Brazilian Inflammation Society (BIS, Brazil)

Mauro Teixeira
Fernando de Queir¢z Cunha

British Inflammation Research Association (BIRA, UK)

Neville Punchard
Matt Barnes

Groupe de Recherche et d'Etude des Médiateurs de l'Inflammation (GREMI, France)

Michel Chignard
Vincent Lagente

Inflammation Research Association (IRA, USA)

Arpita Maiti
Joel E. Tocker

Inflammation Research Network (IRN, Canada)

John L. Wallace
Jason J. McDougall

Italian Inflammation Group (IIG, Italy)

Salvatore Cuzzocrea
Carlo Riccardi

Japanese Society of Inflammation and Regeneration (JSIR, Japan)

Ikuo Morita
Tetsuya Taga

Russian Inflammation Society (RIS, Russia)

Nikita V. Lomakin
Ludmila I. Buryachkovskaya

Society for Cytokines, Inflammation and Leukocytes (SCIL, Australia)

Stephen Holdsworth
Samuel Breit

IRA Officers

Joel E. Tocker, President
Lisa Schopf, Vice-President
Liwu Li, Treasurer
Caralee Schaefer, Secretary

IRA Board Members

Alison Budelsky
Larry Burgess
Anne M. Fourie
Howard Kartstein
Erik Lubberts
Arpita Maiti, Past-President
Michael S. McQueney
Alison O'Mahony
Matthew A. Sleeman
Edward Yurkow

General Information

All Congress activities will be held at the Seaport Hotel and Seaport World Trade Center located at 200 Seaport Boulevard, Boston, Massachusetts, unless noted otherwise.

Participation in WCI 2015 is limited to registered delegates. Full congress registration includes admission to all WCI sessions such as keynote lectures, symposia, mini-symposia, patient perspectives sessions, exhibits, poster sessions, coffee breaks, and opening reception.

Congress Registration – Atrium Lobby Plaza Level

Registration for WCI 2015 will be open during the following days and hours:

Saturday, August 8 ..... **0900 – 1900**
Sunday, August 9 ..... **0700 – 1730**
Monday, August 10 ..... **0730 – 1730**
Tuesday, August 11 ..... **0730 – 1730**
Wednesday, August 12 ..... **0800 – 1030**

One-Day Registration is available for Saturday, August 8, Sunday, August 9, Monday, August 10, Tuesday, August 11, and Wednesday, August 12. It includes admission to all scientific sessions, exhibits and social events scheduled for the day purchased.

Refund Policy:
No refunds will be issued after July 8, 2015.

Exhibitor Registration – Atrium Lobby Plaza Level

Exhibitor registration provides admittance into the Exhibit Hall only. Exhibitor registration will be open during the following days and hours:

Friday, August 7 ..... **1400 – 1800**
Saturday, August 8 ..... **0700 – 1900**
Sunday, August 9 ..... **0830 – 1730**
Monday, August 10 ..... **0830 – 1730**
Tuesday, August 11 ..... **0830 – 1730**
Wednesday, August 12 ..... **0800 – 1030**

Badges

Participation in WCI 2015 is limited to registered attendees. The official badge is required for admittance to all sessions, social activities and the exhibit hall. A fee may be charged to reissue lost or misplaced badges. Please do not place a business card into the badge holder as identification. If there is an error on a badge, please have it corrected at the registration desk.

Business Center

There is a 24 hour self-service Business Center next to the front desk of the Seaport Hotel on the lobby level. There is also a Business Center that is open Monday-Friday 0830-1700 at the World Trade Center (WTC). The WTC Business Center is located on the Harbor level (bottom level) of the Trade Center on the backside of the escalators.

Banking and Currency Exchange

Foreign currency exchange and other bank transactions can be done during regular bank business hours at Santander Bank, 200 Seaport Blvd #721, Boston, MA 02210. ATMs are also available in the Seaport Hotel and Seaport World Trade Center.

Cell Phones

Cell phone use is prohibited. Please turn off all cell phones and pagers prior to entering a session room. If you must leave a session early, please use the rear entrance and exit quietly.

Congress Management Desk, Atrium Lobby, Plaza Level

The Congress Management Desk is located in the Atrium Lobby, Plaza Level.

Tel: 617-385-4920

Family Room, South End, Plaza Level

The family room is equipped with electrical outlets for pumps, private areas for nursing, and a small area for rest.

Sunday, August 9 ..... **0800 – 1730**
Monday, August 10 ..... **0800 – 1730**
Tuesday, August 11 ..... **0800 – 1730**
Wednesday, August 12 ..... **0800 – 1200**

Note: children under the age of 16 are not permitted in the exhibit hall without parent or guardian supervision.

Companion/Guest Registration

Registered attendees of WCI 2015 may sign up a spouse/guest as a Companion. Companion registration allows entrance to all social functions, coffee breaks and the Award Ceremony. This registration category does not include admittance to educational sessions or exhibits.

Disabilities and Special Needs

Attendees requiring special assistance during the Congress should visit the Congress Management Desk. We will do our best to accommodate requests; however, we cannot assure that special needs will be met without prior notice.

Internet/Wireless Access

Wireless internet access is available free-of-charge at the Seaport Hotel and Seaport World Trade Center, including all meeting rooms and common areas, and the Exhibit Hall. To connect to the WiFi, please log onto the "Seaport Wireless" or "Seaport Legacy" network on older phones. No password is needed.

Mobile App

Download the WCI 2015 mobile app via iPhone/iPad and Android native apps or via Blackberry, Windows Phone, and your desktop through mobile web. To access the WCI 2015 mobile site go to **http://ddut.ch/wci2015**.

Parking

The Seaport Boston Parking Garage is located beneath the Seaport Hotel, and offers quick and convenient Boston parking for hotel guests and visitors to Boston's Seaport District. The parking garage is accessible from D Street, B Street, Seaport Boulevard, and Congress Street. Direct elevator access is also available from the garage to the lobbies of Seaport Hotel, Seaport West, and Seaport East.

Poster Presentations – Commonwealth Complex (Harbor Level)

Over 360 poster presentations will be on display in the Exhibit Hall. Please refer to the Poster Board Map in the Congress Addendum for the assigned location of presentations. Please refer to the schedule below for viewing hours.

Sunday, August 9

0730 – 1030	Authors must set up posters on pre-assigned boards
1230 – 1430	Poster Viewing
1630 – 1800	Poster Session 1 (Authors must be present at their poster to answer questions and discuss their presentation)

Monday, August 10

1230 – 1430	Poster Viewing
1630 – 1800	Poster Session 2 (Authors must be present at their poster to answer questions and discuss their presentation)

Tuesday, August 11

1230 – 1430	Poster Viewing
1630 – 1800	Poster Session 3 (Authors must be present at their poster to answer questions and discuss their presentation)

All posters must remain on boards from Sunday, August 9 to Tuesday, August 11.
All posters must be removed between 0730 – 1030 on Wednesday, August 12, 2015.

Poster Competition

Scientific posters that have been accepted by the 12th World Congress on Inflammation into the official General Poster Sessions are eligible for, and are automatically entered into the competition. Judges will view all posters throughout the day on Sunday and Monday. Name of winners will be listed on the announcement board in the Exhibit Hall and posted on the mobile app Tuesday morning. Winners are invited to attend the Awards Banquet on Tuesday evening to receive their prize.

There are three award categories:
Greatest Scientific Impact on Human Disease
Advances in Understanding of Mechanisms
Development/Application of Technology

Each category will have a first, second, and third prize. Judges will award prizes for the top three posters, in each of the categories, describing work with the "highest scientific impact" at the Award Banquet in Lighthouse on Tuesday, August 11, from 1900 – 2300.

Practical Information for Boston

Dialing Codes

The International access code for the United States is 1. The area code in Boston is 617. While in the United States, you can call the directory information service number 411 for assistance in finding a phone number. Calls to area codes 800, 877, and 866 are toll-free in the United States. To make an international call, dial 011 followed by the country code, city code, and telephone number.

Eating Out

Boston offers world-class dining, allowing visitors to taste the distinctive flavors of the neighborhood. Some of Boston's most inventive restaurants are within walking distance of the Seaport Boston.

The Seaport Hotel offers a full-service restaurant as well as a bar and in-room dining. TAMO Bistro & Bar services lunch, dinner and snacks and is open from 1130 – midnight Sunday – Thursday, 1130 – 1300 Friday and Saturday. Aura Restaurant is open daily for breakfast. Lunch and dinner are being served in the newly expanded TAMO Bistro & Bar daily. **The concession stand inside the Exhibit Hall (Commonwealth Complex) of the Seaport World Trade Center will be open from 1030 – 1430 Sunday – Tuesday.**

Electricity

Voltage in the United States is 120 voltage (60 HZ). Outlet sockets use either a Type A plug which is a class II ungrounded plug with two flat parallel prongs, or a Type B plug which is a class I plug with two flat parallel prongs and a grounding pin.

Language

The official language of the Congress is English. Translation services will not be provided.

Tax

Sales tax in Boston is 6.25%

Recording

Recording any presentation or session (oral or poster) by any means (photographing, audio taping, videotaping) is prohibited, except by WCI authorized agent for official purposes or by first authors who want to photograph their own poster presentations. All other photography and/or videotaping is prohibited in the Exhibit Hall.

Speaker Ready Room – Federal Complex and Washington (Mezzanine Level)

All speakers are requested to go to the Speaker Ready Room to review and check the compatibility of their presentation at least 4 hours prior to their session. Speakers must arrive in the session room 30 minutes prior to the scheduled start of their session to allow the operator to load their presentation onto the computer. The operator will be seated at the table near the stage. We are not responsible for slides, laptops, or cables left in session rooms.

Speakers are not required to bring a laptop. All session rooms will be equipped with a data projector and PC. Please bring your presentation on a Windows reusable USB flash drive or CD-ROM. We recommend that you bring a backup presentation format.

Transportation

Commuter Rail/Subway/Bus

The MBTA (Massachusetts Bay Transportation Authority) Silver Line Waterfront (SL1) provides service from the WTC Station to Logan International Airport terminals every 10 minutes on weekdays and every 15 minutes during the weekend. The Silver Line station is located adjacent to the Seaport Hotel.

Taxi

Taxis are readily available from the lobby of the Seaport Hotel. The Seaport Hotel is about 3 miles from Logan International Airport.

Uber

Sign up for Uber with the promotion code **WCI2015** and your first ride is free up to $40 (not valid on Taxi)! Once you have downloaded the app, create an account at ***http://www.uber.com/go/WCI2015*** and login with the account information you created. It's only for the first ride. Any additional fare beyond $40 will be charged to the rider's account.

Boston City Map



Property Map

Seaport World Trade Center

Seaport Hotel



Seaport World Trade Center

Plaza Level



Mezzanine Level



Seaport World Trade Center

Harbor Level



Seaport Hotel

Plaza Level



Program at-a-Glance

Time	Saturday August 8	Sunday August 9	Monday August 10	Tuesday August 11	Wednesday August 12
0800 – 0900		**Patient Perspectives on Psoriatic Arthritis** *Harborview Ballroom*	**Patient Perspectives:** Unmet Medical Need – Inflammatory Bowel Disease *Harborview Ballroom*	**Patient Perspectives:** Unmet Medical Need –Lupus *Harborview Ballroom*	**Outstanding Scientist Award Presentation** *Harborview Ballroom*
0900-1000	REGISTRATION 0900 – 1900	**Keynote Lecture** Charles Dinarello Blocking Interleukin-1 in a Broad Spectrum of Inflammatory Diseases *Harborview Ballroom*	**Keynote Lecture** Luke O'Neill New Frontiers in Inflammation Research *Harborview Ballroom*	**Keynote Lecture** Diane Mathis Immunological Control of Non-Immunological Processes *Harborview Ballroom*	**Keynote Lecture** Peter Libby Inflammation in Atherosclerosis – A Translational Tale *Harborview Ballroom*
		Keynote Lecture Ruslan Medzhitov Inflammation and Homeostasis and Disease *Amphitheater*	**Keynote Lecture** Arlene Sharpe Functions of Co-Inhibitory Pathways in Controlling T-cell Responses and Inflammation *Amphitheater*		
1000 – 1030		**Coffee Break** *Exhibit Hall, Commonwealth Complex*	**Coffee Break** *Exhibit Hall, Commonwealth Complex*	**Coffee Break** *Exhibit Hall, Commonwealth Complex*	**Coffee Break** *Harborview Foyer*
1030 – 1230		**Symposium 1** Innate Memory and Programming in Acute and Chronic Inflammation *Amphitheater*	**Symposium 13** MicroRNAs (miRNAs) in Inflammation *Waterfront Ballroom 2*	**Symposium 25** Complement Targeted Therapies – Is There Light at the End of the Tunnel? *Waterfront Ballroom 1*	**Symposium 37** Novel Targets and/or Novel Therapies – Sponsored by Celgene *Harborview Ballroom*
		Symposium 2 Mechanisms Underlying Microbiome-Mediated Inflammation *Harborview Ballroom*	**Symposium 14** Mucosal Immunity: Hot Topics in IBD *Harborview Ballroom*	**Symposium 26** Regenerative Medicine and Stem Cells in Inflammation *Waterfront Ballroom 2*	**Symposium 38** Cardiovascular Inflammation *Amphitheater*
		Symposium 3 Disease Modification in Osteoarthritis: Myth or Reality? *Cityview Ballroom 1*	**Symposium 15** Inhibitory Receptor/ Immune Checkpoints/ Immunotherapeutics – Sponsored by IRA-USA *Cityview Ballroom 2*	**Symposium 27** iNKT Cells-Mediators at the Interface of Inflammation and Immunity *Harborview Ballroom*	**Symposium 39** Predictive Toxicity *Cityview Ballroom 2*
		Symposium 4 The "Eicosanoid Storm" *Beacon Hill Complex*	**Symposium 16** Mechanisms of Fibrosis *Amphitheater*	**Symposium 28** Infection and Immunity – Sponsored by BIS-Brazil *Beacon Hill Complex*	**Symposium 40** Translational Medicine *Cityview Ballroom 1*
		Symposium 5 Cytokines and Inflammation – Sponsored by ICIS *Cityview Ballroom 2*	**Symposium 17** Therapeutics with Localized Actions – Optimal Ways to Treat Tissue Inflammation *Waterfront Ballroom 1*	**Symposium 29** Biomarkers in Inflammation: Focus on Rheumatoid Arthritis *Cityview Ballroom 2*	**Symposium 41** Innate Lymphoid Cells *Waterfront Ballroom 2*
		Symposium 6 Novel Biologic Therapies for Immune and Inflammatory Disorders – Sponsored by SCIL-AUS *Waterfront Ballroom 1*	**Symposium 18** Ion Channels and Inflammation – Sponsored by IRN-Canada *Beacon Hill Complex*	**Symposium 30** SLE: Current Therapeutic Landscape and Future Promises *Amphitheater*	Congress Adjourns
		Symposium 7 New Therapeutic Strategies for Respiratory Diseases – Sponsored by ERS *Waterfront Ballroom 2*	**Symposium 19** Harnessing Novel Resolution Mechanisms to Control Inflammation *Cityview Ballroom 1*	**Mini-Symposium 3** Mechanisms Driving Mucosal Inflammation in the Gut *Cityview Ballroom 1*	

Time	Saturday August 8	Sunday August 9	Monday August 10	Tuesday August 11	Wednesday August 12
		1230 – 1330 **Meet the Professionals** *Beacon Hill Complex* *Advance registration required*	1230 – 1400 **Smooth Transitions – Top 10 List: Things Scientists Ask About Moving Out of Academia** *Beacon Hill Complex* *Advance registration required*	1230 – 1330 **Meet the Professionals** *Beacon Hill Complex* *Advance registration required*	
1230 – 1430		**Poster Viewing/ Lunch Break** *Exhibit Hall, Commonwealth Complex*	**Poster Viewing/ Lunch Break** *Exhibit Hall, Commonwealth Complex*	**Poster Viewing/ Lunch Break** *Exhibit Hall, Commonwealth Complex*	
1430 – 1630	**REGISTRATION** **0900 – 1900**	**Symposium 8** The Neutrophil: An Old Dog with New Tricks Sponsored by GREMI (France) *Waterfront Ballroom 1*	**Symposium 20** Skeletal Muscle Inflammation *Waterfront Ballroom 1*	**Symposium 31** New Visions in Ocular Therapy *Cityview Ballroom 2*	
		Symposium 9 Ocular Inflammation, Translation-Focused – Sponsored by Ora, Inc. *Beacon Hill Complex*	**Symposium 21** Regulation of Inflammation in Tissues by Co-Stimulatory and Co-Inhibitory Pathways *Harborview Ballroom*	**Symposium 32** Tregs in Human Autoimmunity *Cityview Ballroom 1*	
		Symposium 10 Glucocorticoids in the Regulation of Inflammatory Responses – Sponsored by Italian Inflammation Group *Amphitheater*	**Symposium 22** Atopic Dermatitis, Psoriasis and IL-4/IL-17 Biology *Amphitheater*	**Symposium 33** Gaseous Mediators as the Basis for Novel Anti-Inflammatory Drugs - Sponsored by IRN-Canada *Waterfront Ballroom 1*	
		Symposium 11 A Role for Epigenetics in Inflammatory Disease: Spotlight on Monocytes and Macrophages *Harborview Ballroom*	**Symposium 23** Defining Sub-Phenotypes in Chronic Respiratory Diseases to Improve Drug Development and Disease Management *Waterfront Ballroom 2*	**Symposium 34** Therapeutic Pathways in Inflammation: New Faces of Old Friends – Sponsored by RIS-Russian *Beacon Hill Complex*	
		Symposium 12 Next Generation Kinase Inhibitors –Sponsored by BIRA-UK *Cityview Ballroom 1*	**Symposium 24** Biological and Non-Biological Therapies of Autoimmune Diseases – Sponsored by JSIR-Japan *Cityview Ballroom 2*	**Symposium 35** Clinical Developments in Fibrosis *Amphitheater*	
		Mini-Symposium 1 Novel Models of Inflammation *Waterfront Ballroom 2*	**Mini-Symposium 2** Cellular and Molecular Mechanisms of Fibrosis *Cityview Ballroom 1*	**Symposium 36** Novel Therapies in RA *Harborview Ballroom*	
		Women in Inflammation Science Award Winner Presentation *Cityview Ballroom 2*	**New Investigator Award Winner Presentations** *Beacon Hill Complex*	**Mini-Symposium 4** Signaling in Inflammation *Waterfront Ballroom 2*	
1630 – 1800		**Poster Session & Mixer** *Exhibit Hall, Commonwealth Complex*	**Poster Session & Mixer** *Exhibit Hall, Commonwealth Complex*	**Poster Session & Mixer** *Exhibit Hall, Commonwealth Complex*	
	1900 – 2000 **Congress President's Lecture** *Harborview Ballroom*	1830 – 1930 **New Investigators Awards Reception** *By invitation only* *Lighthouse*	1830 – 2000 **Not Networking 101 – Building Relationships for Success** *Cityview Ballroom 1*	1900 – 2300 **Awards Banquet** *Lighthouse* *Advance ticket purchase required*	
	2000 – 2100 **Welcome Reception** *Headhouse Concourse/ Boulevard of Flags*				

Keynote Speakers

Charles Dinarello

Charles A. Dinarello is Professor of Medicine and Immunology at the University of Colorado School of Medicine and Professor of Experimental Medicine at Radboud University in the Netherlands. Dr. Dinarello received his medical degree from Yale University, clinical training at the Massachusetts General Hospital and from 1971 77, he was at the National Institutes of Health in Bethesda. Dr. Dinarello is considered one of the founding fathers of cytokines. He was the first to purify interleukin-1β (IL 1β) in 1977 and identified IL 1α in 1974. His group reported the first cDNA for IL 1β in 1984. He has published over 700 original research articles and 250 reviews and book chapters on inflammatory cytokines, particularly on IL 1, the IL 1 family and related cytokines. He has trained over 50 investigators, many of whom are recognized experts in their fields. The Institute for Scientific Information listed Dinarello as the world's 4th most-cited scientist during the 20 years 1983-2002 and from 1996 to 2011, he was listed as one of 400 of the world's most influential biomedical researchers.

In 1998, Dinarello was elected to the United States National Academy of Sciences and in 2010, he was made a foreign member of the Royal Netherlands Academy of Sciences. He is a member of the Board of Governors of the Weizmann Institute (Israel) and Ben Gurion University (Israel) and former Vice President of the American Society of Clinical Investigation and President of the International Cytokine Society. He has received honorary degrees from the University of Marseille (France), the Weizmann Institute (Israel), the University of Frankfurt (Germany) and Roosevelt University (USA), Albany Medical College (USA), Radboud University (Netherlands) and Trinity College (Ireland). In November 2014, Dinarello received a doctorate in medicine *honaris causa* from the University of Bonn (Germany).

For his contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland) and in 2012, the Bonazinga Award (USA). In November 2013, Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies on the role of lipids in cytokine-mediated inflammation. In June, 2014, he received the Drexel Prize in Immunology.

Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports research on cytokines to young investigators.

Ruslan Medzhitov

Ruslan Medzhitov obtained his BA degree from Tashkent State University in 1990 and PhD degree from Moscow State University in 1993. He began his career in 1993 as a visiting student at the University of California at San Diego and became a Postdoctoral Associate with Howard Hughes Medical Institute in 1994 working with Dr. Charles A. Janeway, Jr. at Yale University School of Medicine. He became an Assistant Professor at Yale University School of Medicine in the Section of Immunobiology in 1999. He is currently a David W. Wallace Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute.

Dr. Medzhitov contributed to the characterization of the function of Toll-like receptors in the mammalian immune system. He helped to define the mechanisms of TLR-mediated signaling, gene induction, and inflammatory responses in physiological and pathological conditions. He contributed to the characterization of the role of innate immune system in the regulation of adaptive immune responses.

His most recent awards include: Lewis S. Rosenstiel Award "For Pioneering Studies of Innate Immune System", Brandeis University; Member, National Academy of Sciences, USA; Member, Connecticut Academy of Science & Engineering; Fellow, American Academy of Microbiology; The Shaw Prize in Life Science and Medicine Award; Fellow, American Association for the Advancement of Science; Doctor Honoris Causae, Utrecht University; Professor Honoris Causae, Moscow University.



Luke O'Neill

Professor Luke O'Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. on the pro-inflammatory cytokine IL-1 and innate immune signaling. His research is in the area of the molecular basis to inflammatory diseases. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, The Irish Society for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence, the Science Foundation Ireland Researcher of the Year Award and in 2014 the European Federation of Immunology Societies Medal. He was elected a member of EMBO in 2005. In 2014 he was named by Thompson Reuters as one of the world's most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology. He is a co-founder and director of Opsona Therapeutics, a drug development company working in the area of Toll-like receptors.

Arlene Sharpe

Arlene Sharpe M.D. Ph.D. is the George Fabyan Professor of Comparative Pathology at Harvard Medical School, Head of the Division of Immunology in the Department of Microbiology and Immunobiology, Co-Director of the Harvard Institute of Translational Immunology, and a member of the Department of Pathology at Brigham and Women's Hospital. Dr. Sharpe earned her M.D. and Ph.D. degrees from Harvard Medical School, and completed her residency in Pathology at Brigham and Women's Hospital. Dr. Sharpe's laboratory investigates T cell costimulatory pathways and their immunoregulatory functions. Her laboratory studies the roles of T cell costimulatory and coinhibitory pathways in regulating immune responses needed for the induction and maintenance of T cell tolerance and effective antimicrobial and antitumor immunity. A major focus of her laboratory is elucidating the role of coinhibitory molecules in mediating tissue tolerance and controlling inflammation. Her laboratory is also involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases, chronic infections, and cancer.

Diane Mathis

Dr. Diane Mathis obtained a Ph.D. from the University of Rochester, and performed postdoctoral studies at the Laboratoire de Génétique Moléculaire des Eucaryotes (LGME) in Strasbourg, France and at Stanford University Medical Center. She returned to France at the end of 1983, establishing a laboratory at the LGME [later the Institut de Genetique et de Biologie Moleculare et Cellulaire (IGBMC)] in Strasbourg, in conjunction with Dr. Christophe Benoist. The lab moved to the Joslin Diabetes Center, Boston, MA at the end of 1999. Through 2008, Dr. Mathis was a Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, and an Associate Research Director and Head of the Section on Immunology and Immunogenetics at Joslin, where she held the William T. Young Chair in Diabetes Research. Dr. Mathis is currently Professor and Head of the Division of Immunology in the Department of Microbiology and Immunobiology at HMS, and holder of a Morton Grove-Rasmussen Chair in Immunohaematology. She is also a Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Faculty Member of the Broad Institute. She presently serves on Scientific Advisory Boards of the Howard Hughes Medical Institute, Genentech, Fidelity Biosciences, and MedImmune, as well as of several research institutes worldwide. She is cofounder of Tempero, a biotech start-up that aims to produce novel therapeutics in the autoimmunity/inflammation space. Dr. Mathis was elected to the US National Academy of Sciences in 2003, the German Academy in 2007, and the American Academy of Arts and Sciences in 2012. The lab works in the fields of T cell differentiation and autoimmunity.

Peter Libby

Peter Libby, MD, is a cardiovascular specialist at Brigham and Women's Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998 - 2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments, including the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), and the Distinguished Achievement Award of the Heart Failure Association of the European Society of Cardiology (2014).

Dr. Libby's professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and elected honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the President of the Association of University Cardiologists. He also has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He presided over the American College of Cardiology's Research Allocations Peer Review Committee for two terms. He has frequently consulted for the National Heart, Lung, and Blood Institute, including a 5-year term on the Board of Scientific Councilors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards, and has received continuous funding from the NHLBI for several decades.

An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including *Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine,* and *Nature.* He is an Editor of Braunwald's Heart Disease. Dr. Libby also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of *Harrison's Principles of Internal Medicine.* He has held numerous visiting professorships and delivered more than 80 major named or keynote lectures throughout the world.

Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France.

Please Plan to Attend These Special Events!

Saturday

2000 – 2100, Headhouse Concourse/Boulevard of Flags

Welcome Reception

Sunday

0800 – 0900, Harborview Ballroom

Patient Perspectives on Psoriatic Arthritis

1230 – 1330, Beacon Hill Complex

Meet the Professionals

Boxed lunch will be served. Pre-registration is required.

1430 – 1630, Cityview Ballroom 2

Women in Inflammation Science Award Winner Presentation

1830 – 1930, Lighthouse

New Investigators Awards Reception *(By invitation only)*

Monday

0800 – 0900, Harborview Ballroom

Patient Perspectives:

Unmet Medical Need – Inflammatory Bowel Disease

1230 – 1400, Beacon Hill Complex

Smooth Transitions – Top 10 List:

Things Scientists Ask about Moving Out of Academia

Boxed lunch will be served. Pre-registration is required.

1430 – 1630, Beacon Hill Complex

New Investigator Award Winner Presentations

1830 – 2000, Cityview Ballroom 1

Not Networking 101 – Building Relationships for Success

Pre-registration is required.

Tuesday

0800 – 0900, Harborview Ballroom

Patient Perspectives:

Unmet Medical Need – Lupus

1230 – 1330, Beacon Hill Complex

Meet the Professionals

Boxed lunch will be served. Pre-registration is required.

1900 – 2300, Lighthouse

Awards Banquet

Pre-registration is required.

Wednesday

1830 – 2000, Harborview Ballroom

Outstanding Scientist Award Presentation

Daily Program

Saturday, August 8, 2015

0900 – 1900, Atrium Lobby, Plaza Level

Registration

1400 – 1600, Beacon Hill Complex

New Investigator Award Presentations

Open to Committee Members Only

1900 – 2000, Harborview Ballroom

Opening Ceremony

Harnessing Patterns of Inflammation in the Pursuit of Novel Therapeutics
Rod Flower. Congress President, Centre for Biochemical Pharmacology; William Harvey Research Institute, St. Bart's and the London School of Medicine and Dentistry

2000 – 2100, Headhouse Concourse/Boulevard of Flags

Welcome Reception

Sunday, August 9, 2015

0800 – 0900, Harborview Ballroom

Patient Perspectives on Psoriatic Arthritis

Chair
Heather Jones, Pfizer, Inc.

Objective: To increase awareness of the true unmet medical need left by current therapeutic options for psoriatic arthritis (PsA) and understand what this means to the patient.

The importance of recognizing the true unmet medical need in PsA is immense. The prevalence of psoriasis among patients with arthritis in the general population is 2–3%, but among patients with arthritis it is 7%. No drug has so far been able to cure PsA, only to help reduce pain, maintain joint movement and help clear skin. To progress science and clinical development there must be a focus on understanding the pathogenesis of the disease. From a medical perspective we need to consider the patient as a whole human being and not only based on the organ(s) involved. PsA is a degenerative disease that worsens over time and may become severe enough to make daily tasks difficult.

The morning session will begin by emphasizing the unmet medical need followed by an interview with a patient suffering from psoriatic arthritis, with an emphasis on what they see as key objectives for further development.

At the end of the session an invited professor will summarize the signs and symptoms and the treatment algorithm for PsA, as well as the need for biomarkers to define the disease, ensure safety, guide treatment and predict treatment response.

001
Patient Perspectives on Osteoarthritis
Heather Jones. Pfizer Inc., Collegeville, PA

0900 – 1000, Harborview Ballroom

Keynote Lecture

Blocking Interleukin-1 in a Broad Spectrum of Inflammatory Diseases
Charles Dinarello. University of Colorado Denver, Denver, CO

0900 – 1000, Amphitheater

Keynote Lecture

Inflammation and Homeostasis and Disease
Ruslan Medzhitov. Yale University School of Medicine, New Haven, CT

1000 – 1030, Exhibit Hall, Commonwealth Complex

Coffee Break

The number above abstract title reference the corresponding number of the author's abstract in the "Abstract Issue."

1030 – 1230, Amphitheater

Symposium 1: Innate Memory and Programming in Acute and Chronic Inflammation

Co-Chairs
Liwu Li, Virginia Polytechnic Institute and State University
Alberto Mantovani, Humanitas Research Hospital

Plasticity is a characteristic of phagocytes which sustain inflammation. In response to inflammatory signals myelomonocytic cells undergo functional reprogramming, short and long term. The long term reshaping of innate immunity has been referred to as "trained," "memory," "adaptive." Epigenetic changes underlies innate immunity "memory." The symposium will consider the phenomenology, molecular mechanisms, and implications for inflammation and immunity of myelononocytic cell "memory."

002
PTX3 as a Paradigm for the Interplay between Cellular and Humoral Innate Immunity in Inflammation and Cancer
Alberto Mantovani. Humanitas Univ., Rozzano, Italy

003
The Macrophage Epigenome and the Control of the Inflammatory Gene Expression Program
Gioacchino Natoli. European Institute of Oncology, Milan, Italy

004
Epigenetic Regulation of Macrophage Activation and Function
Lionel Ivashkiv. Hosp. for Special Surgery, Weill Cornell Med. Col., New York, NY

005
Dynamic Programming of Innate Immunity in Health and Disease
Liwu Li. Virginia Tech, Blacksburg, VA

The number listed above the abstract title references the corresponding number in the Abstract Issue.

1030 – 1230, Harborview Ballroom

Symposium 2: Mechanisms Underlying Microbiome-Mediated Inflammation

Co-Chairs
Yasmine Belkaid, National Institute of Allergy and Infectious Diseases, NIH
Jason Brenchley, National Institute of Allergy and Infectious Diseases, NIH

The session will delve into site-specific microbiomes and how they interact with the immune system locally, and how alterations in either the microbiome or local immune system can lead to systemic inflammation driven by the microbiome.

006
Dysbiotic Microbes Translocate from the GI Tract in Progressive SIV Infection
Jason Brenchley*, Zachary Klase.* Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

No Abstract
How HIV Guts the Immune System: Linking an Altered Microbiome to Inflammation
Cara Wilson. University of Colorado Denver, Denver, CO

No Abstract
Skin Commensal-Dendritic Cell Interactions Specify Local Immunity
Yasmine Belkaid. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

007
Symbiotic Sphingolipids Shape the Host Immune Development and Homeostasis
Dingding An. Boston Children's Hosp.; Harvard Med. Sch., Boston, MA

1030 – 1230, Cityview Ballroom 1

Symposium 3: Disease Modification in Osteoarthritis: Myth or Reality?

Co-Chairs
Lisa Olson, AbbVie
Raj Kamath, AbbVie

Osteoarthritis (OA) is a disease that affects several million individuals worldwide resulting in functional failure of joints. The clinical symptoms of OA are pain and functional impairment that includes joint stiffness and dysfunction. The signature pathologic feature of OA is articular

cartilage loss leading to joint destruction. At present, most therapies for OA are symptomatic while disease modifying therapies that dramatically improve the disease course and management are lacking. Consequently, no pharmaceutical treatments are currently approved that modify disease in OA patients. This symposium will focus on current status of basic research, cell therapy, biomarkers and OA therapeutics to reduce or stop the progression of OA disease.

008
New Targets for Joint Damage and Associated Pain in Osteoarthritis
Anne-Marie Malfait. Rush Univ. Med. Ctr., Chicago, IL

009
Cell-Based Therapies for Osteoarthritis: From Synthetic Materials to Synthetic Biology
Farshid Guilak, *Jonathan M. Brunger, Ananya Zutshi, Vincent P. Willard, Katherine A. Glass, Alison K. Ross, Franklin T. Moutos, Bradley T. Estes, Charles A. Gersbach.* Duke Univ. Med. Ctr., Durham, NC

010
Advances in Biomarker Qualification to Facilitate Osteoarthritis Clinical Trials
Virginia B. Kraus. Duke Univ., Durham, NC

No Abstract
ABT 981: Bench to Bedside
Raj Kamath. AbbVie, Inc.

1030 – 1230, Beacon Hill Complex

Symposium 4: The "Eicosanoid Storm"

Co-Chairs
Leslie Crofford, Vanderbilt University School of Medicine
Rod Flower, William Harvey Research Institute

The release of eicosanoids following tissue damage or infection is responsible for many of the familiar symptoms of inflammatory diseases. The acute appearance of large concentrations of these potent biological mediators – the eicosanoid 'storm' – may disturb homeostasis, sometimes with fatal results. This session examines some features of this phenomenon and the mechanisms by which it is initiated. Furthermore, we explore the consequences of failure to control the storm.

011
Inflammation, Inflammatory Mediators and Cancer Progression
Raymond N. DuBois. Arizona State Univ.; Mayo Clinic Arizona, Tempe

012
Induction of Eicosanoids by the Inflammasome
Karsten Gronert. Univ. of California Berkeley, Berkeley, CA

013
PGE2 and the Innate Immune Response
Mariano Sanchez Crespo. IBGM, CSIC, Univ. de Valladolid, Spain

B153
Colony-Stimulating Factor-1 and Tumor Necrosis Factor-α in Arthritic Pain and Disease
Reem A. Saleh, Derek Lacey, John Hamilton, Andrew Cook. Royal Melbourne Hosp., The Univ. of Melbourne, Parkville, Australia

1030 – 1230, Cityview Ballroom 2

Symposium 5: Cytokines and Inflammation – Sponsored by ICIS

Co-Chairs
Vijay Rathinam, University of Connecticut Health Center
Kate Fitzgerald, University of Massachusetts Medical School

Inflammation is a hallmark of the host immune responses. While inflammation is beneficial in the elimination of microbial and endogenous dangers, uncontrolled and persistent inflammation is the underlying cause of several diseases. This session will focus on the molecules, particularly cytokines, which regulate inflammatory responses.

014
Resolvins and Pro-resolving Lipid Mediators: Resolving the Storm
Charles N. Serhan, *Nan Chiang, Jesmond Dalli.* Harvard Insts. of Med.; Brigham and Women's Hosp.; Harvard Med. Sch., Boston, MA

015
TAM Receptor Tyrosine Kinases Regulate the Magnitude of the Immune Response
Carla Rothlin. Sch. of Med., Yale Univ., New Haven, CT

016
Frenemies in the Gut – Infectious Agents That Defy Classificiation
Ken Cadwell. New York Univ. Sch. of Med., NY

017
Innate Immune Sensing of LPS in the Cytosol
Vijay Rathinam. UConn Health, Farmington, CT

1030 – 1230, Waterfront Ballroom 1

Symposium 6: Novel Biologics Therapies for Immune and Inflammatory Disorders – Sponsored by SCIL-AUS

Co-Chairs
Stephen Holdsworth, Monash University
Mark Hogarth, Burnet Institute

This session showcases a spectrum of potential novel therapeutic entities and targets. Monoclonal antibodies, engineered proteins or non- proteaceous biologicals will be described, directed at novel targets in established inflammatory pathways or novel pathways and applications in inflammatory pain, arthritis or vascular targeting in cancer.

018
Targeting GM-CSF in Inflammatory Diseases
Ian P. Wicks. Walter & Eliza Hall Institute of Med. Research; Royal Melbourne Hosp.; The Univ. of Melbourne, Australia

019
GM-CSF and Inflammatory Pain
Andrew D. Cook. The Univ. of Melbourne, Parkville, Australia

020
IL-3Ra as a Therapeutic Target for Lupus
Nicholas J. Wilson, *Shereen Oon, Eric Morand, Ian Wicks, Katherine Monaghan.* CSL Limited, Parkville, Australia; The Walter and Eliza Hall Institute of Med. Research; The Royal Melbourne Hosp.; The Univ. of Melbourne; Monash Univ., Australia

021
Targeting TLR-Inducible Inflammatory Pathways in Macrophages
Matthew J. Sweet. The Univ. of Queensland, St. Lucia, Australia

022
A New Cancer Therapeutic That Targets Angiogenic Vessels
Jennifer R. Gamble, *Yang Zhao, Kaka Ting, Jia Li, Thorleif Moller, Mathew A. Vadas.* Centenary Institute, Sydney, Australia; Univ. of Sydney, Australia; Mirrx Therapeutics, Lyngby, Denmark

023
Glucocorticoid-Induced Leucine Zipper as a Novel Therapeutic in Inflammatory Disease
Michael J. Hickey, *Qiang Cheng, Eric F. Morand.* Sch. of Clin. Science at Monash Health, Monash Univ., Australia

1030 – 1230, Waterfront Ballroom 2

Symposium 7: New Therapeutic Strategies for Respiratory Diseases – Sponsored by ERS

Co-Chairs
Maria Belvisi, Imperial College London
Iain Kilty, Pfizer, Inc.

Despite huge unmet needs in respiratory disease, it has proved very difficult to discover new and safe therapies. Very few new classes of drug have been introduced for respiratory diseases over the last 40 years, and these are either poorly effective or suitable for only small populations of patients. There appear to be greater barriers to respiratory drug discovery compared to other therapeutic areas. However, more recently there has been success in delivering promising new targets and, in some cases, therapeutics for idiopathic cough, pulmonary fibrosis, asthma and cystic fibrosis. These will be described in talks that detail basic mechanisms, clinical studies and drug discovery challenges in these areas from bench to bedside.

024
Anti-Cytokine Therapy in Asthma: Focus on TSLP
Paul M. O'Byrne. McMaster Univ., Hamilton, ON, Canada

No Abstract
Role of ATP in Respiratory Reflexes: Possible Novel Anti-Tussive Strategies
Jacky Smith. University of Manchester, UK

025
Therapeutic Strategies for the Treatment of Cystic Fibrosis
Stuart Elborn. Queen's Univ. Belfast, Northern Ireland, UK

026
New Treatment Options for Pulmonary Fibrosis
Toby M. Maher. Imperial Col., London; Royal Brompton Hosp., London, UK

1230 – 1330, Beacon Hill Complex

Meet the Professionals

This year IAIS and IRA will have a "Meet the Professionals" session on Sunday, August 9, 2015 from 1230-1330. The purpose on this session is to allow attendees the opportunity to meet our Keynote Speakers who are the leading experts in their field, learn about the speaker's professional experiences, ask questions for which there was not enough time in the sessions, and foster interaction and collaboration among attendees. We strongly encourage you to participate in this session. Boxed lunches will be served. There is no fee to attend, but pre-registration and a ticket are required for a boxed lunch. You may register on-site at the WCI registration counter in the Atrium Lobby. Registration will be on a first-come, first-served basis. If you are interested in attending and did not register, you are welcome to participate on a space-available basis.

1230 – 1430, Exhibit Hall, Commonwealth Complex

Poster Viewing/Lunch Break

Concession open for lunch purchase.

1430 – 1630, Waterfront Ballroom 1

Symposium 8: The Neutrophil: An Old Dog with New Tricks – Sponsored by GREMI (France)

Co-Chairs
Mustapha Si-Tahar, INSERM
Nathalie Vergnolle, INSERM

At the dawn of the 19th century, Paul Ehrlich described a white blood cell with a tendency to retain neutral dyes, hence the "neutrophil" and Elie Metchnikoff showed that this cell migrates toward sites of infection and is able to destroy microbes. In fact, this is the main characteristic of this cell that is of primary importance for the innate defense system. Since that time, around 14,000 publications with "neutrophil" in the title are currently listed in PubMed. Physical (phagocytosis) and biochemical (serine proteases, reactive oxygen species) armaments are old very efficient "tricks" that have been studied at length as the main players of neutrophil defense. In recent years however, this "old dog" has revealed functions not previously observed, making him more attractive to experts and novices in the field. The session will be devoted to these still debatable new properties of the neutrophil.

027
News about NETs
Sylvie Chollet-Martin. Bichat Hosp. and INSERM Paris-Sud Univ., Paris, France

028
Unexpected Neutrophil Contributions to Antibody-Induced Reactions
Pierre Bruhns. Institute Pasteur, INSERM U760, Paris, France

029
Deciphering the Cytosolic Scaffold of the Proliferating Cell Nuclear Antigen to Control Neutrophil Survival in Inflammatory Diseases
Veronique Witko-Sarsat, *Clémence Martin, Delphine Ohayon, Pierre-Regis Burgel.* INSERM U1016, Institute Cochin; Univ. Paris Descartes; Lab. d'Excellence INFLAMEX, Paris; Cochin Hosp., Paris, France

B232
Intravital Imaging of Vasculature Reveals That Neutrophil Extracellular Trap (NET) Components Attach to von Willebrand Factor in a Dnase-Independent Manner
Elzbieta Kolaczkowska, Craig N. Jenne, Bas G. Surewaard, Ajitha Thanabalasuriar, Woo-Yong Lee, Maria-Jesus Sanz, Kerri Mowen, Ghislain Opdenakker, Paul Kubes. Univ. of Calgary, AB, Canada; Jagiellonian Univ., Krakow, Poland; Univ. of Leuven, Belgium; The Scripps Research Institute, La Jolla, CA

B204
Recognition of Products from Neutrophil Degranulation by Toll-Like Receptors Mediate Killing of Leishmania Amazonensis in Macrophages
Natalia M. Tavares, Lilian Afonso, Martha Suarez, Mariana R. Ampuero, Stella d´Arêde, Aldina Barral, George dos Reis, Valéria M. Borges, Cláudia Brodskyn. FIOCRUZ, Salvador, Brazil; Federal Univ. of Rio de Janeiro, Brazil; Federal Univ. of Bahia, Salvador, Brazil

B282
Neutrophil Proteases Alter the Interleukin-22-Receptor-Dependent Lung Antimicrobial Defence
Antoine Guillon, Youenn Jouan, Deborah Brea, Fabien Gueugnon, Emilie Dalloneau, Thomas Baranek, Clémence Henry, Eric Morello, Jean-Christophe Renauld, Muriel Pichavant, Philippe Gosset, Yves Courty, Patrice Diot, Mustapha Si-Tahar. INSERM UMR 1100 CEPR; Univ. François Rabelais de Tours; CHRU de Tours; Ludwig Institute for Cancer Research, Brussels; Univ. Catholique de Louvain, Brussels; Univ. Lille Nord de France; Institute Pasteur de Lille; CNRS, Lille; INSERM, U1019, Lille, France

1430 – 1630, Beacon Hill Complex

Symposium 9: Ocular Inflammation, Translation Focused – Sponsored by Ora, Inc.

Co-Chairs
Claire Gelfman, Ora, Inc.
Rachel Caspi, National Eye Institute, NIH

Understanding the basic mechanisms involved in innate and adaptive immunity is a prerequisite for translating such discoveries into potential therapeutic approaches for the treatment of ocular immune-mediated disease. In this session, we will learn about the role of IFN gamma produced from NK cells and how it, along with other interacting factors, dampens the adaptive response and consequently autoimmune disease. We will also review the role of complement in both cellular homeostasis and disease and will review how basic mechanisms have translated into treatment approaches for age-related macular degeneration (AMD). Evidence for an imbalance during the innate immune response to favor M2 macrophages during AMD will also be presented. Therapeutic approaches including ROCK inhibition which restores M1 macrophages during human disease will be explored as a therapeutic alternative. Finally, we will hear from a company developing a potassium channel blocker required for sustained intracellular calcium influx during activation of effector memory T cells. The compound was efficacious in several models of autoimmune disease, was well tolerated in a psoriasis phase 1 trial, and topical delivery reduced inflammation in the experimental anterior autoimmune uveitis model. Translating basic science discoveries of immune-related mechanisms into opportunities to treat the unmet medical needs of ophthalmology is ongoing and without limits.

030
NK-DC Crosstalk Triggers an Innate IFN-γ /IL-27 Loop That Controls the Autopathogenic Th17 Response
Rachel R. Caspi, *Wai Po Chong, Nicholas van Panhuys, Jun Chen, Phyllis B. Silver, Yingyos (Ed) Jittayasothorn, Ronald N. Germain.* Natl. Eye Institute, NIH; Natl. Institute of Allergy and Infect., NIH, Bethesda, MD

031
Complement: More Than a "Guard" against Pathogens
John D. Lambris. Univ. of Pennsylvania, Philadelphia, PA

032
ROCK-Isoform Specific Polarization of Macrophages Associated with Age-Related Macular Degeneration
Ali Hafezi-Moghadam. Harvard Med. Sch.; Brigham and Women's Hosp., Boston, MA

033
Dalazatide (ShK-186), a Kv1.3 Potassium Channel Blocker, Significantly Reduces Inflammatory Cell Infiltrates and Disease in an Experimental Autoimmune Anterior Uveitis Model
Ernesto J. Munoz, *David W. Peckham, Kayla Norton, Shawn P. Iadonato.* Kineta, Inc., Seattle, WA

1430 – 1630, Amphitheater

Symposium 10: Glucocorticoids in the Regulation of Inflammatory Responses – Sponsored by Italian Inflammation Group

Co-Chairs
Carlo Riccardi, University of Perugia
Salvatore Cuzzocrea, University of Messina

Glucocorticoids (GC) are necessary for life after birth and regulate numerous biological processes in man, including inflammation. GC synthetic derivatives are extensively prescribed as anti-inflammatory agents, irrespective of patient gender. However, since the inflammatory diseases present differences in gender prevalence and GC are the primary physiological anti-inflammatory hormone, the sexually dimorphic actions of GC on gene expression may contribute to the dimorphic basis of inflammatory pathologies. In fact GC administration expand the profile of sexually dimorphic genes. Moreover, pathway analysis in humans identifies sex-specific glucocorticoid-regulated gene expression in several canonical pathways involved in susceptibility to progression of diseases with gender differences in prevalence.

GC protect extremely well against acute inflammatory conditions and the cross talk between GC and cytokines is important. However, the exact mechanism of the anti-inflammatory function of GC is still unclear. Notably, large groups of patients respond insufficiently to GC, a condition called GC resistance. This problem occurs in some 5% of asthma patients and in most of the sepsis patients. Sepsis is a form of systemic inflammatory response syndrome (SIRS) and a huge unmet medical need. Study of the mechanism of loss of GC protection, when GC are given after the onset of SIRS, indicate an intense cross talk between TNF and GC.

Products of transcriptional regulation, consequent to interaction of GC with glucocorticoid receptor (GR), are important for GC effects and transcriptional products, such as Glucocorticoid-Induced Leucine Zipper (GILZ), are mediators of the GR-mediated effects. In particular, GILZ regulates T and B cell activation, differentiation, cytokine production and inflammatory process development. Notably, GILZ is an essential mediator for GC-induced development of T regulatory cells (Treg), a T cell subpopulation responsible of anti-inflammatory effect.

These evidences provide new mechanistic explanation for pharmacological action of GC and also give indications for new therapeutic approaches.

No Abstract
Glucocorticoids, Sex, Inflammation and Death
John Cidlowski. NIEHS, NIH, Research Triangle, Park, NC

034
Intense Cross-Talk between TNF and Glucocorticoid Receptor
Claude Libert. VIB, Ghent, Belgium

035
Role of GILZ in Mediating the Anti-inflammatory Actions of Glucocorticoids
Carlo Riccardi, *Monica Cimino, Tiziana Frammartino, Daniele Sorcini, Michele Biagioli, Oxana Bereshchenko, Stefano Bruscoli.* Univ. of Perugia, Italy

036
Glucocorticoid and B Cell Development: Role of Glucocorticoid-Induced Leucine Zipper
Stefano Bruscoli, *Michele Biagioli, Oxana Bereshchenko, Tiziana Frammartino, Daniele Sorcini, Monica Cimino, Carlo Riccardi.* Univ. of Perugia, Perugia, Italy

1430 – 1630, Harborview Ballroom

Symposium 11: A Role for Epigenetics in Inflammatory Disease: Spotlight on Monocytes and Macrophages

Co-Chairs
James Mobley, Cayman Chemical Company
Robert Philibert, University of Iowa

Macrophages are one of the most important cell types in both acute and chronic inflammatory responses. They are the target of multiple anti-inflammatory therapeutics including small-molecule drugs (methotrexate, corticosteroids, NSAIDS) as well as biological agents (anti-TNF-alpha) Macrophages are also one of the more heterogeneous and differentially plastic cells in the body. Newly-produced blood monocytes have the capacity to differentiate into an astonishingly diverse array of tissue macrophages with many non-overlapping functions, including brain microglia, lung alveolar macrophages, liver Kupffer cells, and inflammatory tissue macrophages. The latter can be further differentiated into M1 or M2 phenotypes based upon the stimulation or activation conditions in the local tissue microenvironment. Epigenetics is the study of heritable reversible changes in gene activity that occur without an underlying change in the gene sequence. Epigenetic alterations are believed to be a major factor in the differentiation and development of macrophage non-overlapping functions. Understanding and targeting these epigenetic changes will be important for the development of novel anti-inflammatory therapeutics. This symposium will explore epigenetic regulation in inflammatory macrophages in a number of inflammatory disease states.

037
The Epigenetic Signature of Inflammation in White Blood Cells and Pulmonary Macrophages from Smokers: Where There Is Smoke, There Is Fire
Robert A. Philibert. Univ. of Iowa, Iowa City, IA

038
Suppression of Type 1 Diabetes by Epigenetic Modulation
Wenxian Fu, *Julia Farache, Rab Prinjha, Christophe Benoist, Diane Mathis.* Harvard Med. Sch., Boston, MA; Univ. of California San Diego, La Jolla, CA; GlaxoSmithKline, Chelmsford, UK

039
Epigenetic Dysregulation in Immune Tolerance: Two Sides to the Same Coin – Cancer and Autoimmunity
S. A. Litherland, *Michael J. Clare-Salzler, Juan Pablo Arnoletti.* Florida Hosp. Cancer Institute, Orlando; Univ. of Florida Col. of Med., Gainesville; Sanford-Burnham Med. Research Institute, Orlando, FL

040
The Epigenetic-Associated Family of Bromodomain "Reader" Proteins as Drug Targets to Regulate Actions of the Immune System
Eleonore Beurel. Univ. of Miami, Miami, FL

1430 – 1630, Cityview Ballroom 1

Symposium 12: Next Generation Kinase Inhibitors – Sponsored by BIRA-UK

Co-Chairs
Ian Adcock, Imperial College London
Paul Kirkham, University of Wolverhampton

Kinase inhibitors have been in clinical use for many years and are beginning to show marked efficacy in patients with specific types of cancers. Inflammation drives the activation of many key hub kinases and these would appear to be obvious targets for novel anti-inflammatory drugs. Early drugs, however, showed marked side-effects which severely limited their use in chronic inflammatory conditions. This sessions looks at the development of next generation kinase inhibitors and how they may impact upon chronic inflammatory diseases where side-effect concerns are much greater.

No Abstract
Developing a Pan JAK Inhibitor for Asthma
Ian Adcock. Imperial College London, London, UK

041
Targeting IRAK4 as a Central Regulator in Innate Immunity
Iain Kilty. Pfizer Inc., Cambridge, MA

042
A New Generation of Inhaled Kinases Inhibitors for Inflammatory Airway Diseases
Christopher S. Stevenson. Respivert Ltd, London, UK

1430 – 1630, Waterfront Ballroom 2

Mini-Symposium 1: Novel Models of Inflammation

Chair
David Howat, Evgen Ltd

This mini-symposium has selected speakers from submitted abstracts to highlight some novel models or twists on existing animal models of Inflammation. The talks will discuss the models and their characteristics together with their potential utility in novel drug discovery research.

B071
Cigarette Smoke Enhances Adaptive Immune Response in Murine Model of Allergic Airway Inflammation
Thayse R. Bruggemann, Paula Fernandes, Jessica M. Oliveira, Beatriz M. Saraiva-Romanholo, Mílton A. Martins, Fernanda M. Arantes-Costa. Sch. of Med. of São Paulo, Brazil

B092
Disease Relevant In Vitro and In Vivo Models for Lung Fibrosis
Jeroen DeGroot, Krista Ouwehand, Blandine Mille-Baker, Alan Young, McElroy Mary, Joe Cornicelli, David Bonnel, Jonathan Stauber, David F. Fischer. Charles River Laboratories, Leiden, Netherlands; Charles River Laboratories, Oxford, UK; Charles River Laboratories, Edinburgh, UK; Charles River Laboratories. Wilmington, MA, USA; ImaBiotech, Lille, France

B002
Synchrotron Microbeam Irradiation Induces Inflammation and Selective Vascular Damages in Adult Zebrafish
Daniel Brönnimann, Audrey Bouchet, Werner Graber, Jean A. Laissue, Valentin Djonov, Raphael Serduc, Elke Bräuer. Univ. of Bern, Switzerland; European Synchrotron Radiation Facility, Grenoble, France

B191
Development of a Model of Dermal Inflammation and Irritation (Urticaria) in the Miniature Swine
Miao Zhong, Alain Stricker-Krongrad, Jason Liu, Guy Bouchard. Sinclair Research Ctr. LLC, Auxvasse, MO

B237
In Vitro Modelling Acute and Chronic Inflammation Based on Human Monocytes: Analysis of the Modulation of IL-1 Family Members
Paola Italiani, Ettore Mosca, Luciano Milanesi, Diana Boraschi. Institute of Protein Biochem., Natl. Research Council of Italy, Naples; Institute of Biomed. Technologies, Natl. Research Council of Italy, Milan

B239
Dynamic Equilibrium of Neutrophil Trafficking at Sites of Inflammation and Infections
Daniel Irimia. Massachusetts General Hosp.; Harvard Med. Sch.; Shriners Burns Hosp., Charlestown, MA

B235
Spontaneous Mutation in ZFP-Binding Region of TNF Gene Causes Chronic Polyarthritis and Heart Valve Disease
Derek C. Lacey, Peter Hickey, Benedicta D. Arhatari, Lorraine O'Reilly, Leona Rohrbeck, Helen Kiriazis, Xiao-Jun Du, Philippe Bouillet. The Walter and Eliza Hall Institute of Med. Research, Parkville; Univ. of Melbourne; La Trobe Univ., Victoria; Baker IDI Heart and Diabetes Institute and Central Clin. Sch., Monash Univ., Melbourne, Australia

B179
Maternal IL17 Pathway Promotes Autism–Like Phenotypes in Offspring
Jun Huh. Univ. of Massachusetts Med. Sch., Worcester, MA

1430 – 1630, Cityview Ballroom 2

Women in Inflammation Science Award Winner Presentation

Stefanie N. Vogel, University of Maryland, School of Medicine, Baltimore, MD

Many respiratory pathogens elicit a detrimental inflammatory response that leads to acute lung injury (ALI). We previously reported that Eritoran (E5564; Eisai Inc.), a potent antagonist of Toll-like receptor 4 (TLR4) signaling, blocked ALI and lethality in a model of murine influenza. These findings have been extended in highly mechanistic ways and have confirmed the role of TLR4-mediated signaling in influenza-mediated ALI. Thus, blocking the inflammatory response induced by influenza-mediated TLR4 signaling may represent a new therapeutic, host-directed approach not only for influenza, but also, for other agents that induce ALI.

1630 – 1800, Exhibit Hall, Commonwealth Complex

Poster Session and Mixer

1830 – 1930, Lighthouse

New Investigators Awards Reception (By invitation only)

Monday, August 10, 2015

0800 – 0900, Harborview Ballroom

Patient Perspectives on IBD: Unmet Medical Need on Inflammatory Bowel Disease

Chair
Heather Jones, Pfizer, Inc.

Objective: To increase awareness of the true unmet medical need left by current therapeutic options for IBD and understand what this means to the patient.

The importance of recognizing the true unmet medical need in autoimmune diseases is higher than ever. No drug has so far been able to cure IBD, only to induce remission. To progress science and clinical development there must be a focus on understanding the pathogenesis of the disease. From a medical perspective we need to consider the patient as a whole human being and not only based on the organ(s) involved. Autoimmune diseases in most cases are systemic disorders that affect more than one organ.

The morning session will begin by emphasizing the unmet medical need followed by an interview with a patient with IBD, with an emphasis on what they see as key objectives for further development.

At the end of the session the co-chairs will summarize the signs and symptoms and the treatment algorithm for IBD, as well as the need for biomarkers to define the disease, ensure safety, guide treatment and predict treatment response.

043
Patient Perspectives on IBD
Heather Jones. Pfizer Inc., Collegeville, PA

0900 – 1000, Harborview Ballroom

Keynote Lecture

New Frontiers in Inflammation Research
Luke O'Neill. Trinity College Dublin, Dublin, Ireland

0900 – 1000, Amphitheater

Keynote Lecture

Functions of Co-inhibitory Pathways in Controlling T Cell Responses and Inflammation
Arlene Sharpe. Harvard Medical School, Boston, MA

1000 – 1030, Exhibit Hall, Commonwealth Complex

Coffee Break

1030 – 1230, Waterfront Ballroom 2

Symposium 13: MicroRNAs (miRNAs) in Inflammation

Co-Chairs
Kathryn Moore, NYU School of Medicine
Luke O'Neill, Trinity College Dublin

miRNAs play critical roles during the initiation, propagation, and resolution phases of inflammatory processes. A clear understanding of these events will lead to potential therapeutic strategies for both acute and chronic inflammatory diseases. This session will provide pressing updates about key miRNAs involved in inflammation, their roles in leukocyte activation, as well as their pathophysiological relevance.

044
Metabolic Regulation by miR-33 in Macrophages Controls Immune Effector Responses
Kathryn J. Moore, *Hasini Ediriweera, U. Mahesh Gundra, Katey J. Rayner, P'ng Loke, Philip Zamore, Gregory Steinberg, Mireille Ouimet.* New York Univ. Sch. of Med., New York, NY; Univ. of Massachusetts Med. Sch., Worcester, MA; Univ. of Ottawa Heart Institute, Ottawa, ON, Canada; McMaster Univ., Hamilton, ON, Canada

045
MicroRNA Regulation of Endothelial Inflammation
Mark W. Feinberg. Brigham and Women's Hosp., Harvard Med. Sch., Boston, MA

046
Morphine Induced Exacerbation of Sepsis Is Mediated by Tempering Endotoxin Tolerance through Modulation of miR-146a
Sabita Roy, *Santanu Banerjee, Jingjing Meng, Sundaram Ramakrishnan.* Univ. of Minnesota, Minneapolis, MN

1030 – 1230, Harborview Ballroom

Symposium 14: Mucosal Immunity: Hot Topics in IBD

Co-Chairs
John Parkinson, Janssen R&D
Thaddeus Stappenbeck, Washington University School of Medicine

The Mucosal Immunology symposium highlights cutting edge basic and translational research into the molecular pathways that drive inflammatory bowel diseases (IBD) and that offer new approaches to drug discovery and disease treatment. Prof. Monteleone (Rome, Italy) will present the scientific rationale and promising mid-stage clinical trial results in moderate/severe Crohn's disease patients for the novel oral anti-sense DNA oligonucleotide GED-0301, which targets Smad7/TGFb signalling in regulatory T cells. Prof. Blumberg (Boston, USA) will provide a leading perspective on the interplay between ER stress, autophagy and other pathways identified in human GWAS studies as IBD susceptibility loci. His international collaborative network has exploited intestinal epithelial lineage-specific genetic modulation of these pathways in mice in order to break fundamentally new ground in understanding epithelial barrier function for mucosal homeostasis and pathology. Prof. Stappenbeck (St. Louis, USA) will present state-of-the-art studies to isolate, propagate and expand primary human intestinal stem cell-derived spheroid cultures from clinical biopsy samples of the gastrointestinal tract. This breakthrough offers an unprecedented path to obtain GI region-specific and differentiated epithelial cultures (stomach, ileum, colon, rectum) directly from patients and healthy donors and a platform with which to interrogate epithelial interactions with the human microbiome and effector immune cells.

047
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, in Active Crohn's Disease
Gerald Horan, *Giovanni Monteleone, Markus F. Neurath, Sandro Ardizzone, Antonio Di Sabatino, Massimo Claudio Fantini, Fabiana Castiglione, Maria Lia Scribano, Alessandro Armuzzi, Flavio Caprioli, Giacomo Carlo Sturniolo, Francesca Rogai, Maurizio Vecchi.* Celgene Corp, Summit, NJ; Univ. of Tor Vergata, Rome; Univ. of Erlangen-Nürnberg; "L. Sacco" Univ. Hosp., Milan; Univ. of Pavia; Hosp. San Camillo-Forlanini, Rome; Catholic Univ., Rome; Univ. of Milan; Univ. of Padova; AOU Careggi Univ. Hosp., Florence; "Casa Sollievo Sofferenza" Hosp., IRCCS; Univ. of Genoa; Sandro Pertini Hosp., Rome; Univ. of Palermo; Univ. "Federico II" of Naples, Italy

048
The Unfolded Protein Response and Intestinal Inflammation
Richard Blumberg. Harvard Med. Sch., Boston, MA

049
Emerging Utility of Cultured Intestinal Epithelial Cells in Personalized Medicine
Thaddeus Stappenbeck. Washington Univ. Sch. of Med., Saint Louis, MO

B209
Absence of Dietary Fibre or the Metabolite Sensor GPR43 Exacerbates Neutrophil Recruitment during Acute Inflammatory Responses
Connie H. Wong, Marjon Kamp, Raymond Shim, Ana Carolina Oliveira, Linda J. Mason, Lauren Binge, Charles R. Mackay. Monash Univ., Australia; Univ. Federal do Rio de Janeiro, Brazil

B032
A Novel Iron-Mediated Mechanism for Development of Inflammatory Bowel Disease
Shirly M. Belizowski, Abraham Nyska, Avi Zuckerman, Fabio Cominelli, Orly Savion, Esther Meyron-Holtz. Technion–Israel Institute of Technology, Haifa, Israel; Tel Aviv Univ. and Consultant in Toxicologic Pathology, Timrat, Israel; Aviv Projects, Ness Ziona, Israel; Case Western Reserve Univ., Cleveland, OH

1030 – 1230, Cityview Ballroom 2

Symposium 15: Inhibitory Receptor/ Immune Checkpoints/Immunotherapeutics – Sponsored by IRA-USA

Co-Chairs
Andrew Glasebrook, Eli Lilly Company
Alison O'Mahony, DiscoveRx Corp

Our immune system must maintain a fine balance between activation and inhibition; it is imperative that we are able to mount an effective immune response to target non-self molecules while simultaneously not harming self. Essential to this process is the ability to control the recognition, timing and location of activation plus subsequently limit and eventually stop the response. A family of inhibitory immune receptors, or checkpoints, has evolved to serve as "brakes" on the immune system with a goal of restoring homeostasis after an immune response. Failure to apply the brakes can lead to persistent immune activation and inflammation, while excessive braking can lead to immune suppression and cancer. Therapeutics that agonize or antagonize immune checkpoints therefore represent a new direction for development of disease-modifying drugs. The focus of this session will be on the novel development in targeting immune checkpoints for treating autoimmune and/or inflammatory diseases, using oncology examples where appropriate.

050
Prevention of Collateral Damage by Immune Inhibitory Receptors
Linde Meyaard. Univ. Med. Ctr. Utrecht, Netherlands

051
ITIM and ITAM Bearing Inhibitory Receptors on Treatment of Inflammatory Diseases
Renato C. Monteiro. Ctr. for Research on Inflammation, UMR 1149 INSERM; Inflamex Consortium; Paris Diderot Univ., Paris, France

No Abstract
Targeting Pilra Inhibitory Receptor in Inflammatory Diseases
Ali Zarrin, Genentech

1030 – 1230, Amphitheater

Symposium 16: Mechanisms of Fibrosis

Co-Chairs
Thomas Wynn, NIAID-NIH
Caralee Schaefer, Blade Therapeutics

Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix leading to organ scarring, which can ultimately contribute to organ failure. Fibrotic tissue remodeling is a final common pathway in many forms of chronic inflammatory disease affecting multiple organ systems. Nevertheless, the mechanisms leading to fibrosis are poorly understood and novel therapeutics that target the mechanisms of fibrosis have shown limited efficacy. Consequently, there is an urgent need to better understand the pathogenesis of fibrosis. This symposium will feature four presentations focusing on the mechanisms of fibrosis in a variety of organ systems.

052
Basic Mechanisms of Kidney Fibrosis
Jeremy S. Duffield. Biogen, Cambridge, MA; Univ. of Washington, Seattle, WA

No Abstract
Role of Fibroblasts and Stroma in Tumorigenesis
Raghu Kalluri. MD Anderson Cancer Center, Houston, TX

053
Targeting Nox Enzymes in Pulmonary Fibrosis
Victor J. Thannickal. Univ. of Alabama at Birmingham, Birmingham, AL

054
Combinatorial Targeting of TSLP, IL-25, and IL-33 and Type-2 Cytokine Signaling in Chronic Inflammation and Fibrosis
Kevin M. Vannella, Thirumalai R. Ramalingam, Allen W. Cheever, Lee A. Borthwick, Luke Barron, Kevin M. Hart, Robert W. Thompson, Kristen N. Kindrachuk, Sandra White, Alison L. Budelsky, Michael R. Comeau, Dirk E. Smith, ***Thomas A. Wynn.*** Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; BioMed. Research Institute, Rockville, MD; Institute of Cellular Med., Newcastle Univ., Newcastle upon Tyne, UK; Amgen, Seattle, WA

1030 – 1230, Waterfront Ballroom 1

Symposium 17: Therapeutics with Localized Actions – Optimal Ways to Treat Tissue Inflammation

Co-Chairs
Tatiana Ort, Janssen R&D
Jeff Karp, Brigham and Women's Hospital Harvard Medical School

Conventional drugs are distributed throughout the body through the systemic blood circulation and for most therapeutics, only a small portion reaches the organ to be affected. Targeted drug delivery aims to concentrate the therapeutic in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues. A drug can be targeted on the level of a whole organ, on the level of certain cells specific for a given organ, or even on the sub-cellular level of specific tissue. In this session, advances in the field of targeted drug delivery and new therapeutic platforms for treatment of tissue inflammation will be discussed.

055
Targeted Polymeric Nanoparticles: From Discovery to Clinical Trials
Omid C. Farokhzad. Brigham and Women's Hosp.; Harvard Med. Sch., Boston, MA

056
Immune Targeting Nanoparticles Containing siRNAs to Curtail Leukocyte-Implicated Diseases
Dan Peer. Tel Aviv Univ., Tel Aviv, Israel

No Abstract
Ultrasound-Mediated Gastrointestinal Drug Delivery
Giovanni Traverso. Harvard Med. Sch., Boston, MA

057
An Inflammation Responsive Platform for Controlled Drug Delivery
Nitin Joshi. Brigham and Women's Hosp. Harvard Med. Sch., Boston, MA

1030 – 1230, Beacon Hill Complex

Symposium 18: Ion Channels and Inflammation – Sponsored by IRN-Canada

Co-Chairs
Jason McDougall, Dalhousie University
Nathalie Vergnolle, INSERM

Ligand-gated and voltage-gated ion channels are major targets for inflammatory pain. Commonly, inflammation induced by injury, infections or autoimmune diseases drive the release of inflammatory mediators at the site of inflammation to activate and sensitize primary afferent sensory neurons. Ion channels participate in transducing inflammatory signals into neuronal signals leading to action potential propagation along the afferent pain pathway culminating in increased pain perception. In sensory neurons, activation of Transient Receptor Potential (TRP) Channels leads to the release of neuropeptides, which modulate the inflammatory response, through a process called neurogenic inflammation. Dr. Christophe Altier's work suggests that this physiological response contributes to the sensitization of TRPV1 channels in visceral afferents to promote the establishment of persistent visceral pain post colitis. More recently, TRP channels have also been described on cell types other than neurons, notably epithelial cells. Recent results from Dr. Mustapha Si-Tahar identified the calcium permeant TRPV4 and calcium dependent proteases calpains as key mediators of microbial-triggered lung inflammation. Along these lines, a growing body of evidences now suggests that ion channels participate in the generation of inflammatory responses to infection. Indeed, recent fascinating work from Dr. Clifford Woolf and colleagues proposes that following infection, a direct activation of primary afferent neurons by bacteria and bacteria products occurs independently of leukocyte, monocyte and lymphocyte recruitment (published in Nature 2013). Elsewhere, Dr. Felix Vianna's group recently identified the sensor of irritant stimuli, the transient receptor potential channel TRPA1, as the main mediator of lipopolysaccharide (LPS)-mediated pain and neurogenic inflammation (published in Nature Comm. 2014).

058
Bacterial Signals to Sensory Neurons That Modulate Inflammation and Pain
Isaac M. Chiu, *Clifford J. Woolf.* Harvard Med. Sch., Boston, MA; Boston Children's Hosp., Boston, MA

059
TRPA1 Channels Are Early Sensors of Gram-Negative Bacterial Endotoxins
Felix Viana, *Victor Meseguer, Yeranddy A. Alpizar, Enoch Luis, Sendoa Tajada, Bristol Denlinger, Jan-Albert Manenschijn, Otto Fajardo, Carlos Fernández-Peña, Arturo Talavera, Tatiana Kichko, Belén Navia, Alicia Sánchez, Rosa Señarís, Peter Reeh, María Ter.* UMH-CSIC, Alicante, Spain; KULeuven, Leuven, Belgium; UV-CSIC, Valladolid, Spain; Univ. of Erlangen-Nuremberg, Erlangen, Germany; Univ. of Santiago de Compostela, Spain

060
Role of the Cation Channel TRPV4 in Lung Inflammation
Mustapha Si-Tahar. INSERM U1100, Ctr. d'Etude des Pathol. Respiratoires (CEPR), Tours, France

061
Sensitization of the Transient Receptor Potential Vanilloid 1 Channel in Neurogenic Inflammation and Pain
Christophe Altier. Univ. of Calgary, Calgary, AB,Canada

1030 – 1230, Cityview Ballroom 1

Symposium 19: Harnessing Novel Resolution Mechanisms to Control Inflammation

Chair
Charles Serhan, Harvard Medical School

Uncontrolled inflammation is a unifying component of many diseases, including arthritis, asthma, vascular diseases, neurodegenerative diseases and cancer, which are now all recognized as 'inflammatory diseases'. While excess inflammation alone is not likely causative in these diseases, it plays a key role in progression and ultimately organ failure. New evidence indicates that resolution of inflammation is an active process driven by multiple chemical mediators. Elucidation of the biochemical pathways contributing to the resolution of inflammation has provided many new anti-inflammatory and pro-resolution target receptors and signaling as well as an opportunity for resolution-based pharmacology for treatment. This symposium will present recent discoveries and advances in the field from Investigators at the cutting edge and founders of this new field that holds promise for clinical translation to human disease.

062
Resolvins and SPM in Resolution and Their Relationship to Infection and Tissue Regeneration
Charles N. Serhan, *Jesmond Dalli, Nan Chiang, Paul Norris, Sesquile Ramon, Romain Colas.* Harvard Institutes of Med.; Brigham and Women's Hosp.; Harvard Med. Sch., Boston, MA

063
Therapeutic Innovation in Inflammation: Targeting Pro-resolving Receptor Signaling
Mauro Perretti. Queen Mary Univ. of London, London, UK

064
Mechanisms of Inflammatory Resolution in Humans
Derek W. Gilroy. University Col. London, UK

1230 – 1400, Beacon Hill Complex

Smooth Transitions – Top 10 List: Things Scientists Ask about Moving Out of Academia

These days, staying in academia is really the "alternative" career for scientists. The majority of young scientists will not end up in a traditional academic research position. This presentation will give you some criteria to consider in deciding which non-academic path may be right for you and then will provide concrete tools and resources for preparing for a transition. Boxed lunches will be served. There is no fee to attend, but pre-registration and a ticket are required for a boxed lunch. You may register on-site at the WCI registration counter in the Atrium Lobby. Registration will be on a first-come, first-served basis. If you are interested in attending and did not register, you are welcome to participate on a space-available basis.
Speaker
Joanne Kamens, Addgene

1230 – 1430, Exhibit Hall, Commonwealth Complex

Poster Viewing/Lunch Break

Concession open for lunch purchase.

1430 – 1630, Waterfront Ballroom

Symposium 20: Skeletal Muscle Inflammation

Co-Chairs
Stephen A. Stimpson, Bristol-Myers Squibb
David Glass, Novartis

Skeletal muscle is more important that you know! Loss of skeletal muscle mass and function are critical determinants of morbidity and mortality in many common inflammatory diseases and cancer (cachexia) and aging (sarcopenia), and genetically-defined diseases such as muscular dystrophies. While inflammation is known to play critical roles during injury and repair in many tissues, its role in skeletal muscle is less understood. New work is pointing to important roles for inflammation, as well as related innate and adaptive immune processes, in skeletal muscle physiology. This symposium will examine the role of inflammatory pathways in the healthy regenerative response to tissue injury as well as pathophysiologic roles that suggest potential new therapeutic approaches in skeletal muscle disease.

No Abstract
NFkB Signaling as a Regulator of Muscle Pathology in Duchenne Muscular Dystrophy
Denis Guttridge. Ohio State University

065
Different Macrophage Subsets Control Matrix Remodeling and Fibrosis during Muscle Regeneration versus Chronic Degenerative Myopathies
Bénédicte Chazaud, *Marielle Saclier, Gaëtan Juban, Lin Yang, Basil J. Petrof, Rémi Mounier.* Univ. Claude Bernard Lyon 1, Villeurbanne; Institute Cochin, INSERM, Paris; Univ. of Florida, Gainesville; McGill Univ., Montreal, Canada

066 *Canceled*
Cytokine-Modulated Cellular Responses in Skeletal Muscle Damage and Repair
Andrew N. Billin. GlaxoSmithKline, Durham, NC

067
Modulation of Fibrosis by Inflammatory Cells Disrupted in Chronic Muscle Injury
Fabio Rossi, *Dario Lemos, Farshad Babaeijandaghi, Marcela Low, Chih–Kai Chang, Daniela Fiore, Regan–Heng Zhang, Sergei Nedospasov, A. Nedospasov.* Univ. of British Columbia, Vancouver BC, Canada; Sapienza Univ. of Rome, Italy; Engelhardt Institute of Molecular Biology and Lomonosov Moscow State Univ., Moscow, Russia; German Rheumatism Research Ctr., Berlin

No Abstract
Signaling Mechanisms Maintaining Muscle Homeostasis
David Glass. Novartis Institutes for Biomedical Research, Cambridge, MA

1430 – 1630, Harborview Ballroom

Symposium 21: Regulation of Inflammation in Tissues by Co-Stimulatory and Co-Inhibitory Pathways

Chair
Arlene Sharpe, Harvard Medical School

T cell co-stimulatory and co-inhibitory pathways play critical roles in regulating T cell activation, tolerance and inflammation. This session will focus on the roles of these key immunoregulatory pathways in regulating anti-tumor immunity, autoimmunity and resolution of inflammation.

068
Targeting Co-inhibitory Receptors in Cancer
Ana C. Anderson. Harvard Med. Sch.; Brigham and Women's Hosp., Boston, MA

069
Control of Fibrotic Activity in the Lung and Skin by LIGHT (TNFSF14)
Michael Croft. La Jolla Institute for Allergy and Immunol., La Jolla, CA

070
Immunoregulatory Mechanisms That Limit Autoimmunity and Cancer
Dario A.A. Vignali. Univ. of Pittsburgh, PA

No Abstract
Inhibition of beta1 Integrin Signaling by CD80/B7-1: from Bench to Bedside
Peter Mundel. Harvard University, Boston, MA

1430 – 1630, Amphitheater

Symposium 22: Atopic Dermatitis, Psoriasis and IL-4/IL-17 Biology

Co-Chairs
Emma Guttman-Yassky, Mount Sinai Medical Center
Jennifer Hamilton, Regeneron Pharmaceuticals, Inc.

Psoriasis has been a model disease for translational medicine. Targeted therapeutics have not only provided great therapeutic benefit in psoriasis, but also resulted in a better understanding of the underlying inflammatory pathogenic drivers. These efforts have established psoriasis as a Th17/IL-23 driven disease, and opened the door to a similar approach for another common inflammatory skin disease, atopic dermatitis. New targeted therapies are in development for atopic dermatitis, and show promising results in early phase trials for atopic dermatitis, as well as asthma and other Th2-mediated diseases. Through targeted therapeutics we will be able to understand key disease mechanisms and differentiate disease endotypes.

071
Psoriasis: An IL-23/Th17-Driven Disease
James Krueger. The Rockefeller Univ., New York, NY

072
The Translational Revolution in Atopic Dermatitis Ctr.ed on Th2/Th22 Cytokines
Emma Guttman-Yassky. Icahn Sch. of Med. at Mount Sinai Med. Ctr., New York, NY

073
From Pathway to Targeted Therapy: IL-4 and IL-13 in Allergic Diseases
Jennifer D. Hamilton. Regeneron Pharmaceuticals Inc., Tarreytown, NY

074
Prediction of Clinical Therapeutic Responses in Inflammatory Skin Diseases Based on Early Time Point Gene Expression Data
Mayte Suarez-Farinas, *Joel Correa da Rosa.* Mount Sinai Sch. of Med.; Rockefeller Univ., New York, NY

1430 – 1630, Waterfront Ballroom 2

Symposium 23: Defining Sub-Phenotypes in Chronic Respiratory Diseases to Improve Drug Development and Disease Management

Co-Chairs
Chris Stevenson, RespiVert, Ltd.
Avi Spira, Boston University

The goal of the session is to describe current approaches aiming to refine disease management by identifying the clinical and molecular characteristics that define sub-groups of patients who suffer from chronic pulmonary syndromes, such as asthma, COPD and IPF. Examples of how these approaches can impact target selection, choices for clinical outcomes, and enrollment criteria to improve clinical development programs will be discussed.

075
Biomarker Discovery and Companion Diagnostic Development in Asthma
Joseph R. Arron. Genentech Inc., South San Francisco, CA

076
Integrating Clinical and Molecular Features to Identify Distinct Asthma Sub-Phenotypes
Frederic Baribaud. Janssen R&D, Springhouse, PA

No Abstract
Translating the Airway and Lung Transcriptome into Personalized Approaches to COPD Management
Avi Spira. Boston University, Boston, MA

1430 – 1630, Cityview Ballroom 2

Symposium 24: Biological and Non-Biological Therapies of Autoimmune Diseases – Sponsored by JSIR-Japan

Co-Chairs
Ikuo Morita, Tokyo Medical and Dental University
Tetsuya Taga, Tokyo Medical and Dental University

There has been a much progress in in improving the prognosis of autoimmune disease patients. This has been achieved by the development of new treatment strategies with the use of biological and non-biological drugs. The bottom line is the successful translation of basic biological findings into new protein-based drugs and the optimization of the use of key non-biologic drugs. From the viewpoint that we need to take these both

into consideration in treating the autoimmune patients with a variety of backgrounds and health conditions, this symposium is aimed to bring together scientists for discussion on fundamentals and applied aspects of biological and non-biological therapiadcioces of autoimmune diseases.

077
Molecular Understanding of Targeted Therapies in Patients with Rheumatoid Arthritis
Tsutomu Takeuchi. Keio Univ. Sch. of Med., Tokyo, Japan

078
Low Molecular Weight Immunosuppressant Therapy of Autoimmune Diseases
Shinichi Kawai. Toho Univ. Sch. of Med., Tokyo, Japan

B034
Wonderbumin: A Fully Synthetic Alternative to IgT for Autoimmune Disease
Anne S. De Groot, Filipa Antunes, Eduardo Guillen, Sandra Lelias, Ryan Harvey, Christine Boyle, William Martin, Paul Barrett, Darrell Sleep. EpiVax Inc., Providence, RI; Univ. of Rhode Island; Novozymes Biopharma Ltd., Nottingham, UK

B047
Neutralizing the Pro-metastatic Immune Responses of MDSC and T Cells through B Cell Targeting
Monica Bodogai, Kanako Moritoh, Catalina Lee Chang, Christine M. Hollander, Li Yang, Robert Wersto, Arya Biragyn. Natl. Institute on Aging, NIH, Baltimore, MD; Natl. Cancer Institute, NIH, Bethesda, MD

1430 – 1630, Cityview Ballroom 1

Mini-Symposium 2: Cellular and Molecular Mechanisms of Fibrosis

Chair
Leon Collis, Pfizer, Inc.

Fibrosis is a disease area with significant therapeutic and diagnostic challenges, driven in part by a current lack of understanding of the cellular and molecular pathways responsible. This mini-symposium will review current thoughts around numerous aspects of the pathogenesis of fibrosis, including the roles of the innate and adaptive immune systems and utility of these pathways as therapeutic targets. This series of talks will also examine the diversity of fibrogenic cells and the novel tools used to assess cell and tissue phenotypes.

B093
Lineage Tracing of Resident Fibroblasts by the Intratracheal Cell Transfer Elucidates the Cellular Origin of Activated Fibroblasts in Pulmonary Fibrosis
Tatsuya Tsukui, Satoshi Ueha, Shigeyuki Shichino, Yutaka Inagaki, Kouji Matsushima. Grad. Sch. of Med., Univ. of Tokyo, Japan; Grad. Sch. of Med., Tokai Univ., Kanagawa, Japan; Japan Science and Technol. Agency-CREST Program, Tokyo, Japan

B097
Crosstalk between Macrophages and Human Hepatic Fibroblasts Show That Inflammatory Response Attenuate the Activation of Fibroblasts in the Fibrosis Response
Sacha Robert, Thomas Gicquel, Aude Bodin, Alain Fautrel, Vincent Lagente, Elisabeth Boichot. UMR991 INSERM and H2P2, Univ. de Rennes, France

B094
Pericyte MyD88 Controls Inflammatory and Fibrotic Responses to Tissue Injury
Irina Leaf, Ivan Gomez, Shunsaku Nakagawa, Bryce Johnson, Jin Joo Cha, Julia Lichtnekert, Kristen Mittelsteadt, Alan Aderem, Bill Altemeier, Jeremy Duffield. Biogen, Cambridge, MA; Univ. of Washington, Seattle; Seattle BioMed, Seattle, WA

B095
Polycystic Liver Disease Is Suppressed by IL-4/IL-13 and TGF-ß Signaling
David A. Cantu, Kristen Kindrachuk, Lee Borthwick, Doug Morris, Danielle Donahue, David Dorwood, Brenda Klaunberg, Thirumalai Ramalingam, Sandy White, Robert Thompson, Thomas Wynn. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Magnetic Resonance Imaging Research Facility/Mouse Imaging Facility, NIH, Bethesda, MD; Research Technologies Branch, NIAID/Rocky Mountain Labs, Hamilton, MT

B096
Evaluating IL-13Ra2 as a Therapeutic Target for Pulmonary Fibrosis
Nikhil Jiwrajka, Thirumalai Ramalingam, Josh Sciurba, Sandy Oland, Rafael Prado, Kevin Hart, Trisha Pasricha, Kevin Vannella, Bernadette Gochuico, Marion T. Kasaian, Thomas A. Wynn. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Natl. Human Genome Research Institute, NIH, Bethesda, MD; Pfizer Research, Cambridge, MA

B091
Identification of Both Immunomodulatory and Anti-fibrotic Actions of Nintedanib and Pirfenidone Using Biomap® Human Primary Cell-Based Disease Models
Sharlene Velichko, Sylvie Privat, Dat Nguyen, Hannah Cho, Alison O'Mahony. BioSeek, a division of DiscoveRx,, South San Francisco, CA

B025
The Syk Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma Mouse Model: Efficacy in Syk Inhibition in Animal Scleroderma
Omer N. Pamuk, Guray Can, Sulayman Can, Turan Karaca, Gulsum E. Pamuk, Selim Demirtas, George C. Tsokos. Trakya Univ. Med. Faculty, Istanbul, Turkey; Harvard Univ. Med. Faculty, Boston, MA

1430 – 1630, Beacon Hill Complex

New Investigator Award Winner Presentations

Chair
John Somerville, Bristol-Myers Squibb (ret.)

B061
Combating Skin Inflammation with CXCL12 Chemokine Neutraligands
Dayana Abboud. CNRS, Univ. de Strasbourg, Illkirch, France

B050
The Role of Resolvin D1 in the Regulation of Inflammatory and Catabolic Factors in Osteoarthritis
Houda Benabdoune, *Shi Qin, Julio Fernandes, Pierre Ranger, Hassan Fahmi, Mohammed Benderdour.* Univ. de Montréal, Hôp. du Sacré-Cœur de Montréal; Ctr. hospitalier de l'Univ. de Montréal, Quebec, Canada

B099
Acetate Protects the Ischemic Intestine from Reperfusion Injury
Zoe V. Schofield, *Reena Halai, Matthew A. Cooper, Trent M. Woodruff.* Sch. of Biomed. Science, The Univ. of Queensland, Brisbane, Australia

B246
Identification of CD44bright, a Novel Subset of Uterine NK Cells Correlated to Abortion in Recurrent Pregnancy Loss Model Mice
Jun Tanaka, *Yuki Fukunaga.* Japan Blood Products Org., Kobe, Japan

B266
A Novel Role for BK Channel in Regulating Metalloprotease Activity
Minae Yoshida, Dean Willis. University Col. London, London, UK

1630 – 1800, Exhibit Hall, Commonwealth Complex

Poster Session and Mixer

1830 – 2000, Cityview Ballroom 1

Not Networking 101 – Building Relationships for Success

Networking has gotten a really bad name these days. I take your card, you take my card and then we don't call each other. This workshop is designed to reintroduce you to how strong professional relationships can be necessary for most people to succeed in their careers. It will provide practical tools for meeting people and for nurturing new and established connections. Refreshments will be available. Advance registration is required. You may register on-site at the WCI registration counter in the Atrium Lobby.
Speaker
Joanne Kamens, Addgene

Tuesday, August 11, 2015

0800 – 0900, Harborview Ballroom

Patient Perspectives: Unmet Medical Need – Lupus

Chair
Heather Jones, Pfizer, Inc.

Objective: To increase awareness of the true unmet medical need left by current therapeutic options for SLE and understand what this means to the patient.

The importance of recognizing the true unmet medical need in autoimmune diseases is higher than ever. No drug has so far been able to cure the SLE, only to induce remission. To progress science and clinical development there must be a focus on understanding the pathogenesis of the disease. From a medical perspective we need to consider the patient as a whole human being and not only based on the organ(s) involved. Autoimmune diseases are systemic, in most cases affecting more than one organ.

The morning session will begin by emphasizing the unmet medical need followed up by an interview of a patient with SLE, telling their story, with an emphasis on what they see as key objectives for further development.

At the end of the session the chair will summarize the signs and symptoms and the treatment algorithm for SLE, as well as the need for biomarkers to define the disease, ensure safety, guide treatment and predict treatment response.

079
Patient Perspectives on Systemic Lupus Erythematosus
Heather Jones. Pfizer Inc., Collegeville, PA

0900 – 1000, Harborview Ballroom

Keynote Lecture

Immunological Control of Non-immunological Processes
Diane Mathis. Harvard Medical School, Boston, MA

1000 – 1030, Exhibit Hall, Commonwealth Complex

Coffee Break

1030 – 1230, Waterfront Ballroom 1

Symposium 25: Complement Targeted Therapies – Is There Light at the End of the Tunnel?

Co-Chairs
Cara Williams, Pfizer, Inc.
Simeon Ramsey, Pfizer, Inc.

The complement system forms a critical component of the innate defense against microbial infection. Its main biological function is to recognize and eliminate pathogenic microorganisms through opsonisation, lysis and the orchestration of a classical inflammatory response through the generation of potent proinflammatory anaphylatoxins. The complement system plays a similar role in the detection and clearance of damaged host components. As well as generating an innate inflammatory response the complement system serves a role in the regulation of the adaptive immune system by controlling certain functions of B-cell and T-cell biology (viability, proliferation and amplitude of response).

Dysregulation of the complement system has been implicated in the pathogenesis and progression of various inflammatory diseases and syndromes. Excessive and inappropriate complement activation can cause tissue damage in diseases such as rheumatoid arthritis and syndromes including sepsis. Insufficient activity can increase the susceptibility to infection and development of autoimmune diseases including systemic lupus erythematosus.

Over the past three decades a plethora of attempts have been made to regulate the actions of the complement system through therapeutic intervention. However with the exception of the C5 specific antibody Eculizumab (Solaris®) there has been little success. This could all be set to change with two agents that target the actions of C5a reaching pivotal stages in clinical development. Is this nut about to be cracked and if so will these agents provide breakthrough therapies in the treatment of acute and chronic inflammatory diseases that affect the lives of millions of people worldwide?

080
Linkages between Complement, Histones and Acute Lung Injury
Peter A. Ward. Univ. of Michigan Med. Sch., Ann Arbor, MI

081
Fine-Tuning Inflammation: 'Designer' Ligands for the Complement Peptide Receptors
Peter N. Monk. Univ. of Sheffield, Sheffield, UK

082
Compstatin Cp40: An Immune Modulator on a Journey from Disease Models to Clinical Development
John D. Lambris, *Alexandra Primikyri, Sophia Koutsogiannaki, Malvina Papanastasiou, Jihyoung Seong, HongBin Wang, Gang Chen, Markus Huber-Lang, Martijn van Griensven, Bo Nilsson, Kristina Nilsson-Ekdahl, Alireza Biglarnia, Richard J. Smith, George Hajishe.* Univ. of Pennsylvania Perelman Sch. of Med., Philadelphia, PA; Huazhong Univ. of Science and Technology, Wuhan, China; Ulm Univ., Germany; Technical Univ. Munich, Germany; Uppsala Univ., Sweden; Univ. of Iowa, Ames, IA; Univ. of Pennsylvania Sch. of Dentistry, Philadelphia, PA; Amyndas Pharmaceuticals, S.A., Glyfada, Greece; Federico II Univ., Naples, Italy

083
A Subcutaneously Administered RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement Mediated Diseases
Anna Borodovsky, *Benny Sorensen, Jorg Taubel, James Bush, Noriyuki Kawahata, Lauren Melton, Jeffrey Cehelsky, Christine Powell, Kristina Yucius, Prasoon Chaturvedi, Garvin Warner, David Salant, V. Michael Holers, Nirmal Banda, Linda Kusner, Henry Kaminski.* Alnylam Pharmaceuticals, Cambridge, MA; Richmond Pharmacology, London, UK; Covance Clinical Research Unit, Huddersfield, UK; Boston Univ. Med. Sch.; Univ. of Colorado Med. Sch.; George Washington Sch. of Med., Washington, DC

1030 – 1230, Waterfront Ballroom 2

Symposium 26: Regenerative Medicine and Stem Cells in Inflammation

Chair
Lynne Murray, MedImmune

Chronic disease in multiple tissue sites is associated with a deficiency in endogenous stem cell function and impaired repair mechanisms. This session will look at how regenerative medicine, and in particular stem cell biology, could be a novel approach to help promote repair. Moreover, mechanisms that regulate stem cell number and function will be presented.

084
The Role of Stem Cell Exhaustion in Aging and Disease
Johnny Huard. Univ. of Texas Health Science Center at Houston, Houston, TX

085
Inhibiting Chronic Skeletal Muscle Inflammation in Aging Restores the Satellite Cell Niche and Improves Muscle Regeneration
Amy J. Wagers. Harvard Univ., Cambridge, MA

No Abstract
p53 Regulation of Airway Epithelial Progenitor Cells in Homeostasis and Disease
Barry Stripp. Cedars-Sinai Medical Center

B121
Dysregulation of Resolution of Acute Inflammation in Aged Humans
Roel P.H. De Maeyer, Madhur Motwani, Justine S. Newson, Derek W. Gilroy. Ctr. for Clinical Pharmacology and Therapeutics, University Col. London, UK

B190
Protective Effect of Hematopoietic Stem Cells in Stroke
Felicity N.E. Gavins, Helen K. Smith, Shantel Vital, D. Neil Granger. LSU Health Sciences Ctr.-Shreveport, LA

1030 – 1230, Harborview Ballroom

Symposium 27: iNKT Cells – Mediators at the Interface of Inflammation and Immunity

Co-Chairs
Robert Schaub, NKT Therapeutics, Inc.
Jenny Gumperz, University of Wisconsin – Madison

Invariant Natural Killer T (iNKT) cells are a subset of innate T lymphocytes that have attracted attention for their ability to influence outcomes of a wide variety of different immune responses. They do this by rapidly producing cytokines and other factors in response to either exogenous compounds (e.g. foreign microbes) or endogenous signals (e.g. danger-associated molecular patterns). Their expression of a unique semi-invariant T cell receptor, allows iNKT cells to be readily and specifically targeted for clinical applications. Activation or inhibition of iNKT cells in vivo is a therapeutic approach that may be valuable for treating diverse types of inflammatory responses. This session will provide an overview of the biology of iNKT cells, and then discuss emerging insights into their functions in the context of acute inflammation, methods for imaging and tracking iNKT cells in vivo, and their roles in cancer and intestinal inflammation.

086
Human Invariant Natural Killer T Cells Activate Monocyte-Derived DCs to Initiate a Pathway of Sterile Inflammation That Promotes Host Defense
Jenny E. Gumperz. Univ. of Wisconsin Sch. of Med. and Publ. Health, Madison, WI

087
Imaging iNKT Cells In Vivo – Different Functions in Different Organs
Paul Kubes. Univ. of Calgary, AB, Canada

088
Harnessing the Immunostimulatory Properties of Invariant Natural Killer T (iNKT) Cells in Novel iNKT Cell-Based Therapies for Cancer
Rupali Das, Peng Guan, Elizabeth Evans, Felix Scheuplein, Maurice Zauderer, Robert Schaub, ***Kim E. Nichols.*** Children's Hosp. of Philadelphia, Philadelphia, PA; Vaccinex, Inc. Rochester, NY; NKT Therapeutics, Waltham, MA; St. Jude Children's Research Hosp., Memphis, TN

089
iNKT Cells – Mediators at the Interface of Inflammation and Immunity
Torsten Olszak, Dingding An, Joana F. Neves, Marie Dowds, Sungwhan Oh, Arthur Kaser, Dennis Kasper, Sebastian Zeissig, ***Richard S. Blumberg.*** Brigham and Women's Hosp.; Harvard Med. Sch.; Univ. Med. Ctr. Schleswig-Holstein, Kiel, Germany

1030 – 1230, Beacon Hill Complex

Symposium 28: Infection and Inflammation – Sponsored by BIS-Brazil

Chair
Mauro Teixeira, Universidade Federal de Minas Gerais

Inflammation is an essential part of the host response to infection. The influx of cells and plasma extravasation provide a first line of defense against infection and prime the immune system to mount an adequate adaptive immune response. However, inflammatory responses may cause undesired tissue damage and contribute to disease after certain infections. In this symposium, we will discuss molecular mechanisms of inflammation during infection and how unraveling these mechanisms may aid in the development of novel adjunctive therapies for infectious diseases.

090
Mechanisms Involved in the Immune-Dysfunctions Induced by Severe Sepsis
Fernando Q. Cunha. Univ. of São Paulo, Sch. of Med. Ribeirão Preto, Brazil

091
Specialized Pro-resolving Mediators in Lung Inflammation and Injury
Bruce D. Levy. Brigham and Women's Hosp.; Harvard Med. Sch., Boston, MA

092
Chikungunya Virus-Induced Inflammatory Disease
Suresh Mahalingam. Griffith Univ., Gold Coast, QLD, Australia

093
Mechanisms of Disease and Protection during Viral Infections
Mauro M. Teixeira, *Luciana Padua, Cristiana C. Garcia, Daniele G. Souza.* Univ. Federal de Minas Gerais; Institute de Oswaldo Cruz, Fiocruz; Belo Horizonte, Brazil

1030 – 1230, Cityview Ballroom 2

Symposium 29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis

Co-Chairs
Anthony Marotta, Augurex Life Sciences Corp.
Eric Sasso, Crescendo Bioscience

Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory disease that typically requires lifelong monitoring and adjustment of treatment to limit irreversible joint damage and physical disability. The diagnosis of RA and the long-term monitoring of RA disease activity are based predominantly on signs and symptoms, including physical examination of joints. Objective, biomarker measurements are needed to improve the understanding of RA heterogeneity and to optimize use of the many available therapies. Dr. Iain McInnes will discuss recent advances made in defining biosignatures that may predict natural history and therapeutic response characteristics in RA. He will also address unresolved issues surrounding the challenges of using transcriptomics, proteomics and metabolomics to define a molecular profile for RA. Dr. Anthony Marotta will discuss the role of the mechanistic blood protein biomarker, 14-3-3eta, for the management of RA. Dr. Eric Sasso will discuss Vectra DA, a multi-biomarker blood test that measures RA disease activity and is a predictor of risk for future joint damage. Dr. Charles Peterfy will review the performance of magnetic resonance imaging (MRI) for assessing inflammation and structural damage in patients with RA, and will elucidate the capabilities of MRI for clinical trials and its role in clinical practice.

094
Towards a Molecular Taxonomy in Rheumatoid Arthritis – Can We Derive Clinically Useful Prognostics and Therapeutic Predictors?
Iain B. McInnes. Univ. of Glasgow, Scotland, UK

095
14-3-3η: A Joint-Derived Marker with Autoimmune and Personalized Medicine Applications
Anthony Marotta. Augurex Life Sciences Corp., North Vancouver, BC, Canada

096
Vectra DA, a Multi-biomarker Disease Activity Blood Test That Predicts Risk for Joint Damage in Patients with Rheumatoid Arthritis
Eric H. Sasso. Crescendo Bioscience, South San Francisco, CA

097
MRI Biomarkers for Disease Activity and Structural Damage in Rheumatoid Arthritis
Charles Peterfy. Spire Sciences Inc., Boca Raton, FL

1030 – 1230, Amphitheater

Symposium 30: SLE: Current Therapeutic Landscape and Future Promises

Co-Chairs
Li Chun Wang, AbbVie Bioresearch Center, Inc.
Tim Zheng, Biogen

Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disorder with multi-organ involvement. While recent clinical trial experiences continue to highlight the complex nature of SLE, both genetic and translational studies in the past decade have also revealed potential molecular and cellular mechanisms underlying both disease pathogenesis and heterogeneity. This session will focus on how these basic science and clinical advancements in recent years have begun to change the clinical management of SLE and yielded promising therapeutic approaches based on targeting novel SLE disease mechanisms and innovative patient stratification strategies.

No Abstract
SLE Clinical Landscape Covering Both Trial Experiences and Potential Promising Therapeutics on the Horizon
Betty Diamond. The Feinstein Institute for Medical Research, Manhasset, NY

132 *See addendum for abstract*
SLE Signatures and its Potential Implication in Patient Stratification Strategies
Virginia Pascual. Baylor Institute for Immunology Research, Dallas, TX

098
Modulation of Plasmacytoid Dendritic Cells for Treating Autoimmune Diseases like Lupus
Jo Viney. Biogen, Cambridge, MA

No Abstract
Rare and Common Risk Variants in Systemic Lupus Erythematosus
Robert Graham. Genentech, South San Francisco, CA

1030 – 1230, Cityview Ballroom 1

Mini-Symposium 3: Mechanisms Driving Mucosal Inflammation in the Gut

Chair
Anthony Slavin, AbbVie

This mini symposium focuses on the utility of animal models for interrogating the mechanisms involved in the pathogenesis of Inflammatory Bowel Disease, Crohn's Disease and other inflammatory conditions in the gut. The talks will highlight the cells and genes involved in modulating immune responses in the gut and how these translate to human patients.

B031
Multiple Mesenteric Lymphatic Anomalies in Murine Crohn's Disease
Pierre-Yves von der Weid, Sonia Rehal. Univ. of Calgary, AB, Canada

B028
Enhancements to the Predictability and Clinical Relevance of Two Murine Models of Chronic Inflammation: Adoptive Transfer-Induced Colitis and GVHD
Dominic R. Beal, Sean M. Graham, Brett Van Dam, Gregory D. Lyng, Stephen T. Sonis. Biomodels LLC, Watertown, MA

B215
Critical Role of Plasmacytoid Dendritic Cells in Immunoregulation Initiated by a Commensal Microbial Polysaccharide
Suryasarathi Dasgupta, Dennis L. Kasper. Harvard Med. Sch., Boston, MA

B013
Suppressing Inflammatory Bowel Disease by Modulating Pro-inflammatory Gene Expression and Immune Cell Populations
Anh T. Do, Praveer Gupta, Abishek Iyer, David P. Fairlie. Univ. of Queensland, St. Lucia, Australia

B020
Amelioration of Chronic Colitis in Mice by Genetic Deletion of the IL-13 Decoy Receptor
Trisha Pasricha, Thirumalai Ramalingam, Thomas Wynn. Natl. Inst. of Allergy and Infectious Diseases, NIH, Bethesda, MD

B252
Filgotinib, JAK1-Selective Inhibitor, Represses Similarly JAK1/STAT3 Pathway in the Colon of Mice with DSS-Induced Colitis and in Cultures of Colon Biopsies from Inflammatory Bowel Disease Patients
Sonia Dupont, Carole Delachaume, Veerle De Vriendt, Debby Laukens, Béatrice Vayssière, Didier Merciris, Steve De Vos, Marie-Christine Ceccotti, Christelle David, Laetitia Perret, Martine De Vos, Reginald Brys, René Galien. Galapagos SASU, Romainville, France; Galapagos NV, Mechelen, Belgium; Ghent Univ. Hosp., Belgium

1230 – 1330, Beacon Hill Complex

Meet the Professionals

This year IAIS and IRA will have a "Meet the Professionals" session on Tuesday, August 11, 2015 from 1230-1330. The purpose on this session is to allow attendees the opportunity to meet our Keynote Speakers who are the leading experts in their field, learn about the speaker's professional experiences, ask questions for which there was not enough time in the sessions, and foster interaction and collaboration among attendees. We strongly encourage you to participate in this session. Boxed lunches will be served. There is no fee to attend, but pre-registration and a ticket are required for a boxed lunch. You may register on-site at the WCI registration counter in the Atrium Lobby. Registration will be on a first-come, first-served basis. If you are interested in attending and did not register, you are welcome to participate on a space-available basis.

1230 – 1430, Exhibit Hall, Commonwealth Complex

Poster Viewing/Lunch Break

Consession open for lunch puchase

1430 – 1630, Cityview Ballroom 2

Symposium 31: New Visions in Ocular Therapy

Co-Chairs
Lisa Schopf, Kala Pharmaceuticals
Rod Flower, William Harvey Research Institute

Leaders in the field of ophthalmology will present their cutting edge research on new directions and novel approaches to tackle inflammatory conditions in the eye.

No Abstract
Exploiting the Annexin-A1 Pathway to Treat Ocular Allergic Inflammation
Samia Yazid. TRIO Medicines Ltd, London, UK

No Abstract
Targeting Effector Memory T Cells in Ocular Inflammation
Richard Lee. University of Bristol, UK

099
Topical Delivery of Novel Mucus-Penetrating RTKis for Successful Angiogenesis Blockade
Lisa R. Schopf, *Elizabeth M. Enlow, Pawel Nowak, Winston Ong, Jim Bourassa, Kim Brazzell, Hongming Chen.* Kala Pharmaceuts., Waltham, MA

1430 – 1630, Cityview Ballroom 1

Symposium 32: Tregs in Human Autoimmunity

Co-Chairs
David Huss, Biogen
Marc Gavin, Benaroya Research Institute

Regulatory T (Treg) cells are critical mediators of immune tolerance to self. Treg cell dysfunction is implicated in the pathogenesis of numerous human autoimmune and autoinflammatory diseases. This symposium will focus on novel aspects of Treg cell dysfunction in human autoimmunity and present a number of current therapeutic approaches to modulate Treg cell number and function.

100
Are miRNAs Responsible for the Treg Defects Observed in Multiple Sclerosis?
Amy Lovett-Racke, *Mary Severin, Mireia Guerau-de-Arellano, Michael Racke.* The Ohio State Univ., Columbus, OH

101
Disentangling the Roles of IL-2 in Immune Activation and Suppression
Jason D. Fontenot. Biogen, Cambridge, MA

No Abstract
High-Throughput Phenotypic Screening Identifies a Small-Molecule that Induces the Expression of FOXP3 in Human T Cells
Jonathan Hill. GlaxoSmithKline, Cambridge, MA

102
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
David J. Huss, *Devangi S. Mehta, Akanksha Sharma, Xiaojun You, Katherine A. Riester, James P. Sheridan, Lakshmi S. Amaravadi, Jacob S. Elkins, Jason D. Fontenot.* Biogen, Cambridge, MA; AbbVie Biotherapeutics, Redwood City, CA

103
Modulating IL-2/IL-2R Interactions to Therapeutically Shift the Balance between Regulatory T Cells and Effector Lymphocytes
Marc A. Gavin, *Li Li, Dina Alcorn, Margaret Karow, Jacqueline Kirchner, Kevin Gorski, David Martin, Katsu Ishida, Guna Kannan, Joshua Pearson.* Benaroya Research Institute, Seattle, WA; Amgen Inc., Thousand Oaks, CA

1430 – 1630, Waterfront Ballroom 1

Symposium 33: Gaseous Mediators as the Basis for Novel Anti-Inflammatory Drugs – Sponsored by IRN-Canada

Co-Chairs
John Wallace, University of Calgary
Jane Mitchell, Imperial College London

Endogenous gaseous molecules are increasingly implicated in many physiological and pathophysiological processes. This session will provide a review of the state-of-the-art knowledge of this class of signaling molecules, which includes nitric oxide, carbon monoxide and hydrogen sulfide. Leading experts will provide overviews of the roles of each of these mediators in disease processes, and the potential for development of novel therapies based on release of a gaseous mediator.

104
It's Just the Beginning – NO, CO, H2S and Other Gasotransmitters
Rui Wang. Laurentian Univ., Sudbury, ON, Canada

No Abstract
Carbon Monoxide
Jane Mitchell. Imperial College London, UK

105
Hydrogen Sulfide-Based Anti-inflammatory Therapeutics
John L. Wallace. Univ. of Calgary, Canada

106
Switching "Off" Chronic Neuropathic Pain by Switching "On" the A3 Adenosine Receptor Subtype
Daniela Salvemini. Saint Louis Univ. Sch. of Med., St. Louis, MO

1430 – 1630, Beacon Hill Complex

Symposium 34: Therapeutic Pathways in Inflammation: New Faces of Old Friends – Sponsored by RIS

Co-Chairs
Liudmila Buryachkovskaya, Russian Cardiology Research Complex
Nikita Lomakin, Central Clinical Hospital of the Presidential Department of Russian Federation

A major focus of this session will be on possible treatment approaches for both prevention and intervention in different diseases. New immunologic features of the well-known drugs will be also discussed. The role of lymphotoxin pathway in gut immune homeostasis and the new approach for the anticytokine treatment of inflammatory bowel diseases; the anti-inflammatory and anti-apoptotic properties of activated protein C (independent of its anticoagulant activity) in different diseases, including chronic wound healing; the possible anti-inflammatory properties of the well-known respiratory drugs – beta-agonists and anticholinergics and clinical relevance of these features in asthma and COPD will be discussed.

107
The New Method of Evaluation of β-Adrenoreceptor's Activity
Kirill A. Zykov, *Olga Y. Agapova, Yuri S. Skoblov, Valery P. Masenko, Irina E. Chazova.* Moscow State Univ. of Med. and Dent. named after A.I. Evdokimov, Moscow, Russian Federation; Shemyakin-Ovchinnikov Institute of Bioorganic Chem., RAS, Moscow, Russian Federation; Russian Cardiology Research and Production Complex, Moscow, Russian Federation

108
Cellular Sources of Proinflammatory Cytokines in Disease and Cell Type-Restricted Cytokine Targeting
Sergei A. Nedospasov. Engelhardt Institute of Molecular Biology and Lomonosov Moscow State Univ., Moscow, Russia; Lobachevsky Univ., Nizhni Novgorod, Russia; German Rheumatism Research Ctr., a Leibniz Institute, Berlin, Germany

109
Coxsackie-Adenovirus Receptor Expression on Cardiomycytes and Platelets in Patients with Inflammatory Cardiac Pathology
Liudmila I. Buryachkovskaya, ***Elena M. Gupalo,*** *Irina A. Uchitel, Peter V. Chumachenko, Natalia A. Mironova.* Russian Cardiology Research Complex, Ministry of Health, Moscow, Russia

B117
p38delta MAPK – A Novel Effector in NLRP3 Inflammasome Activation Upregulated in Human Coronary Atherosclerotic Lesions
Kristiina Rajamaki, Mikko I. Mayranpaa, Jarno Tuimala, Katariina Nurmi, Kari K. Eklund, Katariina Oorni, Petri T. Kovanen. Wihuri Research Institute, Helsinki, Finland; Haartman Institute, Univ. of Helsinki and Meilahti Labs of Pathology, Helsinki; Helsinki Univ. Central Hosp.; RS Training, Helsinki, Finland

B125
Control of Lung Cancer with Aspirin-Triggered Stimulation of Resolution
Molly M. Gilligan, Megan L. Sulciner, Sesquile Ramon, Romain A. Colas, Sui Huang, Charles N. Serhan, Dipak Panigrahy. Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA; Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA; Brigham and Women's Hosp., Harvard Med. Sch., Boston, MA; Institute for Systems Biology, Seattle, WA

1430 – 1630, Amphitheater

Symposium 35: Clinical Developments in Fibrosis

Co-Chairs
Thomas Wynn, NIAID-NIH
Caralee Schaefer, Blade Therapeutics

Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix leading to organ scarring, which can ultimately contribute to organ failure. Fibrotic tissue remodeling is a final common pathway in many forms of chronic inflammatory disease affecting multiple organ systems. Nevertheless, the mechanisms leading to fibrosis are poorly understood and novel therapeutics that target the mechanisms of fibrosis have shown limited efficacy. This symposium will feature four presentations focusing on clinical developments in fibrosis.

110
Targeting IL13 in Idiopathic Pulmonary Fibrosis
Joseph R. Arron. Genentech Inc., South San Francisco, CA

No Abstract
The New Wave of Anti-fibrotic Mechanisms
Lynne Murray. MedImmune, Gaithersburg, MD

111
Small Molecule Inhibitors of Loxl2 for Fibrosis
Wolfgang Jarolimek. Pharmaxis Ltd., Frenchs Forest, NSW, Australia

112
Targeting LPA as a Core Fibrotic Pathway: Similarities and Differences across Organs
Andrew M. Tager. Massachusetts General Hosp.; Harvard Med. Sch., Charlestown, MA

1430 – 1630, Harborview Ballroom

Symposium 36: Novel Therapies in RA

Co-Chairs
Gary Sims, MedImmune
Ernest Choy, Cardiff University

This symposium will look at current standard of care in Rheumatoid Arthritis and discuss unmet medical needs. The symposium will discuss new therapeutic approaches and novel targets currently in development that could further advance the treatment of RA. Topics will include treat-to-target, improving remission, precision medicine, GMCSF pathway and Toll-like receptors as therapeutic targets and tolerogenic dendritic cells as treatment for RA.

113
Rheumatoid Arthritis: Where We Are and What Is the Future
Ernest H. Choy. Cardiff Univ., Wales, UK

114
GM-CSF: A New Target for Intervention in Rheumatoid Arthritis
Michael E. Weinblatt. Brigham and Women's Hosp., Boston, MA

115
A New Therapeutic Approach for RA Treatment Using an Anti-TLR4 Monoclonal Antibody Inhibiting TLR4 and FcgammaR Signaling and Exploiting Citrullinated Protein Immune Complexes as Potential Biomarkers for Personalized Med
Emmanuel Monnet, *Limin Shang, Geneviève Lapeyre, Eric Hatterer, Kathy deGraaf, Venassa Buatois, Greg Elson, Walter Ferlin, Cem Gabay, Jeremy Sokolove, Simon Jones, Ernest H. Choy, Iain B. McInnes, Marie Kosco-Vilbois, Cristina de Min.* Novimmune SA, Geneva; Geneva Univ. Hosps., Switzerland; Stanford Univ., Palo Alto, CA; Cardiff Institute of Infection and Immunity, Wales, UK; Glasgow Biomed. Research Ctr., Scotland, UK

116
Cell Therapies in Rheumatoid Arthritis
John D. Isaacs. Newcastle Univ., Newcastle upon Tyne, UK

B259
14-3-3 Eta as a Novel RA Drug Target: Anti-14-3-3 Eta Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice
Anthony Marotta, Abedelnasser Abulrob, Mario Mercier, Slavisa Corluka, Roger MacKenzie, Shalini Raphael, Sara Michienzi, Jane Savill, Yuan Gui, Walter P. Maksymowych. Augurex Life Science Corp., North Vancouver, BC; Natl. Research Council; Univ. of Alberta, BC, Canada

B316
Restoration of Treg Cell Function with PD-L1 Fc Protein in Rheumatoid Arthritis
Kaustav Chowdhury, Dipendra Kumar Mitra, Uma Kumar, Soumabha Das, Prabin Kumar, Uma Kanga, Jaydeep Chaudhuri, Santu Bandyopadhaya, Parasar Ghosh, Ravi Kiran Basyal, Maumita Kanjilal. All India Institute of Med. Science, New Delhi; Indian Institute of Chemical Biology, Kolkata; IPGMER, Kolkata, India

1430 – 1630, Waterfront Ballroom 2

Mini-Symposium 4: Signaling in Inflammation

Chair
Jim Ellis, GlaxoSmithKline

This mini-symposium has selected speakers from submitted abstracts to highlight some of the many facets of signaling in inflammation. The talks will discuss the roles of cytokines, kinases, toll-like receptors and other key components in inflammation signaling and cover multiple disease states from asthma, rheumatoid arthritis, skin inflammation, malaria to fibrosis.

B139
Salt-Inducible Kinases Inhibition in Human Myeloid Cells Modulates TLR and IL-1R Signaling and Induces an Anti-inflammatory Phenotype
Maria Stella Lombardi, Corine Gilliéron, Damien Dietrich, Cem Gabay. Univ. Hosps. Of Geneva and Univ. of Geneva Sch. of Med., Switzerland

B197
RIP Kinase Signaling in Keratinocyte Controls Necroptosis-Mediated Skin Inflammation
Snehlata Kumari, Manolis Pasparakis. Institute for Genetics, Univ. of Cologne, Germany

B281
Blocking LTβR Signaling In Vivo Suppresses the Development of Smooth Muscle Hypertrophy in a Chronic Murine Model of Asthma
Silke N.K. Hobbie, Peter Maier, Erb J. Klaus. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

B069
Opposite Role of Soluble Forms of IL-6 Receptor, sIL-6R and sgp130, on the Regulation of Inflammatory Status in Rheumatoid Arthritis
Kazuyuki Yoshizaki, J Song Soken-Nakazawa, Kazuko Uno. Osaka Univ., Suita, Japan

B082
Combinatorial Targeting of TSLP, IL-25, and IL-33 in Type 2 Cytokine-Driven Inflammation and Fibrosis
Kevin M. Vannella, Thirumalai R. Ramalingam, Allen W. Cheever, Lee A. Borthwick, Luke Barron, Kevin M. Hart, Robert W. Thompson, Kristen N. Kindrachuk, Sandra White, Alison L. Budelsky, Michael R. Comeau, Dirk E. Smith, Thomas A. Wynn. Natl. Institute of Allergy and Infectious Disease, NIH, Bethesda, MD; BioMed. Research Institute, Rockville, MD; Newcastle Univ., Newcastle-upon-Tyne, UK; Amgen Inc., Thousands Oaks, CA

B083
Deciphering the Deleterious Effect of IFN-γ in a New Rodent Model for Experimental Severe Malaria
Norinne Lacerda-Queiroz, Nicolas D. Riteau, Richard Eastman, Alan Sher, Dragana Jankovic, Xin-Zhuan Su. Natl. Institute of Allergy and Infect. Dis., NIH, Rockville, MD

B325
Neuronal TLR Signaling Controls Neuronal Excitability, Neuroinflammation, Pain, and Itch
Ru-Rong Ji, Chul-Kyu Park, Tong Liu, Zhen-Zhong Xu, Qingjian Han, Yong Ho Kim, Temugin Berta. Duke Univ. Med. Ctr., Durham, NC

1630 – 1800, Exhibit Hall, Commonwealth Complex

Poster Session and Mixer

1900 – 2300, Lighthouse

Awards Banquet

Two Hundred Years of Medical Advances
Jeff Drazen. Editor-in-chief, New England Journal of Medicine
Advance ticket purchase required.

Wednesday, August 12, 2015

0800 – 0900, Harborview Ballroom

Outstanding Scientist Award Winner Presentations

Co-Chairs
Graham Wallace, University of Birmingham
John Hamilton, University of Melbourne

Award Winners:
Ian Ahnfelt-Rønne and Michael Parnham

Oxygen-Derived Free Radicals, Sulfasalazine and Inflammatory Bowel Disease (IBD) –
Ian Ahnfelt-Rønne, *Novo Nordisk A/S, Denmark*

Oxygen-derived free radicals are extremely cytotoxic and have been implicated in the tissue-destructive processes that characterize chronic inflammation. Yet, convincing cases for benefits of antioxidants to treat chronic inflammation are sparse and in most cases anecdotal. We have provided evidence that sulfasalazine works by such an antioxidant scavenger mechanism in IBD. The hypothesis builds on our identification of biomarkers related to sulfasalazine metabolism in presence of free radicals. These biomarkers were subsequently detected in IBD patients, and their presence was shown to correlate with a reduction in free radical formation and an improvement in clinical score. Considerations of sulfasalazine pharmacology and biomarker patterns related to treatment lead us to conclude that IBD is a chronic inflammatory disease that is amenable to symptomatic treatment with topical antioxidants.

Past President of IAIS, President of World Congress on Inflammation, Copenhagen 2007, Co-editor of Inflammation Research 1992-2012.

Progress Doesn't Just Come in Giant Leaps
Michael Parnham, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany

The relevance of suitable experimental models for the effective translation of drug effects to clinical inflammatory diseases has a long history. Much emphasis is placed these days on genetically transformed mice, which may have developmental drawbacks. But are established models redundant? Fine tuning of experimental approaches and assessment technologies can often still provide innovative, clinically relevant insights into the potential beneficial effects of drugs and pharmacological agents. Drawn from personal experience, examples will be provided of the success of tinkering with technology in the context of inflammation.
Secretary of the European Inflammation Society 1980-1999
Managing Editor, "Inflammation Research," 1992-2013.

0900 – 1000, Harborview Ballroom

Keynote Lecture

Inflammation in Atherosclerosis – A Translational Tale
Peter Libby. Brigham & Women's Hospital, Harvard Medical School, Boston, MA

1000 – 1030, Harborview Foyer

Coffee Break

1030 – 1230, Harborview Ballroom

Symposium 37: Novel Targets and/or Novel Therapies – Sponsored by Celgene

Co-Chairs
Larry Burgess, Array BioPharma
Kate Blease, Celgene

At this Novel Therapy Symposia, four new immuno-modulatory therapeutics will be presented. A small molecule CRTh2 antagonist, ARRY-502, has recently demonstrated clinically significant benefit to asthma patients while shedding light on strategies to identify Th2-driven responders. Meanwhile, two biologic-based therapies aimed at rheumatoid arthritis are also scheduled. The first talk will unveil a novel bispecific antibody targeting both TNF and IL-17 (ABT-122). The second involves the administration of an endogenous, anti-inflammatory "chaperokine" (immunoglobin binding protein, BiP) to overcome RA-driven auto-antibodies. The final presentation will illustrate the exciting and effective chimeric antigen receptor technology wherein T cells from cancer patients are engineered to express receptors that overcome tumor-derived immunosuppression.

117
Developing CAR T Cells for Cancer
Marcela Maus. Univ. of Pennsylvania, Philadelphia, PA

118
ARRY-502: A Potent, Selective CRTh2 Antagonist for Asthma
Laurence Burgess, *David Chantry, Christine Eberhardt, Robert Hopkins, Michael Saunders, Lisa Anderson, Roger Aitchison, Stacie Bell, Kenji Izuhara, Junya Ono, Jeremy Cole, James D. Wolfe, Sheldon Spector, Lawrence Sher, Edward Kerwin, Sally Wenzel.* Array BioPharma, Boulder, CO; Saga Med. Sch., Saga, Japan; Shino Test Corp., Tokyo, Japan; IPS Research Co., Oklahoma City, OK; Allergy & Asthma Assoc. Santa Clara County Research Ctr.; California Allergy & Asthma Med. Group, Los Angeles, CA; Pennisula Research Assoc., Rolling Hills Estate, CA; Clin. Research Institute of Southern Oregon, Medford, OR; Univ. of Pittsburgh Asthma Institute, Pittsburgh, PA

119
Mechanisms of Dual Inhibition of TNF and IL-17: Translation to Clinical Studies with ABT-122
Carolyn Cuff, *Melanie Ruzek, Robert Padley, Heikki Mansikka, Jeffrey Voss, Margaret Hugunin, Alexander Ivanov, Chung-Ming Hsieh.* AbbVie, Worcester, MA

120
Results of a Single Dose Ascending First-in-Man Trial of a Novel Biologic, Human Stress Protein Rasolvir (BiP), in Rheumatoid Arthritis: The Ragulo Trial
Gabriel S. Panayi, *Bruce Kirkham, Khaldoun Chaabo, Christopher Hall, Angela Vincent, Joana Vasconcelos, Toby Prevost, Toby Garrood, Valerie Corrigall.* Guy's and St Thomas' NHS Hosp. Trust, London, UK; Kings Col. London, UK

1030 – 1230, Amphitheater

Symposium 38: Cardiovascular Inflammation

Co-Chairs
Peter Libby, Brigham & Women's Hospital, Harvard Medical School
Liwu Li, Virginia Tech

Altered inflammatory processes or defective resolution of inflammation are cardinal features during the initiation, propagation, and resolution phases of cardiovascular diseases. This session will host renowned scientists to address some of the fundamental issues involved in these processes, as well as potential intervention strategies. With particular relevance, Dr. Nahrendorf will discuss the involvement of innate immunity in myocardial infarction; Dr. Wagner will highlight the intriguing involvement of netutrophils and NETs in cardiovascular inflammation; Dr. Ridker will speak about inflammation as one of the major risk factors for cardiovascular diseases; and Dr. Tabas will be addressing the defective resolution of inflammation during the progression of atherosclerosis.

121
Myeloid Cells in Ischemic Heart Disease
Matthias Nahrendorf. Massachusetts Gen. Hosp., Boston, MA

122
NETs Fueling Disease and Vice Versa
Denisa D. Wagner. Boston Children's Hosp. Harvard Med. Sch., Boston, MA

No Abstract
Inflammation and Cardiovascular Risk
Paul M. Ridke. Brigham & Women's Hospital, Boston, MA

123
Defective Inflammation Resolution in Atherosclerosis: Mechanisms and Therapeutic Opportunities
Gabrielle Fredman, Nazila Kamaly, Omid Farokhzad, ***Ira Tabas.*** Columbia Univ. Med. Ctr., New York, NY; Harvard Med. Sch., Boston, MA

1030 – 1230, Cityview Ballroom 2

Symposium 39: Predictive Toxicology

Chair
Ellen Berg, BioSeek, Inc.

In this session, we will discuss the topic of drug toxicities in inflammatory diseases and new methods to predict and mitigate these effects.

Patients suffering from inflammatory diseases are at increased risk for other conditions including cancer, cardiovascular disease and other disorders. Understanding the contribution of drug exposure to these risks is important, not only for improving patient health, but for the discovery of safer therapeutic agents.

In 2011, the FDA proposed a strategic plan, Advancing Regulatory Science at FDA that included as the first priority area to "Modernize Toxicology to Enhance Product Safety" and improve preclinical safety predictions by investing in better models and assays, the discovery of new biomarkers, and computational tools and methods.

Here we will present speakers discussing this issue from the FDA's perspective and from groups whose mission has been to develop new tools and computational approaches for predicting adverse effects.

124
Translational Impact of Secondary Pharmacology in Drug Discovery
Laszlo A. Urban. Novartis Insts. For BioMed Research, Cambridge, MA

125
Optimizing Clinical Development: Leveraging Preclinical Disease Models for Assessing Safety and Efficacy
Joy Cavagnaro. Access BIO, Boyce, VA

126
Translational Safety in Drug Development: The Role of Safety Biomarkers in Predictive Toxicology
John Michael Sauer. Critical Path Institute, Tucson, AZ

127
Large Molecule Predictive Safety: Experiences and Points to Consider
Michelle J. Horner. Amgen, Thousand Oaks, CA

1030 – 1230, Cityview Ballroom 2

Symposium 40: Translational Medicine

Chair
Anthony Coyle, Pfizer, Inc.

In recent years, there has been tremendous progress in translating preclinical data into clinical studies in respiratory, Inflammatory and autoimmune diseases. This symposia looks at how our preclinical understanding of disease mechanisms provides opportunities to further understanding human disease. In addition, by understanding and translating these mechanisms into the clinic with new protein and/or small molecule inhibitors may lead to the development of new therapeutic agents

No Abstract
Identification of JAK Inhibitors for the Treatment of Inflammatory Disorders
James Clark, Pfizer, Inc., Cambridge, MA

No Abstract
Role of T Helper Follicular Cells in Autoimmune Diseases
Joseph Craft, Yale University, New Haven, CT

133 *See addendum for abstract*
Role of Eosinophils in Respiratory Diseases
Alison Humbles, MedImmune, Gaithersburg, MD

1030 – 1230, Waterfront Ballroom 2

Symposium 41: Innate Lymphoid Cells

Co-Chairs
Pejman Soroosh, Janssen R&D
Hergen Spits, University of Amsterdam

Innate lymphoid cells (ILC) are a diverse group of immune cells that lack expression of rearranged antigen receptors, share a requirement for the transcription factor ID2 and IL-2 receptor gamma chain for their development and exhibit functional characteristics that closely resemble those of the CD4+ T helper cell subsets Th1, Th2 and Th17. Type 2 ILC (ILC2) represents a critical source of Th2 cytokines in vitro and in vivo and serves an important role in orchestrating the type 2 response to helminths and allergens. In this session we will explore the role of ILC2 specifically in inflammatory lung responses with special attention to allergen-induced and viral-induced type 2 lung diseases.

128
Function and Plasticity of Human ILC Subsets
Hergen Spits. AMC Univ. of Amsterdam, Netherlands

129
Functions of IL-33 and Group 2 Innate Lymphoid Cells in Controlling Allergic Airway Inflammation and Asthma
Hirohito Kita. Mayo Clinic, Rochester, MN

130
Lipid Mediator Regulation of ILC2 Th2 Cytokine Response
David Broide. Univ. of California San Diego, La Jolla, CA

131
Pathways That Govern ILC2s Function and Homeostasis
Omid Akbari. Univ. of Southern California, Los Angeles, CA

Poster Sessions

Exhibit Hall, Commonwealth Complex

Poster Set-Up

Authors must place posters on the assigned board between 0730 – 1030 on Sunday, August 9, 2015.

All posters must remain on boards from Sunday, August 9 to Tuesday, August 11.

Authors must remove posters between 0730 – 1030 on Wednesday, August 12.

Poster Viewing

Sunday, August 9 – Tuesday, August 11, 2015
1230 – 1430

Poster Presentation

Authors must be present at their poster on the day listed next to the board number below, at the following times:

Poster Session 1 Sunday, August 9
1630 – 1800

Poster Session 2 Monday, August 10
1630 – 1800

Poster Session 3 Tuesday, August 11
1630 – 1800

The number listed following the letter "B" signifies the poster board number/location in the Exhibit Hall, Commonwealth Complex.

Angiogenesis

B001 *(Sunday)*
Serum Circulating Angiogenesis Inhibitor Angiostatin Levels in Patients with Familial Mediterranean Fever
Goksal Keskin, Ali Inal, Lale Ozisik, Mehmet Yildiz. Med. Sch., Ankara Univ.; Baskent Univ.; DYBEAH, Ankara, Turkey

B002 *(Monday)*
Synchrotron Microbeam Irradiation Induces Inflammation and Selective Vascular Damages in Adult Zebrafish
Daniel Brönnimann, Audrey Bouchet, Werner Graber, Jean A. Laissue, Valentin Djonov, Raphael Serduc, Elke Bräuer. Univ. of Bern, Switzerland; European Synchrotron Radiation Facility, Grenoble, France

B003 *(Tuesday)*
Suppressive Effects of Soluble Vascular Endothelial Growth Factor Receptor-2 on Lymphogenic Metastasis
Shotora Maehana, Rimika Imai, Rei Murakami, Masaki Nakamura, Fumihiro Ogawa, Fumiaki Kojima, Masataka Majima, Hidero Kitasato. Kitasato Univ. Graduate Sch. of Med. Science; Kitasato Univ. Sch. of Allied Health Sciences; Kitasato Univ. Sch. of Med., Japan

B004 *(Sunday)*
MLN4924 Inhibition of Cullin-Ring Ligases Activates a Hypoxic Response and Secretion of Angiogenesis-Promoting Cytokines in Human MCF-7 Breast Cancer Cells
David Finkel, James Rivard, Amy James, Erin Eliria, Neal Lee, Kathy Brumbaugh, Greta Wegner. R&D Systems Inc., Minneapolis, MN

Apoptosis

B005 *(Monday)*
L-Aminoacid Oxidase, the Major Component of B Leucurus Venom, Induces Direct Nephrotoxicity through ROS, Mitochondrial Dysfunction and Caspases Pathway
Isabel Cristina Oliveira de Morais, Gustavo José da Silva Pereira, Mar Orzáez, Marcos Hikari Toyama, Soraya Soubhi Smaili, Enrique Pérez Payá, Alice Maria Costa Martins. Faculty of Med., Federal Univ. of Ceará, Fortaleza, Brazil; Federal Univ. of São Paulo (UNIFESP), Brazil.; Ctr. de Investigación Príncipe Felipe, Valencia, Spain; Paulista Coastal Campus, São Paulo State Univ. (UNESP), São Paulo, Brazil.; Clin. and Toxicol. Analysis, Federal Univ. of Ceará, Fortaleza, Brazil

B006 *(Tuesday)*
***Bothropoides pauloensis* Venom Cytotoxicity in Renal Tubular Epithelia Cells: Cell Death Signaling Pathways**
Aline Diogo Marinho, Isabel Cristina Oliveira Morais, Roberta Jeane Bezerra Jorge, Ramon Roseo Paula Pessoa Bezerra Menezes, Joao Alison Moraes Silveira, Danya Bandeira Lima, Alice Maria Costa Martins, Helena Serra Azul Monteiro. Federal Univ. of Ceará, Fortaleza, Brazil

B007 *(Sunday)*
Hyperglycemia Favors Th17 Differentiation after Phagocytosis of MRSA-Infected Apoptotic Cells
Naiara N. Dejani, Stephanie Brandt, Nicole L. Glosson-Byers, Soujuan Wang, Alexandra I. Medeiros, C. Henrique Serezani. Univ. of São Paulo, Ribeirão Preto, SP, Brazil; Sch. of Pharmaceutical Science, Univ. Estadual Paulista, Araraquara, SP, Brazil; Indiana Univ. Sch. of Med., Indianapolis, IN

B008 *(Monday)*
MPO-Derived Chlorinated Lipids Induce Endoplasmic Reticulum Stress in Brain Microvascular Endothelial Cells
Nora Kogelnik, Christoph Nusshold, Christine Rossmann, Gerald Rechberger, Helga Reicher, Pierre-Oliver Courad, Ernst Malle, Wolfgang Sattler. Med. Univ. of Graz; Univ. of Graz, Austria; Paris Descartes Univ., France

Autoimmune Diseases – RA, Psoriasis, SLE, IBD, MS

B010 *(Sunday)*
The Tyrosine Kinase Inhibitor Prevents Cytokine Induction in the Progression of Adjuvant-Induced Arthritis
Sheikh Fayaz Ahmad, Mushtaq Ahmad Ansari, Khairy M.A. Zoheir, Saleh A. Bakheet, Sabry M. Attia. King Saud Univ., Riyadh, Saudi Arabia

B011 *(Monday)*
Anti-inflammatory Effects of Tripeptide WOL074-019 in Murine Models of Psoriasis and Colitis
Michael Soeberdt, Carlo Sternemann, Christoph Abels, Thomas A. Luger, Karin Loser. Dr. August Wolff GmbH & Co., Bielefeld, Germany; Univ. of Münster, Germany

B012 *(Tuesday)*
Cytokine Production and Calcium Influx of T Lymphocytes upon Kv1.3 and IKCa1 Channel Inhibition in Rheumatoid Arthritis and Ankylosing Spondylitis
Gergely Toldi, Luis Munoz, Martin Herrmann, Georg Schett, Attila Balog. Semmelweis Univ., Budapest, Hungary; Univ. of Erlangen-Nürnberg, Germany; Univ. of Szeged, Hungary

B013 *(Sunday)*
Suppressing Inflammatory Bowel Disease by Modulating Pro-inflammatory Gene Expression and Immune Cell Populations
Anh T. Do, Praveer Gupta, Abishek Iyer, David P. Fairlie. Univ. of Queensland, St. Lucia, Australia

B014 *(Monday)*
The Clinical Features of Takayasu's Arteritis in Our Hospital (53 Cases)
Takumi Nagamoto, Kenta Misaki, Rintaro Saito, Yuri Nakamura, Yoshie Gon, Toshihiko Yokota. Kurashiki Central Hosp., Kurashiki, Okayama, Japan

B015 *(Tuesday)*
C-Reactive Protein Could Promote Osteoclastogenesis
Sang-Heon Lee, Chong-Hyeon Yoon. Konkuk Univ. Sch. of Med., Seoul; Catholic Univ. of Korea Col. of Med., Seoul, South Korea

B016 *(Sunday)*
A Novel Approach for Treatment of Rheumatoid Arthritis: Combined TNF-α and Sclerostin Inhibition Blocks Inflammation and Restores Bone in a Mouse Collagen-Induced Arthritis Model
Wendy O. Waegell, Alexander V. Ivanov, Regina N. Mario, Shaughn Bryant, Trudi M. Veldman, Lisa M. Olson. AbbVie Bioresearch Ctr., Worcester, MA

B017 *(Monday)*
The Opposing Effects of CerS2 and CerS6 in the Development of EAE
Susanne Schiffmann, Julia Barthelmes, Max Eberle, Yael Pewzner-Jung, Anthony Futerman, Philipp Ebel, Klaus Willecke, Gerd Geisslinger, Sabine Grösch. Weizmann Institute of Science, Rehovot, Israel; Univ. of Frankfurt; Univ. of Bonn; Fraunhofer Institute, Frankfurt am Main, Germany

B018 *(Tuesday)*
ADA2 Deficiency Attenuates M2 Macrophages Differentiation
Dan Yang, Guibin Chen, Qing Zhou, Yuting Huang, Zhen Yu, Avram Walts, Alejandra Negro, Cynthia St. Hilaire, Ivona Aksentijevich, Manfred Boehm. NHLBI, NIH and NHGRI, NIH, Bethesda, MD

B019 *(Sunday)*
Flavonols Modulate the Production of Reactive Oxygen Species and the Chemotactic Activity of Peripheral Blood Neutrophils from Rheumatoid Arthritis Patients
Larissa F. Marchi, Adriana P. Paschoalato, René R. Oliveira, Ana Elisa C. Azzolini, Eduardo A. Donadi, Yara L. Valim. Univ. of São Paulo, Sch. of Pharmaceut. Science of Ribeirão Preto; Univ. of São Paulo, Ribeirão Preto Med. Sch., Brazil

B020 *(Monday)*
Amelioration of Chronic Colitis in Mice by Genetic Deletion of the IL-13 Decoy Receptor
Trisha Pasricha, Thirumalai Ramalingam, Thomas Wynn. Natl. Inst. of Allergy and Infectious Diseases, NIH, Bethesda, MD

B021 *(Tuesday)*
Hydroquinone Exposure Aggravates Collagen Induced Arthritis Development in Rats
Cintia S. Heluany, Leoanrd k. Kupa, Mariana N. Viana, Cristina M. Fernandes, Sandra P. Farsky. Univ. of São Paulo; Butantan Institute, São Paulo, Brazil

B022 *(Sunday)*
Multi-modality Pathway Characterization and Disease Evaluation in Lupus Model
Jie Zhang-Hoover, Alan Byford, Mark Zielstorff, Robert Faltus, Joseph Eckman, Kimberly Bettano, Gain Robinson, Raquel Sevilla, Adam Hartigan, Weisheng Zhang, Milenko Cicmil. Merck Research Labs., Merck & Co. Inc., Boston, MA

B023 *(Monday)*
Increased Serum Chemerin Levels Might Predict Flares of Systemic Lupus Erythematosus
Omer N. Pamuk, Mehmet S. Uyanik, Gulsum E. Pamuk. Trakya Univ. Med. Faculty, Istanbul, Turkey

B024 *(Tuesday)*
The Effects of the Spleen Tyrosine Kinase Inhibitor, Fostamatinib, on an Immune Thrombocytopenia Mouse Model
Gulsum E. Pamuk, Mehmet S. Uyanik, Turan Karaca, Selim Demirtas, Ahmet M. Demir, Omer N. Pamuk. Trakya Univ. Med. Faculty, Istanbul, Turkey

B025 *(Sunday)*
The Syk Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma Mouse Model: Efficacy in Syk Inhibition in Animal Scleroderma
Omer N. Pamuk, Guray Can, Sulayman Can, Turan Karaca, Gulsum E. Pamuk, Selim Demirtas, George C. Tsokos. Trakya Univ. Med. Faculty, Istanbul, Turkey; Harvard Univ. Med. Faculty, Boston, MA

B026 *(Monday)*
Serum and Synovial Fluid C5a Levels in Patients with Rheumatoid Arthritis and Ostearthritis
Dilek Keskin, Göksal Keskin, Ali Inal. Krikkale Univ., Ankara; Ankara Univ.; Univ. of GATA, Turkey

B027 *(Tuesday)*
The Role of Neutrophils and G-CSF in the K/BxN Serum-Transfer Arthritis Model
Anne Deen Christensen, Claus Haase, Andrew D. Cook, John A. Hamilton. Univ. of Melbourne, Royal Melbourne Hosp., Parkville, Victoria, Australia; Novo Nordisk A/S, Måløv, Denmark

028 *(Sunday)*
Enhancements to the Predictability and Clinical Relevance of Two Murine Models of Chronic Inflammation: Adoptive Transfer-Induced Colitis and GVHD

Dominic R. Beal, Sean M. Graham, Brett Van Dam, Gregory D. Lyng, Stephen T. Sonis. Biomodels LLC, Watertown, MA

B029 *(Monday)*
IL-7 Receptor Polymorphisms in Multiple Sclerosis: Mechanism and Therapeutic Implication
Wenqing Li, Julie A. Hixon, Julia Tritapoe, Joao T. Barata, Scott K. Durum. Natl. Cancer Institute, NIH, Frederick, MD; Lisbon Univ. Med. Sch., Lisbon, Portugal

B030 *(Tuesday)*
Serum 14-3-3 Eta Is an RA Specific Mechanistic Marker
Anthony Marotta, Yauheniya Cherkas, Bidisha Dasgupta, Sarah Lamberth, Karen Hayden, Carrie Brodmerkel, Mark Curran. Augurex Life Science Corp., North Vancouver, BC, Canada; Janssen R&D LLC

B031 *(Sunday)*
Multiple Mesenteric Lymphatic Anomalies in Murine Crohn's Disease
Pierre-Yves von der Weid, Sonia Rehal. Univ. of Calgary, AB, Canada

B032 *(Monday)*
A Novel Iron-Mediated Mechanism for Development of Inflammatory Bowel Disease
Shirly M. Belizowski, Abraham Nyska, Avi Zuckerman, Fabio Cominelli, Orly Savion, Esther Meyron-Holtz. Technion–Israel Institute of Technology, Haifa, Israel; Tel Aviv Univ. and Consultant in Toxicologic Pathology, Timrat, Israel; Aviv Projects, Ness Ziona, Israel; Case Western Reserve Univ., Cleveland, OH

B033 *(Tuesday)*
c-kit Is Expressed on a Subset of Th17 Cells and Regulates Their IL-22 Production
Kalil A. de Lima, Jhimmy Talbot, Paula Barbim, Thiago Cunha, José Carlos Alves-Filho, Paulo Louzada, Fernando Q. Cunha. Ribeirão Preto Med. Sch., Ribeirão Preto, Brazil

B034 *(Sunday)*
Wonderbumin: A Fully Synthetic Alternative to IgT for Autoimmune Disease
Anne S. De Groot, Filipa Antunes, Eduardo Guillen, Sandra Lelias, Ryan Harvey, Christine Boyle, William Martin, Paul Barrett, Darrell Sleep. EpiVax Inc., Providence, RI; Univ. of Rhode Island; Novozymes Biopharma Ltd., Nottingham, UK

B

B035 *(Monday)*
Oxysterols and Human Memory Lymphocytes: When Interaction Means Attraction
Aurélie Clottu, Fanny Chalmin, Caroline Pot. Univ. of Geneva; Geneva Univ. Hosps., Geneva, Switzerland

B036 *(Tuesday)*
Healthcare Resource Use and Costs of Adrenocorticotropic Hormone in Relapses of Multiple Sclerosis
Laurie S. Gold, Patricia Schepman, John Niewoehner, Michael Philbin, Ryan Hansen. Univ. of Washington, Seattle, WA; Mallinckrodt Pharmaceuticals

B037 *(Sunday)*
Use of a Balanced Dual Cyclooxygenase-1/2 and 5-Lypoxygenase Inhibitor in Experimental Colitis
Alessandra Bitto, Giovanni Pallio, Gabriele Pizzino, Domenica Altavilla, Francesco Squadrito. Med. Sch., Univ. of Messina, Italy

Biologic Therapies for Targeting Inflammatory and Immune Mechanisms

B038 *(Monday)*
***Myrianthus arboreus* Exhibited Anti-inflammatory Properties in Experimental Models**
Oluwafemi G. Oluwole, Akinyinka Alabi, Olatunde Ganiyu. Faculty of Basic Med. Science, Col. of Med., Univ. of Ibadan, Nigeria; Col. of Med., Olabisi Onabanjo Univ., Ogun State, Nigeria

B039 *(Tuesday)*
A Modified Glycosaminoglycan, GM-0111 Inhibits Inflammatory Molecules Related to Periodontitis
Won Yong Lee, Justin R. Savage, Abigail Pulsipher, Narayanam Rao, Thomas P. Kennedy, Maria E. Ryan, Glenn D. Prestwich. GlycoMira Therapeutics, Inc., Salt Lake City, UT; Univ. of Utah, Salt Lake City; Tulane Univ., New Orleans, LA; Stony Brook Univ., Stony Brook, NY

B040 *(Sunday)*
GM-0111, a Modified Glycosaminoglycan, Prevents Radiation-Induced Mucositis
Abigail Pulsipher, Justin R. Savage, Thomas P. Kennedy, Glenn D. Prestwich, Won Yong Lee. GlycoMira Therapeutics Inc., Salt Lake City, UT; Univ. of Utah, Salt Lake City; Sch. of Med., Tulane Univ., New Orleans, LA

B041 *(Monday)*
The Effect of Dupilumab on Biomarkers in the Peripheral Blood and Nasal Secretions in the Treatment of Chronic Sinusitis with Nasal Polyposis
Brian N. Swanson, Leda Mannent, Jennifer Hamilton, Donghui Zhang, Nian Tian, Ying Wang, Gabriele Holtappels, Lars-Olaf Cardell, Jeffrey E. Ming, Neil Graham, Gianluca Pirozzi, Claus Bachert. Sanofi, Bridgewater, NJ; Sanofi, Chilly Mazarin, France; Regeneron Pharmaceuticals Inc., Tarrytown, NY; Ghent Univ. Hosp., Ghent, Belgium; Karolinska Institute, Stockholm, Sweden

B042 *(Tuesday)*
TSPO Gene Expression on 3T3-L1 Differentiation Process Is Modulated by Diazepam Treatment and LPS
Eric D. Barioni, Rodrigo A. Loiola, Edson M. Oliveira, Ana Campa, Sandra H.P. Farsky. Univ. of São Paulo, Brazil

B043 *(Sunday)*
Novel Anti-inflammatory Effect of Coniferyl Aldehyde by Selective Inhibition of STAT1-iNOS Signaling
Muhammad Akram, Kim Kyeong-A, Ok-Nam Bae. Hanyang Univ., Ansan, South Korea

B044 *(Monday)*
An Investigation of Anti-inflammatory Activities Produced by Schisandrin A and Schisandrin B In Vitro and In Vivo
Pou Kuan Leong, Kam Ming Ko. The Hong Kong Univ. of Science and Technology, Hong Kong

B045 *(Tuesday)*
Overview of New Strategies for Patenting Biologic Agents Targeting Inflammatory Diseases
Iolanda M. Fierro, Rodrigo A. Oliveira, Fernando Tibau, Natalia L. Von Ranke, Adelaide Maria S. Antunes. Univ. do Estado do Rio de Janeiro; Institute Nacional da Propriedade Industrial, Rio de Janeiro; Univ. Federal do Rio de Janeiro, Brazil

B046 *(Sunday)*
ADP Treatment Improves Wound Healing in Diabetic Mice
Claudia F. Benjamim, Paula B. Alvarenga, Janaína L. Georgii, Ariane R. Brogliato, José Roberto Meyer, Robson Coutinho, Josiane S. Neves. Federal Univ. of Rio de Janeiro, Brazil

B047 *(Monday)*
Neutralizing the Pro-metastatic Immune Responses of MDSC and T Cells through B Cell Targeting
Monica Bodogai, Kanako Moritoh, Catalina Lee Chang, Christine M. Hollander, Li Yang, Robert Wersto, Arya Biragyn. Natl. Institute on Aging, NIH, Baltimore, MD; Natl. Cancer Institute, NIH, Bethesda, MD

B048 *(Tuesday)*
Role of Collagen VI to Improve Tissue Integration of Dental Implants
Ramesh Tati, Veronika Dill, Melissa N. Langer, Suado M. Abdillahi, Sara Nordin, Maria Baumgarten, Matthias Mörgelin, Eric Gerner, Christina Gretzer. Lund Univ., Sweden; Dentsply Implants, Sweden

B049 *(Sunday)*
Application of Tregitopes for Treatment of Type 1 Diabetes – Optimization of the Tregitope Delivery Vehicle
Ann S. De Groot, Leslie Cousens, Christine Boyle, Guilhem Richard, William Martin. EpiVax, Inc., Providence, RI; Univ. of Rhode Island, Providence

Cartilage and Bone Remodeling

B050 *(Monday)*
The Role of Resolvin D1 in the Regulation of Inflammatory and Catabolic Factors in Osteoarthritis
Houda Benabdoune, Shi Qin, Julio Fernandes, Pierre Ranger, Hassan Fahmi, Mohammed Benderdour. Univ. de Montréal, Hôp. du Sacré-Cœur de Montréal; Ctr. hospitalier de l'Univ. de Montréal, Quebec, Canada

B051 *(Tuesday)*
Effect of Atorvastatin on Inflammatory Bone Loss in Rats with Glucocorticoid-Induced Osteoporosis: Participation of WNT/ß-Catenin Pathway
Karuza M.A. Pereira, Karianne M. Mendonça, Luzia H.T. Sousa, Ana L. França, Eveline Linhares, Pedro H. Isaias, Ana G.F. Linhares, Danielle R.D. Val, Raul S. Freitas, Mirna M. Bezerra, Hellíada V. Chaves, Gerly Anne D.C. Brito, Conceição D.S. Martins, Joan. Federal Univ. of Ceará; Federal Univ. of Pernambuco, Brazil

Cell Adhesion and Leukocyte Migration

B052 *(Sunday)*
Acute Exposure to Apolipoprotein A1 Inhibits Macrophage Chemotaxis In Vitro and Monocyte Recruitment In Vivo
Asif J. Iqbal, Tessa J. Barrett, Lewis Taylor, Eileen McNeill, Carlota Reico, Gemma E. White, Maximillian H. Brodermann, Dianne Cooper, Keith M. Channon, David R Greaves. Univ. of Oxford, UK; Queen Mary's Univ. of London, UK; NYU Sch. of Med., New York

B053 *(Monday)*
TRPV4 Mediates Matrix Stiffness-Dependent Endothelial Activation
Harry A. Scott, Xiao Yang, Soroush Ardekani, Andrea Cabrera, Kaustabh Ghosh. Univ. of California, Riverside

B054 *(Tuesday)*
DOCK8 Expression in Dendritic Cells Differentially Regulates Cytotoxic T Lymphocyte Responses during Innocuous and Pathogenic Challenges
Manuela Sales Lima Nascimento, Dong Liu, Pei Chen, Lan Xu, Jayendra Kumar Krishnaswamy, Samuele Calabro, Gowthaman Uthaman, Antonia Gallman, João Santana da Silva, Stephanie C. Eisenbarth. Yale Univ. Sch. of Med., New Haven, CT; Ribeirão Preto Med. Sch., Univ. of São Paulo, Brazil

B055 *(Sunday)*
Metformin Modulates Neutrophil Migration: Implication of Endothelial Cell AMPKk, Adhesion Protein Expression and Glycocalyx Integrity
Geneviève Bertheau Mailhot, Giambelluca S. Miriam, Cynthia Laflamme, Nathalie Bourcier, Aline Dumas, Benoît Mailhot, Luc Vallières, Steve Lacroix, Marc Pouliot. Research Ctr., CHU de Québec-Univ. Laval, Quebec City, Canada

B056 *(Monday)*
Chemerin: Inflammatory Biomarker or Anti-inflammatory Mediator?
Daniel Regan-Komito, Asif J. Iqbal, David R. Greaves. Univ. of Oxford, England

B057 *(Tuesday)*
Spin90 Deficiency Increases CXCL13-Mediated B Cell Migration
Sang-Heon Park. Gwangju Institute of Science & Technology, Gwangju, South Korea

B058 *(Sunday)*
Different Modes of LFA-1 Inhibition Translate into Different Downstream Effects In Vitro
Riccardo V. Mancuso, Stephan Krähenbühl, Gabriele Weitz-Schmidt. Univ. Hosp. Basel; AlloCyte Pharmaceuticals AG, Basel, Switzerland

B059 *(Monday)*
The Influence of Melanocortins on Platelet Leukocyte Interactions
Felicity N.E. Gavins, Paul M. Holloway, Helen K. Smith, D. Neil Granger. LSU Health Sciences Ctr.-Shreveport, LA

Chemokines and Chemokine Receptors

B060 *(Tuesday)*
CCL3 Deletion Protects Mice against Oral Squamous Carcinogenesis
Tarcilia A. Silva, Janine M. Silva, Aline C. Batista, Mauro M. Teixeira, Milene A. Rachid, Remo C. Russo. Federal Univ. of Minas Gerais, Belo Horizonte and Federal Univ. of Goiás, Brazil

B061 *(Sunday)*
Combating Skin Inflammation with CXCL12 Chemokine Neutraligands
Dayana Abboud. CNRS, Univ. de Strasbourg, Illkirch, France

B062 *(Monday)*
Role of Inflammatory Chemokine, CCL3, in the Dominant Proliferation of Leukemia Initiating Cells in CML BM
Tomohisa Baba, Naofumi Mukaida. Cancer Research Institute, Kanazawa Univ., Japan

B063 *(Tuesday)*
CCL4-CCR5 Interactions Have Pivotal Roles in Survival of a Murine Breast Cancer Cell Line in Osseous Environment
Soichiro Sasaki. Kanazawa Univ., Ishikawa, Japan

B064 *(Sunday)*
Protective Role of the Atypical Chemokine Receptor D6 during Experimental Sepsis
Fernanda V.S. Castanheira, Fabiane Sonego, Alexandre Kanashiro, Vanessa F. Borges, Paulo H. Melo, Remo C. Russo, Flavio A. Amaral, Mauro M. Teixeira, Gerard J. Graham, Massimo Locati, Thiago M. Cunha, José C. Alves Filho, Fernando Q. Cunha. Sch. of Med. of Ribeirão Preto, Univ. of São Paulo, Brazil; Univ. of Minas Gerais, Brazil; Univ. of Glasgow, Scotland; Humanitas Clinical and Research Ctr., Italy

Co-Stimulatory and Co-Inhibitory Pathways

B065 *(Monday)*
DICAM Attenuates Inflammatory Macrophage Differentiation via Suppression of Integrin αVβ3–Dependent Type I Interferon System
Seungwoo Han, Youn-Kwan Jung, Min-Su Han, Eun-Ju Lee, Hye-Ri Park, Jiae Jang, Gun-Woo Kim. Fatima Research Institute and Daegu Fatima Hosp., Daegu, South Korea

B066 *(Tuesday)*
Abrogation of OX40 and CD30 Signaling Reduces House Dust Mite Driven Allergic Lung Inflammation
Donald T. Gracias, Hideo Yagita, Michael Croft. La Jolla Institute for Allergy & Immunology, La Jolla, CA; Juntendo Univ., Tokyo, Japan

Cytokines in Inflammatory Disease

B067 *(Sunday)*
Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis
Sang-Heon Lee, Kyoung Woon Kim, Hae-Rim Kim. Konkuk Univ. Sch. of Med. and Catholic Univ. of Korea, Seoul, South Korea

B068 *(Monday)*
IL-38: A New Factor in Rheumatoid Arthritis
Shinjiro Kaieda, Shin-ichi Takenaka, Tomoaki Hoshino. Kurume Univ. Sch. of Med., Japan

B069 *(Tuesday)*
Opposite Role of Soluble Forms of IL-6 Receptor, sIL-6R and sgp130, on the Regulation of Inflammatory Status in Rheumatoid Arthritis
Kazuyuki Yoshizaki, J Song Soken-Nakazawa, Kazuko Uno. Osaka Univ., Suita, Japan

B070 *(Sunday)*
Alteration of IL-6 Signaling Is Useful in Rheumatoid Arthritis Treatment: Adjustment of Dosing Interval of Tocilizumab, an IL-6 Receptor-Inihibitor
Shuntaro Saito, Keisuke Izumi, Yuko Kaneko, Katsuya Suzuki, Kunihiro Yamaoka, Tsutomu Takeuchi. Keio Univ. Sch. of Med., Tokyo, Japan

B071 *(Monday)*
Cigarette Smoke Enhances Adaptive Immune Response in Murine Model of Allergic Airway Inflammation
Thayse R. Bruggemann, Paula Fernandes, Jessica M. Oliveira, Beatriz M. Saraiva-Romanholo, Mílton A. Martins, Fernanda M. Arantes-Costa. Sch. of Med. of São Paulo, Brazil

B072 *(Tuesday)*
The Anti-inflammatory Role of Adiponectin in Patients with Chronic Chagas Disease
Kárita C.F. Lidani, Thaisa L. Sandri, Marcia H. Beltrame, Renato M. Nisihara, Iara J.T. Messias-Reason. Clinical Hosp., Federal Univ. of Paraná, Curitiba, PR, Brazil

B073 *(Sunday)*
Aryl Hydrocarbon Receptor Activation by 6-Formylindolo[3,2-b]Carbazole Increases Survival in High-Fat Diet-Fed Mice with Sepsis: Critical Role for NK Cells
Min Zhu, Peng Xiong, Wei Zhang, Hai-Wei Sang, Xiang-Ning Fu. Tongji Hosp., Tongji Med. Col., Huazhong Univ. of Science and Technol.; Wuhan No. 3 Hosp., Wuhan, Hubei, China

B074 *(Monday)*
Chronic Levels of IFN Gamma Decreased Chemotaxis of Bone Marrow-Derived Macrophages at Sites of Inflammation
Julio C. Valencia. LEI, NCI-Frederick, MD

B075 *(Tuesday)*
Haplotype Analysis of Interleukin-6 Gene Promoter Polymorphisms in Patients with Chronic Periodontitis and Diabetes Mellitus
Simona Valova, Petra Borilova Linhartova, Katerina Kankova, Hana Poskerova, Jan Vokurka, Antonin Fassmann, Lydie Izakovicova Holla. Faculty of Med., Masaryk Univ., Brno, Czech Republic; Clin. of Somatol. Insts. shared with St. Anne's Faculty Hosp., Faculty of Med., Masaryk Univ., Brno, Czech Republic

B076 *(Sunday)*
Platymiscium floribundum Vog, a Medicinal Plant, Decreases the Production of Pro-inflammatory TNF-α and IL-1β in a Rat Model of Ligature-Induced Periodontitis
Karuza MA Pereira, Luzia H. Teixeira, Danielle RD Val, Hellíada V. Chaves, Gerly Anne DC Brito, Conceição DS Martins, Paula Goes, Antonia TA Pimenta, Mary Anne S. Lima, Alrieta H. Teixeira, Jordânia MDO Freire, Alice RD Freitas, Janine M. Bastos, Antônia. Federal Univ. of Ceará; Federal Univ. of Pernambuco, Brazil

B077 *(Monday)*
Glycogen Synthase Kinase-3 Signalling and Regulation of TNF mRNA Translation in Human Neutrophils
Miriam S. Giambelluca, Geneviève Bertheau Mailhot, Emmanuelle Rollet-Labelle, Cynthia Laflamme, Marc J. Servant, Marc Pouliot. Research Ctr., CHU de Québec-Univ. Laval; Univ. de Montréal, Faculty of Pharmacy

B078 *(Tuesday)*
Effects of a *Stemodia maritima* Linn Extract on Bone Resorption and TNF-α and IL-1β Levels in Rats with Ligature-Induced Periodontitis
Karuza M.A. Pereira, Luzia H. Teixeira, Danielle R.D. Val, Raul S. Freitas, Hellíada V. Chaves, Paula Goes, Alrieta H. Teixeira, Jordânia M.D.O. Freire, Francisca R.L.D. Silva, Francisco E.A. Rodrigues, Jair Mafezoli, Vicente de Paulo T. Pinto, Gerardo C.. Federal Univ. of Ceará, Brazil; Federal Univ. of Pernambuco, Brazil

B079 *(Sunday)*
High Dose of Leptin Induces Fibrotic Conversion of Endothelial Cells into Fibroblast
Alvaro Becerra, Macarena Rojas, Alejandro Vallejos, Felipe Simon. Univ. Andres Bello, Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile

B080 *(Monday)*
Measuring Receptor Dimerization to Create Functional Cell-Based Assays for >85% of the Interleukin Receptor Family
Scott Gridley, Hyna Dotimas, Sangeetha Gunthuri, Hanako Daino-Laizure, Albert Doan, Phil Achacoso, Jane Lamerdin. DiscoveRx Corp., Fremont, CA

B081 *(Tuesday)*
Cytokines and Chemokines Analysis in Pregnant Women with Erythrocyte Alloimunization
Juliana A.C. Schettini, Thomás V. Gomes, Alexandra Karla S. Barreto, Claudeir D. Silva Júnior, Marina C. da Matta, Isabela C. Coutinho, Maria do Carmo V.C. Oliveira, Leuridan C. Torres. Institute de Med. Integral Prof. Fernando Figueira (IMIP), Recife, Brazil; Fndn. de Hematol. e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil

B082 *(Sunday)*
Combinatorial Targeting of TSLP, IL-25, and IL-33 in Type 2 Cytokine-Driven Inflammation and Fibrosis
Kevin M. Vannella, Thirumalai R. Ramalingam, Allen W. Cheever, Lee A. Borthwick, Luke Barron, Kevin M. Hart, Robert W. Thompson, Kristen N. Kindrachuk, Sandra White, Alison L. Budelsky, Michael R. Comeau, Dirk E. Smith, Thomas A. Wynn. Natl. Institute of Allergy and Infectious Disease, NIH, Bethesda, MD; BioMed. Research Institute, Rockville, MD; Newcastle Univ., Newcastle-upon-Tyne, UK; Amgen Inc., Thousands Oaks, CA

B083 *(Monday)*
Deciphering the Deleterious Effect of IFN-γ in a New Rodent Model for Experimental Severe Malaria
Norinne Lacerda-Queiroz, Nicolas D. Riteau, Richard Eastman, Alan Sher, Dragana Jankovic, Xin-Zhuan Su. Natl. Institute of Allergy and Infect. Dis., NIH, Rockville, MD

B084 *(Tuesday)*
Immune Response to Latency Associated *Mycobacterium tuberculosis* Antigen among Latent and Active TB Patients
Manju Namdeo, Dipendra Kumar Mitra, Deepshi Thakral, Steven G. Reed, Rhea Coler. All India Institute of Med. Science, New Delhi, India; Infectious Disease Research Institute, Seattle, WA

B085 *(Sunday)*
***Porphyromonas gingivalis'* Nucleoside Diphosphate Kinase Contributes to IL-1β Production and Secretion in Macrophages**
Cássio L C Almeida-da-Silva, Gabrielle C. Rocha, Erivan S. Ramos-Júnior, Ana Carolina F. Morandini, Júlio Scharfstein, Özlem Yilmaz, David M. Ojcius, Robson Coutinho-Silva. Federal Univ. of Rio de Janeiro, Brazil; Univ. of Florida, Gainesville, FL; Univ. of the Pacific, Stockton, CA

B086 *(Monday)*
ARF6 Inhibition Stabilizes the Vasculature without Compromising the Immune Response of Cytokines
Dean Li, Weiquan Zhu, Kirill Ostanin, Alan Mueller. Univ. of Utah; Navigen Pharmaceut., Salt Lake City, UT

B087 *(Tuesday)*
Different Phenotypes of Lung Parenchymal CD4+ T Cells Activation during Aggressive Forms of Tuberculosis
Eduardo P. Amaral, Simone C.M. Ribeiro, Caio Cesar Bomfim, Rafael M. Salgado, Veronica R. Lanes, Mario Hirata, Jose M.M. Alvarez, Elena Lassounskaia, M. Regina D'Imperio-Lima. Univ. of São Paulo, São Paulo, Brazil; State Univ. of North Fluminense, Campos dos Goytacazes, Brazil; Faculty of Pharmaceutical Science, Univ. of São Paulo, São Paulo, Brazil

Epigenetics and Regulation of the Immune Response

B088 *(Sunday)*
Lysine Methyltransferase SETD7 Regulates Oxygen Homeostasis through Oxidative Stress Detoxification and Mitochondria Functions
Shuying He, Dafydd Owen, Scott Jelinsky, Lih-Ling Lin. Pfizer, Cambridge, MA

B089 *(Monday)*
Effect of Hydrogen Sulfide on Histone Methylation of LPS-Stimulated Macrophages
Ricardo C. Petroni, Denise F. Barbeiro, Thais M. de Lima, Suely K. Ariga, Francisco G. Soriano. Univ. of São Paulo, Med. Sch., Brazil

B090 *(Tuesday)*
Dual Transcriptome Sequencing Reveals Resistance of TLR4 Ligand-Activated Bone Marrow-Derived Macrophages to Inflammation Mediated by the BET Inhibitor JQ1
Amitabh Das, Jin Choul Chai, Chul-su Yang, Young Seek Lee, Kyoung Hwa Jung, Young Gyu Chai. Hanyang Univ., Seoul, South Korea; Hanyang Univ., Ansan, South Korea

Fibrosis and Tissue Remodeling

B091 *(Sunday)*
Identification of Both Immunomodulatory and Anti-fibrotic Actions of Nintedanib and Pirfenidone Using Biomap® Human Primary Cell-Based Disease Models
Sharlene Velichko, Sylvie Privat, Dat Nguyen, Hannah Cho, Alison O'Mahony. BioSeek, a division of DiscoveRx, South San Francisco, CA

B092 *(Monday)*
Disease Relevant In Vitro and In Vivo Models for Lung Fibrosis
Jeroen DeGroot, Krista Ouwehand, Blandine Mille-Baker, Alan Young, McElroy Mary, Joe Cornicelli, David Bonnel, Jonathan Stauber, David F. Fischer. Charles River Laboratories, Leiden, Netherlands; Charles River Laboratories, Oxford, UK; Charles River Laboratories, Edinburgh, UK; Charles River Laboratories. Wilmington, MA, USA; ImaBiotech, Lille, France

B093 *(Tuesday)*
Lineage Tracing of Resident Fibroblasts by the Intratracheal Cell Transfer Elucidates the Cellular Origin of Activated Fibroblasts in Pulmonary Fibrosis
Tatsuya Tsukui, Satoshi Ueha, Shigeyuki Shichino, Yutaka Inagaki, Kouji Matsushima. Grad. Sch. of Med., Univ. of Tokyo, Japan; Grad. Sch. of Med., Tokai Univ., Kanagawa, Japan; Japan Science and Technol. Agency-CREST Program, Tokyo, Japan

B094 *(Sunday)*
Pericyte MyD88 Controls Inflammatory and Fibrotic Responses to Tissue Injury
Irina Leaf, Ivan Gomez, Shunsaku Nakagawa, Bryce Johnson, Jin Joo Cha, Julia Lichtnekert, Kristen Mittelsteadt, Alan Aderem, Bill Altemeier, Jeremy Duffield. Biogen, Cambridge, MA; Univ. of Washington, Seattle; Seattle BioMed, Seattle, WA

B095 *(Monday)*
Polycystic Liver Disease Is Suppressed by IL-4/IL-13 and TGF-β Signaling
David A. Cantu, Kristen Kindrachuk, Lee Borthwick, Doug Morris, Danielle Donahue, David Dorwood, Brenda Klaunberg, Thirumalai Ramalingam, Sandy White, Robert Thompson, Thomas Wynn. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Magnetic Resonance Imaging Research Facility/ Mouse Imaging Facility, NIH, Bethesda, MD; Research Technologies Branch, NIAID/Rocky Mountain Labs, Hamilton, MT

B096 *(Tuesday)*
Evaluating IL-13Rα2 as a Therapeutic Target for Pulmonary Fibrosis
Nikhil Jiwrajka, Thirumalai Ramalingam, Josh Sciurba, Sandy Oland, Rafael Prado, Kevin Hart, Trisha Pasricha, Kevin Vannella, Bernadette Gochuico, Marion T. Kasaian, Thomas A. Wynn. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Natl. Human Genome Research Institute, NIH, Bethesda, MD; Pfizer Research, Cambridge, MA

B097 *(Sunday)*
Crosstalk between Macrophages and Human Hepatic Fibroblasts Show That Inflammatory Response Attenuate the Activation of Fibroblasts in the Fibrosis Response
Sacha Robert, Thomas Gicquel, Aude Bodin, Alain Fautrel, Vincent Lagente, Elisabeth Boichot. UMR991 INSERM and H2P2, Univ. de Rennes, France

B098 *(Monday)*
Pericyte and Myofibroblast Activation Regulated by the TWEAK/Fn14 Pathway
I*van G. Gomez, Naoki Nakagawa, Timothy S. Zheng, Jeremy S. Duffield, Linda C. Burkly.* Biogen, Cambridge, MA; Univ. of Washington, Seattle, WA

GPCRs in Inflammation

B099 *(Tuesday)*
Acetate Protects the Ischemic Intestine from Reperfusion Injury
Zoe V. Schofield, Reena Halai, Matthew A. Cooper, Trent M. Woodruff. Sch. of Biomed. Science, The Univ. of Queensland, Brisbane, Australia

B100 *(Sunday)*
Primary Microglia Adopt a Proinflammatory Phenotype after Exposure to Increased LPA Levels
Joanna Plastira, Eva Bernhart, Astrid Hammer, Wolfgang Sattler. Med. Univ. Graz, Austria

B101 *(Monday)*
Platelet Activating Factor Receptor Controls Adipose Tissue Macrophages Phenotype and Glucose Metabolism
Luciano R. Filgueiras, Francisco J. Rios, Marianna M. Koga, Paula G. Quaresma, Edson K. Ishizuka, Marlise BA Montes, Patricia O. Prada, Mario S. Saad, Sonia Jancar. Univ. of São Paulo, Brazil; Univ. of Glasgow, UK; State Univ. of Campinas, SP, Brazil

B102 *(Tuesday)* **Abstract Withdrawn**
Gut Microbial Metabolites Protect against Autoimmune Diabetes by Preserving Gut Homeostasis and Promoting Peripheral Treg Biology
Eliana Marino, James L. Richards, Keiran H. McLeod, Dragana Stanley, Yu Anne Yap, Hoey Yein Goh, Jose M. Polo, Jan Kranich, Ana Carolina Oliveira, Alan G. Baxter, Trevor J. Lockett, Julie M. Clarke, David L. Topping, Leonard C. Harrison, Charles R. Mackay. Sch. of Biomed. Science, Faculty of Med., Nursing andHealth Sciences, Monash Univ., Clayton, Australia; Central Queensland Univ. Sch. of Med. and Applied Science, Rockhampton, QLD, Australia; Ludwig Maximilians Univ., Munich, Germany; Univ. Federal do Rio de Janeiro, Brazil; James Cook Univ., Townsville, QLD, Australia; CSIRO Preventative Health Natl. Research Flagship, North Ryde, NSW and Adelaide, SA, Austrakia; Walter & Eliza Hall Institute of Med. Research, Parkville, VIC, Australia; The Univ. of Sydney, Camperdown NSW, Australia

B103 *(Sunday)*
Expression and Activation of the Long-Chain Fatty Acid Receptor GPR40 in Human Neutrophils
Patricia R.S. Souza, Hefin R. Jones, Lucy V. Norling, Mauro Perretti. William Harvey Research Institute, Queen Mary Univ. of London, London, UK

B104 *(Monday)*
Importance of the S1P1 Phosphorylation Domains and Receptor Internalization in Regulating Inflammatory Responses
Manisha Menon, Leigh Maher, Kamal M. Khanna. Univ. of Connecticut Health Ctr., Farmington, CT

Immunotherapeutics

B105 *(Tuesday)*
Deciphering the Human Anti-carbohydrate Repertoire of IgG, IgA and IgM
Christoph Schneider, Marc Wehrli, David F. Smith, Richard D. Cummings, Alex Straumann, Adrian Zürcher, Stephan von Gunten. Univ. of Bern, Switzerland; Emory Univ. Sch. of Med., Atlanta, GA; Kantonsspital, Olten, Switzerland and CSL Behring, Bern, Switzerland

B106 *(Sunday)*
Site-Targeting Nitroglycerin Nanotherapeutic for Local Immunosuppression without Induction of Tolerance
Soroush Ardekani, Shane Eum, Sharad Gupta, Harry A. Scott, Xiao Yang, Alexander R. Brunelle, Sean M. Wilson, Umar Mohideen, Kaustabh Ghosh. Univ. of California, Riverside, CA; Loma Linda Univ. Sch. of Med., Loma Linda, CA; Indian Inst. of Technol., Indore, India

B107 *(Monday)*
Interferon Beta Cell Therapy Showed Anti-tumor Effects Associated with Inhibition of Tumor Cell Proliferation and Activation of Immune Cells
Masaki Nakamura, Lisa Kagawa, Norihiro Nakada, Masashi Satoh, Shotaro Maehana, Fumiaki Kojima, Hideki Amano, Yoshiki Murakumo, Kazuya Iwabuchi, Masataka Majima, Hidero Kitasato. Kitasato Univ. Sch. of Allied Health Sciences; Kitasato Univ. Sch. of Med.; Kitasato Univ. Grad. Sch. of Med. Science, Sagamihara, Japan

B108 *(Tuesday)*
Evaluation of Molecular Markers and Therapeutic Targets in TNBS-Model of Intestinal Inflammation
Aline Witaicenis Fantinati, Alexandre S. Chagas, Alexandre Tanimoto, Luiz C. Di Stasi. São Paulo State Univ. – UNESP, Botucatu, SP, Brazil

B109 *(Sunday)*
Leukotriene B4 Is a Homeostatic Component of Methicillin-Resistant *Staphylococcus aureus* Skin Infection
Stephanie Brandt, Soujuan Wang, Sebastian Carrasco, Stacy Blank, Nathan Delafield, C. Henrique Serezani. Indiana Univ. Sch. of Med., Indianapolis, IN

B110 *(Monday)*
Targeting Normal and Neoplastic Human B Cells In Vitro and In Vivo Using Antibody-Mediated Delivery of siRNA
Gary P. Sims, Fred Karnell III, Lena Shirinian, Vladimir Voynov, Daniel C. Rowe, Marlon C. Rebelatto, Elizabeth Ward, Bo Chen, Nazzareno Dimasi, Changshou Gao, Ronald Herbst. MedImmune, Gaithersburg, MD

B111 *(Tuesday)*
A Nonhuman Primate Model of Allergic Rhinitis as a Mechanistic Model for Food Allergy
Joanne Schiding, Nick Colletti, Mike Shaw, Neil Fitch. Sanofi US Inc, Cambridge, MA

B112 *(Sunday)*
The LPS Tolerance Affects on CD4, Treg and Th17 Lymphocytes
Mariana M. Andrade, Andre Botega, Denise F. Barbeiro, Hermes Barbeiro, Francisco G. Soriano. Med. Faculty of São Paulo Univ., São Paulo, Brazil

B113 *(Monday)*
The Effect of Transcutaneous Cervical Electrical Vagal Nerve Stimulation on Autonomic Indices in Healthy Humans – A Potential Anti-inflammatory Therapy?
J.P. Errico, Christina Brock, Bruce Simon, Qasim Aziz, Asbjorn M. Drewes, Adam D. Farmer. Univ. of Aalborg, Denmark; Barts and the London Sch. of Med., London, UK; ElectroCore Med. LLC, Basking Ridge, NJ

Inflammasomes in Health and Disease

B114 *(Tuesday)*
Involvement of P2X4 and P2X7 Purinergic Receptors in IL-1β Production and NLRP3-Inflammasome Pathway Activation in Human Macrophages
Thomas Gicquel, Sacha Robert, Pascal Loyer, Tatiana Victoni, Aude Bodin, Catherine Ribault, Gleonnec Florence, Isabelle Couillin, Elisabeth Boichot, Vincent Lagente. UMR991 INSERM, Univ. de Rennes; CHU Rennes, France; Univ. d'Orléans, France

B115 *(Sunday)*
Inflammasome Activation by Lanthanide Upconversion Nanoparticles and Its Abrogation by a Surface Coating Peptide
Longping Wen, Yunjiao Zhang, Han Yao. Sch. of Life Science, Univ. of Science & Technol. of China, Hefei, China

B116 *(Monday)*
Whole Exome Analysis of Individuals and Families with Chronic Recurrent Multifocal Osteomyelitis
Allison J. Cox, Benjamin W. Darbro, Xinyu Bing, Alexander G. Bassuk, Polly J. Ferguson. Univ. of Iowa, Iowa City, IA

B117 *(Tuesday)*
p38delta MAPK – A Novel Effector in NLRP3 Inflammasome Activation Upregulated in Human Coronary Atherosclerotic Lesions
Kristiina Rajamaki, Mikko I. Mayranpaa, Jarno Tuimala, Katariina Nurmi, Kari K. Eklund, Katariina Oorni, Petri T. Kovanen. Wihuri Research Institute, Helsinki, Finland; Haartman Institute, Univ. of Helsinki and Meilahti Labs of Pathology, Helsinki; Helsinki Univ. Central Hosp.; RS Training, Helsinki, Finland

B118 *(Sunday)*
NLRC4 Is Involved in Activation of the NLRP3 Inflammasome in Response to *Leishmania amazonensis* Infection
Alexandre L.N Silva, Djalma S. Lima-Junior, Larissa D. Cunha, Dario S. Zamboni. Univ. of São Paulo, Med. Sch. Ribeirão Preto, Brazil; St Jude Children's Research Hosp., Memphis, TN

B119 *(Monday)*
***L. amazonensis* Elimination by P2X7 Receptor and Leukotriene B4 Requires NLRP3 Inflammasome Activation and IL-1R Signaling**
Mariana M. Chaves, Débora A. Sinflório, Maria Bellio, Dario Zamboni, Cláudio Canetti, Robson Coutinho-Silva. Federal Univ. of Rio de Janeiro; Univ. of São Paulo, Brazil

Inflammation and Aging

B120 *(Tuesday)*
Measurement of Nitric Oxide Metabolites as Potential Markers of Inflammation in Dementia
Annie Knight, Miranda J. Smallwood, Emma Taylor, David Llewellyn, Patrick G. Kehoe, Paul G. Winyard. Univ. of Exeter Med. Sch., Exeter, UK; Univ. of Bristol Sch. of Clinical Sciences, Southmead Hosp., Bristol, UK

B121 *(Sunday)*
Dysregulation of Resolution of Acute Inflammation in Aged Humans
Roel P.H. De Maeyer, Madhur Motwani, Justine S. Newson, Derek W. Gilroy. Ctr. for Clinical Pharmacology and Therapeutics, University Col. London, UK

Inflammation and Cancer

B122 *(Monday)*
Role of Inflammation in Promotion and Progression of Endometrial Hyperplasia
Anatoliy V. Kubyshkin, Evgeniia Kovalenko, Leonid Aliev, Vladimir Kubyshkin. V.I. Vernadsky Crimea Federal Univ., Simferopol, Crimea

B123 *(Tuesday)*
IL-1 Receptor Antagonist and Dexamethasone Therapy in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Patients with a Decreased C-Reactive Protein: Interplay between IL-1, IL-6 and IL-17
John A. Lust, Kathleen A. Donovan. Mayo Clinic, Rochester, MN

B124 *(Sunday)*
Analysis of Allelic and Genotypic Frequency of GHRL-4427G>A Polymorphism in a Sample of the Kuwaiti Population and Lymphoma Patients
Maryam H. Alrashid, Suzanne A. Al-Bustan, Jeethu Anu Geo. Kuwait Univ., Safat, Kuwait

B125 *(Monday)*
Control of Lung Cancer with Aspirin-Triggered Stimulation of Resolution
Molly M. Gilligan, Megan L. Sulciner, Sesquile Ramon, Romain A. Colas, Sui Huang, Charles N. Serhan, Dipak Panigrahy. Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA; Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA; Brigham and Women's Hosp., Harvard Med. Sch., Boston, MA; Institute for Systems Biology, Seattle, WA

B126 *(Tuesday)* **Abstract Withdrawn**
Lipoxin A4 Selectively Shifts, In Vitro and In Vivo, the Profile of Tumor-Associated Macrophages, Impairing the Tumor Growth and Angiogenesis
Christina Barja-Fidalgo, Rafael L. Simões, Natalia M. Brito, Hayandra C. Costa, Veronica Morandi, Iolanda M. Fierro. IBRAG, Univ. do Estado do Rio de Janeiro, Brazil

B127 *(Sunday)*
Controlling Breast Cancer through the Stimulation of Resolution
Kristen A. Lehner, Megan Sulciner, Sesquile Ramon, Sui Huang, Charles Serhan, Dipak Panigrahy. Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA; Brigham and Women's Hosp. and Harvard Med. Sch., Boston, MA; Institute for Systems Biology, Seattle, WA

B128 *(Monday)*
Peritoneal Leukocyte Biology Disruption during Inflammatory Ovarian Cancer
James E. Riggs, Kelley DePierri, Naomi Goldman, Gretel Torres, John Somerville. Rider Univ., Lawrence, NJ

B129 *(Tuesday)*
Modulation of Inflammatory Response Induced by Inhibitor Molecules of the Kinesin EG5 with Pronounced Antitumor Activity against Breast Cancer
Luis Felipe F. Silva, Rafael Correa, Breno A.D. Neto, José Raimundo Correa, Kelly G. Magalhães. Univ. of Brasília, Brazil

Inflammation and Metabolic Disorders

B130 *(Sunday)*
Adipose Tissue Inflammation and Remodeling during Weight Cycling in Mice
Cíntia R.P. Caria, Caroline C. Oliveira, Érica M.F. Gotardo, Tanila W. dos Santos, Alessandra Gambero. São Francisco Univ., São Paulo, Brazil

B131 *(Monday)*
Serum Antibodies to Enterobacterial Lipopolysaccharides and Their Relationship with Inflammatory Markers in Diabetes Mellitus
Anatoliy V. Kubyshkin, Andrey Gordienko, Vladimir Beloglazov, Natalia Khimich, Yuliana Shramko. V.I. Vernadsky Crimea Federal Univ., Simferopol, Crimea

B132 *(Tuesday)*
Primary Human Cell-Based Models for Metabolic Syndrome
Jeroen DeGroot, Annelieke Strijbosch, Folkert Verkaar, Blandine Mille-Baker, Joe Cornicelli, David F. Fischer. Charles River Labs, Leiden, Netherlands; Charles River Labs, Wilmington, MA

B133 *(Sunday)*
Inflammatory Markers in Patients with Stable Angina and Diabetes Mellitus of Type 2
Ludmilla I. Gapon, Tatiana I. Petelina, Natalia A. Musikhina, Irina V. Osipova, Vadim A. Kuznetsov. Tyumen Cardiology Ctr., Tyumen, Russia

B134 *(Monday)*
Iron Supplementation Effects on Systemic and Adipose Tissue Inflammation during Obesity in Mice
Alessandra Gambero, Cintia R.P. Caria, Erica M.F. Gotardo. São Francisco Univ., Bragança Paulista, Brazil

B135 *(Tuesday)*
Evaluation of the Uric Acid Effect in Inflammatory Response
Larissa A.C. Carvalho, Eliziane S. Patricio, João P.P. Bonifacio, Flavia C. Meotti. Univ. de São Paulo, Brazil

B136 *(Sunday)*
Physiologically Digested Carrageenan Affects Intestinal Barrier Function
Lulu Fahoum, Uri Lesmes, Esther G. Meyron. Technion-Israel Institute of Technol., Haifa

B137 *(Monday)*
HMW Adiponectin Suppress LPS-Induced IL-1β Expression through Inhibiting Akt-C/EBPβ Inflammatory Signaling in RAW264.7 Macrophage
Toshihiro Tanioka, Yoshinao Tainaga, Michiyo Yamada, Yuuri Kamimura, Mariko Suzuki, Saori Takatori, Yasuko Nakano. Showa Univ. Sch. of Pharmacy, Tokyo, Japan

Inflammatory Cell Signaling

B138 *(Tuesday)*
Erythropietin Protects Endothelial Cell from High Glucose Induced Injury
Yasunori Iwata, Yasuyuki Shinozaki, Haruka Yasuda, Kengo Furuichi, Norihiko Sakai, Takashi Wada. Kanazawa Univ., Japan

B139 *(Sunday)*
Salt-Inducible Kinases Inhibition in Human Myeloid Cells Modulates TLR and IL-1R Signaling and Induces an Anti-inflammatory Phenotype
Maria Stella Lombardi, Corine Gilliéron, Damien Dietrich, Cem Gabay. Univ. Hosps. of Geneva and Univ. of Geneva Sch. of Med., Switzerland

B140 *(Monday)*
Evaluation of Glutamine as Modulator of the Transcription Factor NF-κB in Macrophages from Mice Subjected to Dietary Restriction
Dalila C. Oliveira, Ed W. Santos, Jackeline S. Beltran, Primavera Borelli, Ricardo A. Fock. Univ. of São Paulo Sch. of Pharmaceutical Science, São Paulo, Brazil

B141 *(Tuesday)*
Effect of Uric Acid in the Bactericidal Activity of Innate Immune Cells
João P.P. Bonifacio, Larissa A.C. Carvalho, Flavia C. Meotti. Univ. of São Paulo, Brazil

B142 *(Sunday)*
***Mycobacterium bovis* BCG Enhances PPARγ Expression/Activation through mTOR Dependent Pathways and Compartmentalizes Important Cell Signaling Enzymes within Lipid Droplets**
Alan B. Carneiro, Henrique N.S. Carvalho, Tamyres S. Salles, Giovana H. Carvalho, Miriam B. Werneck, João P. Viola, Heloísa D'Ávila, Patrícia T. Bozza. Institute Oswaldo Cruz, FIOCRUZ-RJ, Brazil; Natl. Cancer Institute, Rio de Janeiro; Univ. Federal de Juiz de For a, MG, Brazil

B143 *(Monday)*
Platelets Mediate Monocyte and Endothelial Cell Activation in Dengue through Platelet-Cell Interaction and Cytokine Signaling
Eugenio D. Hottz, Juliana F. Lopes, Gisele Barbosa-Lima, Isabel Medeiros-de-Moraes, Andrew S. Weyrich, Guy A. Zimmerman, Fernando A. Bozza, Patrícia T. Bozza. IOC, Fiocruz, Rio de Janeiro, Brazil; INI, Fiocruz, Rio de Janeiro, Brazil; Univ. of Utah, Salt Lake City, UT

Inflammatory Mediators

B144 *(Tuesday)*
Insularin Reduces Inflammation in an Experimental Model of Renal Ischemia and Reperfusion
Reinaldo C. Silva, Raphael J.F Felizardo, Marcos A. Cenedeze, Álvaro Pacheo-Silva, Maisa Della-Casa. Univ. of São Paulo; Federal Univ. of São Paulo; Institute Butantan, São Paulo, Brazil

B145 *(Sunday)*
Early Identification of Secondary Bacterial Infections
Praveen Papareddy, Gopinath Kasetty, Erik Malmström, Johan Malmström , Heiko Herwald. Lund Univ., Sweden

B146 *(Monday)*
Dual Functionality of Alpha1-Antitrypsin: An Inflammatory S-Nitrosylated Form Stimulates Macrophages during Bacterial Infections
Ziv Kaner, Galit Shahaf, Shahar Dotan, Rotem Engelman, Yaffa Mizrachi Nebenzahl, Moran Benhar, Eli C. Lewis. Ben-Gurion Univ. of the Negev, Beer Sheva, Israel; Technion Israel Institute of Technology, Haifa, Israel

B147 *(Tuesday)*
Maternal Obesity and Markers of Inflammation in Blood and Human Milk
Mahmi Fujimori, Vanessa Fiorin, Tassiane C. Morais, Eduardo L. França, Adenilda C. Honório-França, Luiz C. Abreu. Univ. of São Paulo; Sch. of Med. of ABC; Federal Univ. of Mato Grosso, Brazil

B148 *(Sunday)* **Abstract Withdrawn**
Mas Receptor Deficiency Exacerbates Lipopolysaccharide-Induced Inflammation in the Mouse Brain
Onésia Cristina Oliveira Lima, Mauro Cunha Xavier Pinto, Johan Duchene, Michael Bader, Natalia Alenina, Robson Augusto Souza Santos, Juliana Carvalho Tavares. Federal Univ. of Minas Gerais, Belo Horizonte, Brazil; Max Delbrück Ctr. for Molecular Med., Berlin, Germany

B149 *(Monday)*
Peritonitis as a Key Tool for Evaluation of Resolution Pharmacology
Vincent Baillif, Gérald Chêne, Charlotte Guigné, Estelle Wanecq, Emeline Van Goethem, Marc Dubourdeau. Ambiotis SAS, Toulouse, France

B150 *(Tuesday)*
Deciphering the Signals Required for Follicular Helper T Cell Generation in the Absence of Exogenous Microbial Stimuli
Nicolas Riteau, Sandy D. Oland, Dragana Jankovic, Alan Sher. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

B151 *(Sunday)*
CTX-4430, a Potential First-In-Class Leukotriene A4 Hydrolase Inhibitor for Treatment of Inflammatory Diseases
E. Springman, R. Grosswald, L. Bhatt, T. Van, S. Ahuja. Celtaxsys Inc., Atlanta, GA

B152 *(Monday)*
Cathelicidin Related Antimicrobial Peptide Contributes to Bacterial Clearance at Early Stage of Pulmonary Infection with *Acinetobacter baumannii*
Seong Gak Jeon, Jun-Young Lee, Yu-Jin Jeong, Min-Jung Kang, Jong-Hwan Park. Konyang Univ., South Korea; Chonnam National Univ., South Korea

Inflammatory Pain and Analgesia

B153 *(Tuesday)*
Colony-Stimulating Factor-1 and Tumor Necrosis Factor-α in Arthritic Pain and Disease
Reem A. Saleh, Derek Lacey, John Hamilton, Andrew Cook. Royal Melbourne Hosp., The Univ. of Melbourne, Parkville, Australia

B154 *(Sunday)*
Limonene Reduces Hyperalgesia Induced by gp120 and Cytokines by Modulation of NF-κB, SOD IL-1 –β in Mice
Candida A.L. Kassuya, Ana Claudia Piccinelli, Priscila N. Morato, Elisabete C. Konkiewitz, Edward B. Ziff, Julio Croda. Federal Univ. of Grande Dourados, Col. of Health Sciences, Dourados, Brazil; New York Univ. Sch. of Med., New York, NY; Oswaldo Cruz Fndn., Campo Grande, Brazil

B155 *(Monday)*
Anti-inflammatory and Anti-oxidant Effects of Standardized Extract of *Ocimum gratissimum* L Leaves in Carrageenan/Kaolin-Induced Monoarthritis in Rats
Abayomi M. Ajayi, Benneth Ben-Azu, Samuel E. Okhale, Olusegun G. Ademowo. Faculty of Basic Med. Science, Col. of Med., Univ. of Ibadan, Ibadan, Nigeria; Natl. Institute for Pharmaceut. R&D, Abuja, Nigeria

B156 *(Tuesday)*
Anti-inflammatory and Antinociceptive Effects of New N-Phenyl-Pyrazole Compound
D*aiany P.B. Silva, Iziara F. Florentino, Daniela C. Vinhal, Luiz C. Cunha, Ricardo Menegatti, Elson A. Costa.* Institute of Biol. Science, Federal Univ. of Goias, Goiânia, GO, Brazil; Faculty of Pharmacy, Federal Univ. of Goias, Goiânia, GO, Brazil

B157 *(Sunday)*
Lectin from *Abelmoschus esculentus* Decreases Levels of TNF-α and IL-1β and Down-Regulates Heme Oxygenase-1 on Zymosan-Induced Temporomandibular Joint Inflammatory Hypernociception in Rats
Mirna M.B. Brayner, Raul S. Freitas, José Thalles J.G.D. Lacerda, Tatiane Santi-Gadelha, Carlos Alberto D.A. Gadelha, Vicente de Paulo T. Pinto, Gerardo C. Filho, Karuza M.A. Pereira, Gerly Anne D.C. Brito, Hermany C. Freitas, Renata F.D.C. Leitão, Ellen. Federal Univ. of Ceará, Sobral; Federal Univ. of Pernambuco; Federal Univ. of Paraíba; Federal Univ. of Ceará, Fortaleza, Brazil

B158 *(Monday)*
A Semi-synthetic Derived from Naturally Occurring *Tephrosia toxicaria* Pers. Reduces TNFα and Il-1β Levels and Activates μ, δ, and κ Receptors in the Model of Formalin-Induced Temporomandibular Joint Inflammatory Hypernociception in Rats
Mirna M.B. Brayner, Danielle R.D. Val, Alice R.D. Freitas, Rodrigo D.S. Santos, Fernanda M.L.D.S. Lopes, Raul S. Freitas, Maria V.S. Teixiera, Aldênia R.D. Santos, Francisca R.L.D. Silva, Angela M.C. Arriaga, Cristina G.D. Macedo, Simone M.S. Lamana, Juli. Federal Univ. of Ceará; Federal Univ. of Pernambuco; State Univ. of Campinas, Brazil

B159 *(Tuesday)*
Anti-inflammatory and Anti-nociceptive Effects of GYY-4137, a Slow-Releasing Hydrogen Sulfide Donor, on Temporomandibular Joint Synovitis Induced by Carrageenan in Rats
Flavia B. Lira, Marcos A. de Paula, Simone A. Teixeira, Mark Wood, Matt Whiteman, Soraia K. Costa, Marcelo N. Muscara. Institute of BioMed. Science, Univ. of São Paulo, Brazil; Univ. of Exeter Med. Sch., UK

B160 *(Sunday)*
Therapeutic Efficacy of Fish Oil Concentrate on Experimental Model of Neuropathic Pain
Ana Luisa P. Miranda, Rafaela V. Silva, Cleverton Kleiton F. Lima, Ewerton P.A. Santos, Bianca W. Lobo. Federal Univ. of Rio de Janeiro, Brazil

Inflammatory Processes in Cardiovascular Diseases

B161 *(Monday)*
Evaluation of the Effects on Cardiovascular Parameters by Chronic Treatment with Selective Cyclooxygenase 2 Inhibitors in Normal Rats
Janetti N. Francischi, Regina M.M. Turchetti-Maia, Ligia F. Brenck, Taissa I.C. Frade, Geovanne D. Cassali, Andrea S. Haibara. Federal Univ. of Minas Gerais, Belo Horizonte, Brazil

B162 *(Tuesday)*
Persistence of Inflammation According to Endomyocardial Biopsy and Cardiac Magnetic Resonance and the Level of Circulating Autoantibodies and Cytokines in Patients with Dilated Cardiomyopathy and Conduction Disturbances
Elena Gupalo, Natalia Mironova, Liudmila Buryachkovkaya, Olga Stukalova, Tatiana Malkina, Tatiana Sharf, Evgeniy Efremov, Petr Chumachenko, Sergei Golitsyn. Russian Cardiology Research and Production Complex, Moscow, Russia

B163 *(Sunday)*
A Complex Atherosclerotic Phenotype of Mif Gene-Deficient Mice in an Atherogenic ApoE-/- Background Uncovers a Novel Connection between MIF and B Cells
Corinna Schmitz, Omar El Bounkari, Christina Klasen, Heidi Noels, Jürgen Bernhagen. RWTH Aachen Univ., Aachen, Germany

B164 *(Monday)*
Macrophage Lipid Loading Leads to Type I Interferon Hyporesponsiveness
Marieke C.S. Boshuizen, Marten A. Hoeksema, Annette E. Neele, Saskia van der Velden, Jan Van den Bossche, Menno P.J. de Winther. Academic Med. Ctr., Univ. of Amsterdam, Netherlands

B165 *(Tuesday)*
Higher Myocardial Inflammation in DCM Patients Submitted to Heart Transplant Was Associated with Good Pulse Therapy Response with Decrease in Bacteria Antigen Levels in the Myocardium
Joyce T. Kawakami, Maria de Lourdes Higuchi, Renata N. Ikegami, Marcia M. Reis, Pablo Pomerantzeff, Sandrigo Mangini, Fernando Bacal, Edmar Bocchi. Heart Institute (InCor) - Univ. of São Paulo Clin. Hosp., São Paulo, Brazil

B166 *(Sunday)*
Heart Failure in Chagas' Disease May Be Related to Microparticles and Archaeal Elements in the Serum
Joyce T. Kawakami, Maria de Lourdes Higuchi, Jaqueline J. Pereira, Barbara Ianni, Sandrigo Mangini, Renata N. Ikegami, Marcia M. Reis, Edmar Bocchi. Heart Institute (InCor) – Univ. of São Paulo Clin. Hosp., São Paulo, Brazil

B167 *(Monday)*
Inflammatory Markers in Patients with Unstable Angina after Coronary Angioplasty and Stenting
Ludmila I. Gapon, Natalia A. Musikhina, Tatiana I. Petelina, Irina V. Osipova, Vadim A. Kuznetsov. Tyumen Cardiology Ctr., Tyumen, Russia

B168 *(Tuesday)*
Small Intestine Modulates Systemic Inflammation and Cardiovascular Function Induced by Dietary Oxidized Fatty Acids through Lysophosphatidylcholine Pathway
Azadeh Esmaeili. David Geffen Sch. of Med., Univ. of California Los Angeles

B169 *(Sunday)*
To Non-invasively Detect and Characterize Myocardial Inflammation in an Experimental Rat Model of Myocarditis
Priyadarshini A. Panjwani, Valérie Boivin-Jahns, Xavier Helluy, Takahiro Higuchi, Yu-Xiang Ye, Franz Kaiser, Karin Klingel, Karl-Heinz Hiller, Peter Jakob, Martin Lohse, Roland Jahns. Univ. of Würzburg; Univ. Hosp. of Würzburg; Research Ctr. Magnetic Resonance Bavaria, Würzburg; Univ. Hosp. of Tübingen, Germany

B170 *(Monday)*
CP-3(iv), a Novel Azapeptide That Binds Scavenger Receptor CD36, Attenuates Infarct Size and Oxidative Stress and Preserves Cardiac Function in a Murine Model of Transient Myocardial Ischemia
David N. Huynh, Valérie L. Bessi, Liliane Ménard, Jérôme Piquereau, Caroline Proulx, Maria Febbraio, William D. Lubell, André C. Carpentier, Yan Burelle, Huy Ong, Sylvie Marleau. Univ. de Montreal; Univ. of Alberta; Univ. de Sherbrooke, Canada

B171 *(Tuesday)*
The Level of Circulating Large Reticulated Platelets and Inflammation in Patients with Acute Coronary Syndrome Treated with Primary Percutaneous Intervention
Nikita V. Lomakin, Ludmila I. Buryachkovskaya, Alexander B. Sumarokov, Irina A. Uchitel. Central Clin. Hosp. of Presidential Administration of Russian Federation; Russian Cardiology Research Complex, Moscow, Russia

B172 *(Sunday)*
Mesenteric Artery Relaxation to Exogenous Nitric Oxide In Vitro Is Impaired in Rats with Ligature-Induced Periodontitis
Flavia N. de Jesus, Elly S. do Amaral Neto, Camila F. Wenceslau, Simone A. Teixeira, Aline Maia-Dantas, Gisele K. Couto, Luciana V. Rossoni, Luis C. Spolidorio, Soraia K. Costa, Marcelo N. Muscara. Univ. of São Paulo; State Univ. of São Paulo, Brazil

B173 *(Monday)*
The Inducible Nuclear Protein IκBζ Regulates the Transition from Adaptive Cardiac Hypertrophy to Heart Failure during Pressure Overload
Yasutomi Higashikuni, Daiju Fukuda, Masataka Sata, Issei Komuro. The Univ. of Tokyo; Univ. of Tokushima, Japan

B174 *(Tuesday)*
Drug A Suppresses Inflammatory Responses Induced by 27-Hydroxycholestreol
Bo Young Kim, Koanhoi Kim. Pusan National Univ. Sch. of Med., Yangsan, South Korea

Inflammatory Processes in Central Nervous System Diseases

B175 *(Sunday)*
Modulation of Immune-Induced and Traumatic CNS Injury by Dendritic Cells' Expression of CEBPD, a Novel Therapeutic Target
Masoud Hassanpour Golakani, Mohammad G. Mohammad, Vicky W. Tsai, Hui Li, Marc Ruitenberg, Samuel N. Breit, Paul E. Sawchenko, David A. Brown. St Vincent's Ctr. for Applied Med. Research and Univ. of New South Wales, Sydney, Australia; The Univ. of Queensland, Brisbane, Australia; The Salk Institute for Biological Studies, La Jolla, CA

B176 *(Monday)*
Annexin A1 Modulates the LPS-Induced TSPO Expression in BV2 Cells
Lorena N. Pantaleao, Rodrigo Azevedo, Erick Barioni, Mauro Perretti, Egle Solito, Sandra P. Farsky. Univ. of São Paulo, Brazil; Queen Mary Univ. of London, England

B177 *(Tuesday)*
Effects of gp120 Glycoprotein Injection at Nucleus Accumbens in Rodent
Elisabete C. Konkiewitz, Ana C. Piccinelli, Priscila N. Morato, José A. Pochapski, Edmar Miyoshi, Edward B. Ziff, Cândida L. Kassuya. Univ. Federal da Grande Dourados, Mato Grosso do Sul, Brazil; New York Univ., New York, NY; Univ. Estadual de Ponta Grossa, Paraná, Brazil

B178 *(Sunday)*
Dynamics of Inflammatory Immune Response in a Mouse Model of Traumatic Spinal Cord Injury
Masoud Hassanpour Golakani, Mohammad G. Mohammad, Hui Li, Marc Ruitenberg, Samuel N. Breit, David A. Brown. St Vincent's Ctr. for Applied Med. Research and Univ. of New South Wales, Sydney, NSW Australia; The Univ. of Queensland, Brisbane, QLD, Australia

B179 *(Monday)*
Maternal IL17 Pathway Promotes Autism–Like Phenotypes in Offspring
Jun Huh. Univ. of Massachusetts Med. Sch., Worcester, MA

B180 *(Tuesday)*
IL-33 Signalling Is Essential to Attenuate the Development of Viral Induced Encephalitis by Downregulating iNOS Expression in the Central Nervous System
Rafael F.O. Franca, Renata S. Costa, Jaqueline R. Silva, Raphael S. Peres, David F. Colon, Fernando Q. Cunha. Oswaldo Cruz Fndn, FIOCRUZ; Univ. of São Paulo, Recife, Brazil

Inflammatory Processes in Shock and Trauma

B181 *(Sunday)*
Role of HMGB1 in Nucleic Acid-Mediated Innate Immune Responses and Inflammatory Diseases
Hideyuki Yanai. Univ. of Tokyo, Japan

B182 *(Monday)*
The Role of Inflammation in Formation of Multiple Organ Dysfunction Syndrome at Critical States
Anatoliy V. Kubyshkin, Ludmila Anisimova, Michail Fedosov, Irina Fomochkina, Vladimir Kharchenko, Viacheslav Mikchailichenko, Olga Malchenko. V.I. Vernadsky Crimea Federal Univ., Simferopol, Crimea

B183 *(Tuesday)*
Phosphatase and Tensin Homolog Controls Macrophage Endotoxin Tolerance
Nicole L. Glosson-Byers, Soujuan Wang, C. Henrique Serezani. Indiana Univ. Sch. of Med., Indianapolis, IN

B184 *(Sunday)*
Estradiol Modulates Leucocytes Mobilization after Intestinal Ischemia/Reperfusion in Female Rats
Evelyn T. Fantozzi, Fernanda Y. Ricardo da Silva, Sara Rodrigues Garbin, Ricardo M. Oliveira Filho, Bernardo B. Vargaftig, Ana Cristina Breithaupt Faloppa, Wothan Tavares de Lima. Univ. of São Paulo; Heart Institute (InCor), São Paulo Univ. Med. Sch., Brazil

B185 *(Monday)*
Estradiol Affects the Leukocyte Mobilization Caused by Intestinal Ischemia and Reperfusion in Male Rats
Evelyn T. Fantozzi, Fernanda Y Ricardo da Silva, Sara Rodrigues Garbin, Ricardo M. Oliveira Filho, Bernardo B. Vargaftig, Ana Cristina Breithaupt Faloppa, Wothan Tavares de Lima. Univ. of São Paulo; Heart Institute (InCor), São Paulo Univ. Med. Sch., Brazil

B186 *(Tuesday)*
Extracellular microRNA Promotes Complement Factor B Expression via TLR7-MyD88 Signaling in Bacterial Sepsis
Lin Zou, Ganqiong Xu, Yan Feng, Wenling Jian, Wei Chao. Massachusetts General Hosp., Harvard Med. Sch., Charlestown, MA

B187 *(Sunday)*
Lung Inflammation and Inducible Nitric Oxide Sintase after Brain Death: Proestrus Female versus Male Donors
Ana Cristina Breithaupt-Faloppa, Sueli G. Ferreira, Guilherme K. Kudo, Roberto Armstrong Junior, Wothan Tavares de Lima, Paulina Sannomiya, Luiz Felipe P. Moreira. Heart Institute, São Paulo Univ. Med. Sch.; ICB, Univ. of São Paulo, Brazil

B188 *(Monday)*
Effects of Co-ultraPEALut on Inflammatory Events Associated with Traumatic Brain Injury
Rosalia Crupi, Giuseppe Bruschetta, Irene Paterniti, Rosalba Siracusa, Marika Cordaro, Emanuela Esposito, Salvatore Cuzzocrea. Univ. of Messina, Italy; Manchester Royal Infirmary, Sch. of Med., Univ. of Manchester, UK

Inflammatory Responses, Stem Cells and Tissue Regeneration

B189 *(Tuesday)*
Factors Secreted from Dental Pulp Stem Cells Show Multifaceted Benefits for Treating Acute Lung Injury in Mice
Hirotaka Wakayama, Naozumi Hashimoto, Yoshihiro Matsushita, Noriyuki Yamamoto, Masaya Nishikawa, Yoshinori Hasegawa, Akihito Yamamoto. Nagoya Univ., Japan

B190 *(Sunday)*
Protective Effect of Hematopoietic Stem Cells in Stroke
Felicity N.E. Gavins, Helen K. Smith, Shantel Vital, D. Neil Granger. LSU Health Sciences Ctr.-Shreveport, LA

Inflammatory Skin Disorders

B191 *(Monday)*
Development of a Model of Dermal Inflammation and Irritation (Urticaria) in the Miniature Swine
Miao Zhong, Alain Stricker-Krongrad, Jason Liu, Guy Bouchard. Sinclair Research Ctr. LLC, Auxvasse, MO

B192 *(Tuesday)*
Does Substance P Play a Role in Allergic Contact Dermatitis?
Francis F.Y. Lam, Ethel S.K. Ng, Nick H. Ng. The Chinese Univ. of Hong Kong, Shatin, Hong Kong

B193 *(Sunday)*
Aggregation of Thrombin C-Terminal Fragments – A Novel Host Defense Mechanism
Jitka Petrlova, Finja Hansen. Lund Univ., Sweden

B194 *(Monday)*
***Korthalsella japonica* Alleviates the Dermal and Epidermal Hyperplasia in a Contact Dermatitis Mice Model**
Jinju Kim. Col. of Pharmacy, Kyung Hee Univ., Seoul, South Korea

B195 *(Tuesday)*
Beyond the Adrenal Gland: The Essential Role of Locally Synthesised Glucocorticoids in Regulating Inflammation in Healthy Skin and Psoriasis
Rosalind F. Hannen, Chinedu Udeh-Momoh, Mike Wright, David Halsall, Rod Flower, Lisa Sevilla, Stafford Lightman, Paloma Perez, Mike Philpott. Queen Mary Univ. of London, UK; Univ. of Bristol, UK; Addenbrookes Hosp., Cambridge, UK; Institute de Biomed. De Valencia, Spain

B196 *(Sunday)*
Pharmacological Validation of the Mouse Imiquimod-Induced Psoriasis Model
Harunor Rashid, Fraser McIntosh, Agathe Bedard, Luc Chouinard, Joe Cornicelli, Rana Samadfam. Charles River Labs, Senneville QC, Canada

B197 *(Monday)*
RIP Kinase Signaling in Keratinocyte Controls Necroptosis-Mediated Skin Inflammation
Snehlata Kumari, Manolis Pasparakis. Institute for Genetics, Univ. of Cologne, Germany

B198 *(Tuesday)*
IL-1ß Producing Monocyte-Derived Dendritic Cells Are Critical for IL-23-Induced Skin Inflammation
Tej Pratap Singh, Howard H. Zhang, Michael N. Hedrick, Brian L. Kelsall, Bjorn E. Clausen, Joshua M. Farber. Natl. Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Univ. Med. Ctr. of Johannes Gutenberg Univ. Mainz, Germany

Inhibitory Receptors and Immune Checkpoints

B199 *(Sunday)*
The Anti-inflammatory Activity of the Nuclear Receptor PXR and the Minor Isoform PXR3
Jerusalem Alleyne, Andrew Bennett. Sch. of Biomed. Science, Univ. of Nottingham, UK

Innate Immunity – Macrophages, Dendritic Cells, Neutrophills, Basophils, Mast Cells, Eosinophils

B200 *(Monday)*
Role of Prostaglandin D2 in Eosinophil Activation Induced by Leptin
Natália Tasmo-Amorim, Ludmilla Dellatorre-Teixeira, Tatiana Luna-Gomes, Patricia Bozza, Clarissa Maya-Monteiro, Christianne Bandeira-Melo. Federal Univ. of Rio de Janeiro; Fndn. Oswaldo Cruz, Brazil

B201 *(Tuesday)*
Internalized *Cryptococcus neoformans* Activates Not Only the Canonical Caspase-1 but Also the Noncanonical Caspase-8 Inflammasomes
Guangxun Meng, Mingkuan Chen, Yue Xing, Ailing Lu, Wei Fang, Wanqing Liao. Institute Pasteur of Shanghai, Chinese Academy of Science, Shanghai; Changzheng Hosp., Shanghai, China

B202 *(Sunday)*
Platelet Activating Acetylhydrolase Involved in Inflammation Resolution in Macrophages and Neutrophils Which Have Been Stimulated with Urate Crystals
Darshna Yagnik. Middlesex Univ., London, UK

B203 *(Monday)*
Bacterial Metabolites, Short Chain Fatty Acids, Attenuate the Immune Response to *Aggregatibacter actinomycetemcomitans*
Renan Oliveira Correa, Aline Vieira, Erica Moraes Sernaglia, Marco Aurelio Ramirez Vinolo. State Univ. of Campinas (UNICAMP), São Paulo, Brazil

B204 *(Tuesday)*
Recognition of Products from Neutrophil Degranulation by Toll-Like Receptors Mediate Killing of *Leishmania amazonensis* in Macrophages
Natalia M. Tavares, Lilian Afonso, Martha Suarez, Mariana R. Ampuero, Stella d´Arêde, Aldina Barral, George dos Reis, Valéria M. Borges, Cláudia Brodskyn. FIOCRUZ, Salvador, Brazil; Federal Univ. of Rio de Janeiro, Brazil; Federal Univ. of Bahia, Salvador, Brazil

B205 *(Sunday)*
PGD2 Mediates Eosinophilic Inflammation during *S. mansoni* Infection
Laís C. Agra, Camila R.R. Pão, Isaac Bellas, Tatiana Luna-Gomes, Valdirene S. Muniz, Ludmilla Dellatorre-Teixeira, Natalia R. Amorim, Ligia A. Paiva, Christianne Bandeira-Melo. Federal Univ. of Rio de Janeiro; Institute Oswaldo Cruz – FIOCRUZ, Rio de Janeiro, Brazil

B206 *(Monday)*
Interferon Regulatory Factor 8 Regulates the Microglial Cell Response to Sterile Injury in the Brain
Iain L. Campbell, Rue Dan Xie, Nàdia Villacampa, Beatriz Almolda, Berta González. Univ. of Sydney, Australia; Autonomous Univ. of Barcelona, Spain

B207 *(Tuesday)*
PAF Impairs MyD88-Enhanced NF-κB P65 Transcriptional Activity in Murine Macrophages
Edson K. Ishizuka, Carlos H. Serezani, Luciano R. Filgueiras, Sonia Jancar. Univ. of São Paulo, Brazil; Indiana Univ. Sch. of Med., Indianapolis, IN

B208 *(Sunday)*
CD39/ENTPD1 Expression on Macrophages Limits ATP-P2X7 Receptor Pro-inflammatory Signaling Responses in Sepsis
Luiz Eduardo B. Savio, Paola A. Mello, Vanessa R. Figliuolo, Thiago Fernandes A. Almeida, Patrícia T. Santana, Suellen D'arc S. Oliveira, Claudia Lucia M. Silva, Linda Feldbrügge , Yan Wu, Simon C. Robson, Robson Coutinho-Silva. Federal Univ. of Rio de Janeiro, Brazil; Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Harvard Univ., Boston, MA; Faculty of Pharmacy, Federal Univ. of Rio Grande do Sul, Porto Alegre, Brazil

B209 *(Monday)*
Absence of Dietary Fibre or the Metabolite Sensor GPR43 Exacerbates Neutrophil Recruitment during Acute Inflammatory Responses
Connie H. Wong, Marjon Kamp, Raymond Shim, Ana Carolina Oliveira, Linda J. Mason, Lauren Binge, Charles R. Mackay. Monash Univ., Australia; Univ. Federal do Rio de Janeiro, Brazil

B210 *(Tuesday)*
NFAT Signaling Pathway in Innate Immune Cells Primes the Inflammatory Process during Skin Fungal Infections
Francesca Granucci, Simona Barresi, Francesca Mingozzi, William Santus, Marina Vai, Ivan Orlandi, Ivan Zanoni. Univ. of Milano-Bicocca, Milan, Italy; Harvard Med. Sch., Boston, MA

B211 *(Sunday)* **Abstract Withdrawn**
Dual Action of Platelets and Glycoprotein VI in Immune Complex-Mediated Inflammation
Angele Gros, Varouna Syvannarath, Lamia Lamrani, Véronique Ollivier, Stéphane Loyau, Tobias Goerge, Bernhard Nieswandt, Martine Jandrot-Perrus, Benoît Ho-Tin-Noé. UMRS-1148 Inserm-Univ. Paris Diderot, Bichat Hosp., Paris; Univ. Hosp. of Münster, Germany; IZKF, Univ. of Münster, Germany; Univ. Hosp. Würzburg & Rudolf Virchow Ctr., Univ. of Würzburg, Germany

B212 *(Monday)*
The Immune Regulation of the *Neisseria gonorrhoeae* Involved Indoleamine 2,3-Dioxygenase-1
Sai Li, Wenjing Le, Xiaohong Su. Institute of Dermatology, Chinese Academy of Med. Science, Nanjing, China

B213 *(Tuesday)*
The Role of MerTK and Its Cleavage in the Resolution of Acute Sterile Inflammation
Bishuang Cai, Gabby Fredman, Ira Tabas. Columbia Univ., New York, NY

B214 *(Sunday)*
Mechanisms and Consequences of Lipid Body-Phagosome Interaction in *Mycobacterium bovis,* BCG Infection
Natalia R. Roque, Silvia L. Lage, Roberta Navarro, Clarissa M. Maya-Monteiro, Jens Rietdorf, Rossana Melo, Heloisa D'Avila, Patricia T. Bozza. Oswaldo Cruz Fndn., Fiocruz; Federal Univ. of Juiz de For a; Ctr. of Technological Development in Health, Fiocruz, Rio de Janeiro, Brazil

B215 *(Monday)*
Critical Role of Plasmacytoid Dendritic Cells in Immunoregulation Initiated by a Commensal Microbial Polysaccharide
Suryasarathi Dasgupta, Dennis L. Kasper. Harvard Med. Sch., Boston, MA

B216 *(Tuesday)*
Stress Concentrations of Glucocorticoids Can Enhance Immune and Inflammatory Pathways
Paul M. Guyre, Jane E. Collins, Nick M. Jensen, Patricia A. Pioli, Fiona Barr, Sara Metzler, Brian D. Sites, Mark P. Yeager. Geisel Sch. of Med. at Dartmouth, Lebanon, NH

B217 *(Sunday)*
Role of Inflammasome-Dependent and -Independent Mechanisms in the Adjuvant Effect of Flagellin
Silvia L. Lage, Carina B. Lima, Eduardo P. Amaral, Kelly C. Matteucci, Lilian M. Massis, Marcelo Y. Icimoto, Adriana K. Carmona, M. Regina D'imperio-Lima, Mauricio M. Rodrigues, Luis C.S. Ferreira, Gustavo P. Amarante-Mendes, Karina R. Bortoluci. Federal Univ. of São Paulo and Univ. of São Paulo, São Paulo, Brazil

B218 *(Monday)* **Abstract Withdrawn**
Engagement of the Aryl Hydrocarbon Receptor in *M. tuberculosis*-Infected Macrophages Has Pleiotropic Effects on Innate Immune Signaling
Babak Memari, Manuella Bouttier, Vassil Dimitrov, John H. White. McGill Univ., Montreal, QC, Canada

B219 *(Tuesday)*
Recombinant Pentraxin-2 Protects Proximal Tubular Epithelial Cells in the Kidney during Cell Stress
Ivan G. Gomez, Naoki Nakagawa, Mark Lupher, Richard Jack, Jeremy S. Duffield. Biogen, Cambridge, MA; Univ. of Washington, Seattle, WA; Promedior Inc., Lexington, MA

Innate Lymphoid Cells

B220 *(Sunday)*
Profiling of Inflammatory Biomarkers from Stimulated Natural Killer Cells
Richard K. Fuerstenberg, Shaya Anderson, Kathy Brumbaugh. R&D Systems Inc., Minneapolis, MN

Lipids, Their Enzymes and Inflammation

B221 *(Monday)*
Emerging Roles of Omega-3 Fatty Acid Metabolites in Controlling Inflammation and Tissue Homeostasis
Makoto Arita. RIKEN-IMS, Yokohama, Japan; Yokohama City Univ.; PRESTO, JST, Japan

B222 *(Tuesday)*
Elucidating the Molecular Mechanisms of Interaction between Maslinic Acid and Human Group IIA-Secreted Phospholipase A2 and Its Effect in Regulating Inflammatory Response
Wei Hsum Yap, Nafees Ahemad, Yang Mooi Lim. Taylor's Univ. Lakeside Campus, Malaysia; Monash Univ. Malaysia; Univ. Tunku Abdul Rahman, Malaysia

B223 *(Sunday)*
Evaluation of Anti-nociceptive and Anti-inflammatory Effect of New Butylated Hydroxytoluene Compound
Roberta Campos Lino, Larissa de Oliveira Gonçalves, Iziara Ferreira Florentino, Ricardo Menegatti, Elson Alves Costa. ICB – Univ. Fed. de Goiás; State Univ. of Goiás – Câmpus Itumbiara-Go; – FF-Univ. Fed. de Goiás, Goiânia, Brazil

B224 *(Monday)*
A Host-Microbiome Interaction Mediates the Opposing Effects of Omega-6 and Omega-3 Fatty Acids on Chronic Low-Grade Inflammation
Jing X. Kang, Kanakaraju Kaliannan. Massachusetts General Hosp. and Harvard Med. Sch., Boston, MA

Microbiome in Health and Disease

B225 *(Tuesday)*
Mesalamine Prevents Translocation of Planktonic Pathobionts Released in Gut Microbiota Biofilms from Inflammatory Bowel Disease Patients, but Not from Healthy Individuals
Jean-Paul Motta, John L. Wallace, Andre G. Buret. Univ. of Calgary, AB, Canada

microRNAs and lncRNAs in Inflammation (microRNAs=miRs; Long Non-Coding RNAs=lncRNAs)

B226 *(Sunday)*
Exosomal APOC3-Transferred lncRNA Promote Osteoclasts Differentiation
Chi-Yuan Li, Kuo-Ting Sun. China Med. Univ. Hosp., Taichung, Taiwan

B227 *(Monday)*
Extracellular RNA Induces Cellular Inflammation via TLR7-MyD88 Signaling
Yan Feng, Hongliang Chen, Lin Zou, Dan Yan, Ganqiong Xu, Wei Chao. Massachusetts General Hosp., Charlestown, MA

Molecular Patterns and Acute Inflammation

B228 *(Tuesday)*
Comparative Sensitivity and Reliability of a Multi-analytes Platform and a Multiplex Flow Cytometry in the Quantitation of Circulating Cytokines Level in a Mouse Model of Endotoxemia
Alain Stricker-Krongrad, Jason Liu, Guy Bouchard, Miao Zhong. Sinclair Research Ctr. LLC, Auxvasse, MO

B229 *(Sunday)*
Copper-Induced Inflammation Leads to Changes in Sirtuin Gene Expression and Altered Behavior in Zebrafish
Talita C B Pereira, Carlos Eduardo Leite, Laura R. Nery, Maria Martha Campos, Mauricio R. Bogo. Pontifical Catholic Univ. of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

Mucosal Immunity

B230 *(Monday)* **Abstract Withdrawn**
Role of NK Cells in IFN-ϵ – Mediated Protection against Female Reproductive Tract Infection
Jemma R. Mayall, Niamh E. Mangan, Malcolm R. Starkey, Richard Y. Kim, Alexandra C. Brown, Paul J. Hertzog, Jay C. Horvat, Philip M. Hansbro. Univ. of Newcastle, New Lambton Heights, Australia; Monash Univ., Melbourne, Australia

Neutrophils, NETs and PADs

B231 *(Tuesday)*
Human Eosinophils Release Extracellular DNA Traps in Response to *Aspergillus fumigatus*
Josiane S. Neves, Valdirene S. Muniz, Mariana S.R. Bica, Yasmim A.V. Braga, Rodrigo T. Figueiredo. Federal Univ. of Rio de Janeiro, Brazil

B232 (Sunday)
Intravital Imaging of Vasculature Reveals That Neutrophil Extracellular Trap (NET) Components Attach to von Willebrand Factor in a Dnase-Independent Manner
Elzbieta Kolaczkowska, Craig N. Jenne, Bas G. Surewaard, Ajitha Thanabalasuriar, Woo-Yong Lee, Maria-Jesus Sanz, Kerri Mowen, Ghislain Opdenakker, Paul Kubes. Univ. of Calgary, AB, Canada; Jagiellonian Univ., Krakow, Poland; Univ. of Leuven, Belgium; The Scripps Research Institute, La Jolla, CA

B233 *(Monday)*
Respiratory Syncytial Virus Infection of Both Alveolar Epithelial Cells and Neutrophils Induces the Formation of Neutrophil Extracellular Traps
Bárbara N. Porto, Stéfanie P. Muraro, Giselle A. Funchal, Natália Jaeger, Rafael S. Czepielewski, Gabriela F. Souza, Renato T. Stein. Pontifical Catholic Univ. of Rio Grande do Sul, Porto Alegre, Brazil

B234 *(Tuesday)*
Autophagy Mediates Interleukin-1 Beta Exportation from Human Neutrophils
Analia S. Trevani, Irene Keitelman, Florencia Sabbione, Carolina C. Jancic, Leonardo Iula. IMEX-CONICET- Natl. Academia of Med., Buenos Aires, Argentina; Univ. of Buenos Aires Faculty of Med., Argentina

New Models of Inflammatory Mechanisms and Diseases

B235 *(Sunday)*
Spontaneous Mutation in ZFP-Binding Region of TNF Gene Causes Chronic Polyarthritis and Heart Valve Disease
Derek C. Lacey, Peter Hickey, Benedicta D. Arhatari, Lorraine O'Reilly, Leona Rohrbeck, Helen Kiriazis, Xiao-Jun Du, Philippe Bouillet. The Walter and Eliza Hall Institute of Med. Research, Parkville; Univ. of Melbourne; La Trobe Univ., Victoria; Baker IDI Heart and Diabetes Institute and Central Clin. Sch., Monash Univ., Melbourne, Australia

B236 *(Monday)*
Down-Regulation of Kynurenine Formation from Tryptophan Attenuates Induction of Insulin Resistance in *Drosophila melanogaster*
Valeriya Navrotska, Lyudmila Vorobyova, Paul Summergrad, Gregory Oxenkrug. Karazin Natl. Univ., Kharkiv, Ukraine; Tufts Univ., Boston, MA

B237 *(Tuesday)*
In Vitro Modelling Acute and Chronic Inflammation Based on Human Monocytes: Analysis of the Modulation of IL-1 Family Members
Paola Italiani, Ettore Mosca, Luciano Milanesi, Diana Boraschi. Institute of Protein Biochem., Natl. Research Council of Italy, Naples; Institute of Biomed. Technologies, Natl. Research Council of Italy, Milan

B238 *(Sunday)*
***Giardia muris* Infection Reduces the Severity of *Citrobacter rodentium*-Induced Colitis**
Jean-Paul Motta, Anna Manko, James A. Cotton, Bruce A. Vallance. Univ. of Calgary, Calgary, AB, Canada; Univ. of British Columbia, Vancouver, BC, Canada

B239 *(Monday)*
Dynamic Equilibrium of Neutrophil Trafficking at Sites of Inflammation and Infections
Daniel Irimia. Massachusetts General Hosp.; Harvard Med. Sch.; Shriners Burns Hosp., Charlestown, MA

B240 *(Tuesday)*
In Vivo Imaging of Mammalian HSCs Engraftment and Colonization into the CHT of Zebrafish Embryos
Margarita M. Parada Kusz, Anne Clatworthy, Humberto Jijon, Eduardo J. Villablanca. Univ. de Chile, Santiago, Chile; Harvard Univ., Cambridge, MA; Massachusetts General Hosp., Harvard Med. Sch., Boston, MA; Solna, Karolinska Institute and Univ. Hosp., Stockholm, Sweden

Novel and Innovative Platforms for Drug Discovery

B241 *(Sunday)*
Assessing NK Cell Killing Activity to Inform Drug Discovery Programs on Clinical Infection Risk
Cristina A. St. Pierre, Laura Engstrom, Alexandra Hicks, Ravisankar A. Ramadas. Merck Research Labs., Boston, MA

B242 *(Monday)*
Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono-arthritic Multi-flare Model of Streptococcal Cell Wall-Induced Arthritis: Further Characterization in a Rodent Model of Collagen-Induced Arthritis
Kalyan Chakravarthy, Robert Faltus, Anwar Murtaza, Milenko Cicmil. Merck Research Labs., Boston, MA

B243 *(Tuesday)*
A Novel Assay for High Throughput shRNA-Based Target Discovery in the IL-17 Pathway
Jeroen DeGroot, Blandine Mille-Baker, David F. Fischer. Charles River Labs, Leiden, Netherlands

Novel Targets and New Drugs in Inflammation

B244 *(Sunday)*
Thymoquinone Inhibits Inflammation in IL-1Beta-Stimulated SK-N-SH Cells
Olumayokun Olajide, Ravikanth Velagapudi, Asit Kumar, Simon Schindler, Bernd L. Fiebich. Univ. of Huddersfield, UK; Univ. of Freiburg Med. Sch., Germany

B245 *(Monday)*
Mechanisms Involved in the Anti-inflammatory Activity of the New Pyrazole Compound 5-(1-(3-Fluorophenyl)-1H-Pyrazol-4-yl)-2H-Tetrazole (LQFM-021)
Iziara F. Florentino, Daiany Priscilla B. Silva, Roberta C. Lino, Taciane S. Silva, Carlos Rogério Tonussi, Ricardo Menegatti, Elson A. Costa. Federal Univ. of Goiás; Federal Univ. of Santa Catarina, Brazil

B246 *(Tuesday)*
Identification of CD44bright, a Novel Subset of Uterine NK Cells Correlated to Abortion in Recurrent Pregnancy Loss Model Mice
Jun Tanaka, Yuki Fukunaga. Japan Blood Products Org., Kobe, Japan

B247 *(Sunday)* **Abstract Withdrawn**
Resveratrol Improves the Pathogenesis of Nonalcoholic Steatohepatitis through Inhibition of Endotoxin-Induced Liver Inflammation and Fibrosis
Takaomi Kessoku, Koichiro Wada, Yasushi Honda, Yuji Ogawa, Kento Imajo, Atsushi Nakajima. Yokohama City Univ.; Shimane Univ. Faculty of Med., Japan

B248 *(Monday)*
New Analogues from IKK-β Inhibitor LASSBio-1524 as Potent Anti-inflammatory Candidates
Natália M. Cordeiro, Rosana H.C. Freitas, Carlos Alberto M. Fraga, Patricia D. Fernandes. Federal Univ. of Rio de Janeiro, Brazil

B249 *(Tuesday)*
Liposomes Loaded with 3-Phenylcoumarin Derivatives and *Baccharis dracunculifolia* Extract Reduce the Infiltrate of Neutrophils in Synovial Fluid of Articular Inflammation Induced by Zymosan
Micássio F. Andrade, Andréa S.G. Figueiredo-Rinhel, Ana Elisa C.S. Azzolini, Jairo K. Bastos, Flávio S. Emery, Mônica T. Pupo, Yara M. Lucisano-Valim. Sch. of Med., Univ. of São Paulo, Ribeirão Preto, Brazil; Sch. of Pharmaceut. Science, Univ. of São Paulo, Ribeirão Preto, Brazil.

B250 *(Sunday)*
LASSBio-1828: A New IKK-β Potential Inhibitor
Tayná S. Valerio, Natália M. Cordeiro, Rosana H.C. Freitas, Carlos Alberto M. Fraga, Patricia D. Fernandes. Federal Univ. of Rio de Janeiro, Brazil

B251 *(Monday)*
Anti-inflammatory Activity of Fractions Obtained from Choisya Aztec-Pearl, a New Hybrid of *Choisya ternata*
Patrícia Ribeiro de Carvalho, Denise Ropero, Fábio Boylan, Patricia Dias Fernandes. Federal Univ. of Rio de Janeiro, Brazil; Trinity Col. Dublin, Ireland

B252 *(Tuesday)*
Filgotinib, JAK1-Selective Inhibitor, Represses Similarly JAK1/STAT3 Pathway in the Colon of Mice with DSS-Induced Colitis and in Cultures of Colon Biopsies from Inflammatory Bowel Disease Patients
Sonia Dupont, Carole Delachaume, Veerle De Vriendt, Debby Laukens, Béatrice Vayssière, Didier Merciris, Steve De Vos, Marie-Christine Ceccotti, Christelle David, Laetitia Perret, Martine De Vos, Reginald Brys, René Galien.

Galapagos SASU, Romainville, France; Galapagos NV, Mechelen, Belgium; Ghent Univ. Hosp., Belgium

B253 *(Sunday)*
GPR84 Inhibition as a Novel Therapeutic Approach in Inflammatory Bowel Disease: Mechanistic and Translational Studies
Sonia Dupont, Ingrid Arijs, Roland Blanqué, Debby Laukens, Kris Nys, Marie-Christine Ceccotti, Didier Merciris, Steve De Vos, Maté Ongenaert, Isabelle Parent, Veerle De Vriendt, Frédéric Labéguère, René Galien, Martine De Vos, Paul Rutgeerts, Nick Vandegh. Galapagos SASU, Romainville, France; Galapagos NV, Mechelen, Belgium; KU Leuven, Belgium; University Hosp., Ghent, Belgium

B254 *(Monday)*
Functional Recovery of Alzheimer's Disease Using Stem Cells from Human Exfoliated Deciduous Tooth-Derived Conditioned Medium
Tsuneyuki Mita, Yoko Hibi, Chiaki Shimojima, Hisasi Hattori, Kiyofumi Yamada, Akihito Yamamoto. Nagoya Univ. Graduate Sch. of Med., Japan

B255 *(Tuesday)*
Novel Cartilage-Protective Mediators in Pro-resolving Exudates
Magdalena K. Kaneva, Sarah E. Headland, Prashant Mori, Adrian Moore, Mauro Perretti. Barts and The London Sch. of Med. and Dentistry, Queen Mary Univ. of London, London, UK; UCB Pharma, Slough, UK

B256 *(Sunday)*
Topically Active Phosphodieasterase Inhibitors Suppress IL-17, IL-23, IL-22 and TSLP Production, Indicating Potential Application in Psoriasis and Atopic Dermatitis
Kurt Jarnagin, Chen Dong, Olga Zemska, Charlotte Frates, Shannon Jonesiatauro, Grober Baltazar, Tsutomu Akama. Anacor Pharmaceuticals, Palo Alto, CA

B257 *(Monday)*
Evaluation of Anti-inflammatory Activity of Isatin, N-Methyl Isatin and Oxopropyl Isatin
Thais B.S. Giorno, Bárbara V. Silva, Angelo C. Pinto, Patricia D. Fernandes. Federal Univ. of Rio de Janeiro, Brazil

B258 *(Tuesday)*
Antiulcer and Antioxidant Activity of Lectin from *Mucuna pruriens* Seeds on Ethanol-Induced Gastropathy in Mice
Vicente de Paulo T. Pinto, Isabela R. Pinto, Danielle R.D. Val, Katia A. Ribeiro, Raul S. Freitas, Samuel M.P. Filho, Auriana S. Vasconcelos, Francisca C.F.D. Sousa, Tatiane Santi-Gadelha, José Thalles J.G.D. Lacerda, Carlos A.D.A. Gadelha, Gerardo C. Fil. Federal Univ. of Ceará; Federal Univ. of Pernambuco; Federal Univ. of Paraíba; Federal Univ. of Rio de Janeiro, Brazil

B259 *(Sunday)*
14-3-3 Eta as a Novel RA Drug Target: Anti-14-3-3 Eta Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice
Anthony Marotta, Abedelnasser Abulrob, Mario Mercier, Slavisa Corluka, Roger MacKenzie, Shalini Raphael, Sara Michienzi, Jane Savill, Yuan Gui, Walter P. Maksymowych. Augurex Life Science Corp., North Vancouver, BC; Natl. Research Council; Univ. of Alberta, BC, Canada

B260 *(Monday)*
LASSBio-1829, a Novel Anti-inflammatory Molecule Derived from LASSBio-1524
Tayná S. Valério, Thaís S. Nascimento, Natália M. Cordeiro, Rosana H.C.N Freitas, Carlos Alberto M. Fraga, Patricia D. Fernandes. Federal Univ. of Rio de Janeiro, Brazil

B261 *(Tuesday)*
A Phase 1 Clinical Study of CTX-4430 in Cystic Fibrosis Patients
E. Springman, R. Grosswald, E. Philpot, G. MacGregor, A. Horsley, D. Bilton, J. Stewart, S. Elborn. Queens Univ. Sch. of Med., Dentistry and BioMed. Science, Belfast, UK; Celtaxsys Inc., Atlanta, GA; West of Scotland CF Ctr., Gartnavel General Hosp., Glasgow, UK; Manchester Adult Cystic Fibrosis Ctr., Univ. Hosp. of South Manchester, Manchester, UK; Royal Brompton Hosp., London, UK; Celerion, Belfast, UK

B262 *(Sunday)*
Site-Specific Immunomodulator: A Novel Immunotherapy for Cancer
David W. Mullins, Shirin Kalyan, Momir Bosiljcic, Ashley Westerbeck, Rebecca Anderson, Daniel Patton, Ralf Kleef, Gauthier Bouche, Nina Ludwig, Simon Sutcliffe, Hal Gunn. Qu Biologics Inc., Vancouver, BC, Canada; Geisel Sch. of Med. at Dartmouth; Reliable Cancer Therapies, Strombeek-Bever, Belgium; Institute for Immunotherapy and Integrative Oncology, Vienna, Austria

Nuclear Hormone Receptors

B263 *(Monday)*
Norethisterone, a Progestin Used in Contraception and HRT, Promotes Inflammation in the Ectocervical Environment via the Glucocorticoid Receptor
Donita J. Africander, Renate Louw-du Toit, Janet P. Hapgood. Univ. of Stellenbosch; Univ. of Cape Town, South Africa

B264 *(Tuesday)*
The Bone Marrow Microenvironment Protects Plasma Cells from the Lympholytic Effects of Glucocorticoids
Derek W. Cain, Johnny A. Cidlowski. Natl. Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC

Ocular Inflammation

B265 *(Sunday)*
Role of Nox4-Derived Ros Production in 4-HNE-Induced Dysfunction and Death of ARPE-19 Adult Retinal Pigment Epithelial Cells
Sajita Shah, Jung-Ae Kim. Yeungnam Univ., Daegu, South Korea

Proteases

B266 *(Monday)*
A Novel Role for BK Channel in Regulating Metalloprotease Activity
Minae Yoshida, Dean Willis. University Col. London, London, UK

B267 *(Tuesday)*
Intestinal Epithelial Cells Secrete an Elastase Which Participates to Mucosal Inflammation in IBD
Céline Deraison, Alexandre Denadai-Souza, Anna Carolina Florence, Anissa Edir, Corinne Roland, Jean-Paul Motta, Chrystelle Bonnart, Elena Verdu, Derek McKay, Laurent Alric, Nathalie Vergnolle. INSERM, U1043, Toulouse, France; Univ. of Calgary Faculty of Science, Calgary, AB, Canada, McMaster Univ., Hamilton, ON, Canada; CHU Purpan, Toulouse, France

B268 *(Sunday)*
Epithelial Cells Release Trypsin Activity in Inflammatory Condition: Role in Irritable Bowel Syndrome
Claire Rolland Fourcade, Alexandre Denadai-Souza, Jean-Paul Motta, Tereza Bautzova, Nicolas Cenac, Ian Spreadbury, Stephen J. Vanners, Céline Deraison, Nathalie Vergnolle. INSERM CPTP, Toulouse, France; Univ. of Calgary, AB, Canada; Queen's Univ., Kingston, ON, Canada

B269 *(Monday)*
Effects of a Protease Inhibitor from the Tick *Rhipicephalus Boophilus microplus* in a Cigarette Smoke-Induced Emphysema
Juliana D. Lourenço, Daniela A.B. Cervilha, Juliana T. Ito, Davi S. Sales, Alyne Riani, Clarice R. Olivo, Adriana Duran, Sergio D. Sasaki, Mílton A. Martins, Fernanda D.T.Q.S. Lopes. Univ. of São Paulo; Univ. Federal do ABC, Santo André, Brazil

B270 *(Tuesday)*
CPM Activity Modulation by Kinin B1 Receptor in Endothelial Cell Models
Paola B. Guimarães, Carolina C. Hoff, Liliam Fernandes, Jair R. Chagas, Thaysa Paschoalin, Adriana K. Carmona, Michael Bader, João B. Pesquero. Federal Univ. of São Paulo, São Paulo Campus, Brazil; Federal Univ. of São Paulo, Diadema Campus, Brazil; Max Delbrück Ctr. for Molecular Med., Berlin, Germany; Paulista Univ., Santos-Rangel Campus, Brazil

Resolution of Inflammation and Tissue Repair

B271 *(Sunday)*
Resolvin D4 Structural Confirmation and Potent Pro-resolving Actions in Inflammation and Infection
Jeremy W. Winkler, Sarah K. Orr, Romain A. Colas, Jesmond Dalli, Nan Chiang, Nicos A. Petasis, Charles A. Serhan. Brigham and Women's Hosp. and Harvard Med. Sch., Boston, MA; Univ. of Southern California, Los Angeles, CA

B272 *(Monday)*
Resolution Factors: Will They Be Good Controllers of the Inflammatory Response?
Flávia C.S. Fonseca, Janetti N. Francischi. Federal Univ. of Minas Gerais, Belo Horizonte, Brazil

B273 *(Tuesday)*
Oxygenated n-3 PUFA Metabolites Present in the Circulation after Acute Consumption of n-3-PUFA Containing Oils Regulate the Angiogenic Potential of Human Endothelial Cells through PPARβ/d- and GPCR-Dependent Pathways
Caroline P.D. Wheeler-Jones, Sally H. Latham, Anna Nicolaou, Alexandra Kendall, Ashton R. Faulkner, David Bishop-Bailey, Mauro Perretti, Thomas Gobbetti, Kathleen M. Botham, Wendy L. Hall, Robert Purcell. Royal Veterinary Col., London, UK; Univ. of Manchester, UK; Queen Mary, Univ. of London; King's Col. London, UK

B274 *(Sunday)*
Old Drugs with New Skills: Biasing the Melanocortin Receptors to Resolve Inflammatory Arthritis
Trinidad Montero-Melendez, Thomas Gobbetti, Sadani N. Cooray, Thomas E.N. Jonassen, Perretti Mauro. Barts and The London Sch. of Med., Queen Mary Univ. of London, UK; Univ. of Copenhagen, Denmark

B275 *(Monday)*
Human Milk Specialized Proresolving Lipid Mediators Stimulate Resolution of Acute Inflammation
Hildur H. Arnardottir, Sarah K. Orr, Jesmond Dalli, Charles N. Serhan. Harvard Insts. of Med.; Brigham and Women's Hosp.; Harvard Med. Sch., Boston, MA

B276 *(Tuesday)*
The Satiated Macrophage: A Key Player in the Resolution of Inflammation
Amiram Ariel, Senthil K. Satyanarayanan, Noa Sher, Sagie Schif-Zuck. Univ. of Haifa, Israel

B277 *(Sunday)*
Satiated Macrophages Upregulate CD24 Expression through Uncoupling Protein 2
Janan Saadi, Senthil K. Satyanarayanan, Nawras Abboud, Sagie Schif-Zuck, Amiram Ariel. Univ. of Haifa, Israel

B278 *(Monday)*
Natural Killer Cells Are Indispensable for Resolution of Antigen-Induced Inflammation in Mice
Ingibjorg Hardardottir, Osk Anuforo, Hulda S. Jonasdottir, Martin Giera, Jona Freysdottir. Faculty of Med., Univ. of Iceland; Landspitali – The Natl. Univ. Hosp. of Iceland, Reykjavik; Leiden Univ. Med. Ctr., Netherlands

B279 *(Tuesday)*
Exudate Suction Blister: A Novel In Vivo Model of Acute Inflammation and Resolution in Humans
Madhur Motwani, Roel De Maeyer, James Fullerton, Daniel Marks, Andrew Smith, Derek W. Gilroy. University Col. London, UK

B280 *(Sunday)*
Specialized-Proresolving Mediators and Trancriptomic Signatures in Bleomycin-Induced Lung Fibrosis
Gérald Chêne, Vincent Baillif, Guigné Charlotte, Belloy Marcy, Wanecq Estelle, Emeline Van Goethem, Marc Dubourdeau. Ambiotis SAS, Toulouse, France

Respiratory Disease and Inflammation

B281 *(Monday)*
Blocking LTßR Signaling In Vivo Suppresses the Development of Smooth Muscle Hypertrophy in a Chronic Murine Model of Asthma
Silke N.K. Hobbie, Peter Maier, Erb J. Klaus. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

B282 *(Tuesday)*
Neutrophil Proteases Alter the Interleukin-22-Receptor-Dependent Lung Antimicrobial Defense
Antoine Guillon, Youenn Jouan, Deborah Brea, Fabien Gueugnon, Emilie Dalloneau, Thomas Baranek, Clémence Henry, Eric Morello, Jean-Christophe Renauld, Muriel Pichavant, Philippe Gosset, Yves Courty, Patrice Diot, Mustapha Si-Tahar. INSERM UMR 1100 CEPR; Univ. François Rabelais de Tours; CHRU de Tours; Ludwig Institute for Cancer Research, Brussels; Univ. Catholique de Louvain, Brussels; Univ. Lille Nord de France; Institute Pasteur de Lille; CNRS, Lille; INSERM, U1019, Lille, France

B283 *(Sunday)* **Abstract Withdrawn**
Stem Cell Factor and Interleukin 31 Expression: Association with Serum IgE Levels and Disease Severity in Atopic and Non-atopic Bronchial Asthma
Mai Moaaz, Salma Aboelnazar. Med. Research Institute, Alexandria Univ., Egypt

B284 *(Monday)*
Functional Defect of MAIT Cells in Patients with Active Tuberculosis Is Mediated by PD-1 Signaling
Xiaoxing Cheng, Jing Jiang, Hongjuan An. Institute of Tuberculosis, 309th Hosp., Beijing, China

B285 *(Tuesday)*
Osteopontin Modulates Cytotoxic Effects of Extracellular Histones in COPD
Gopinath Kasetty, Ravi Kiran Varma Bhongir, Matthias Morgelin, Arne Egesten. Lund Univ., Skåne, Sweden

B286 *(Sunday)*
The Polyphenol Resveratrol Improves the Pulmonary Oxidative Stress in Asthmatic and Obese Mice by SIRT1 Pathway Activation
Diana M. Andre, Marina C. Calixto, Eduardo C. Alexandre, Carolina S. Sollon, Gabriel F. Anhe, Edson Antunes. State Univ. of Campinas, São Paulo, Brazil

B287 *(Monday)*
Lung Epithelial TRPA1 Transduces the Extracellular ROS into Transcriptional Regulation of Lung Inflammation Induced by Cigarette Smoke: The Role of Influxed Ca2+
An-Hsuan Lin, Meng-Han Liu, Hsin-Kuo Ko, Diahn-Warng

Perng, Tzong-Shyuan Lee, Yu Ru Kou. Sch. of Med., Natl. Yang-Ming Univ.; Taipei Veterans Gen. Hosp., Taipei, Taiwan

B288 *(Tuesday)*
N-Acetyl-de-O-Sulfated Heparin Inhibits Lypopolysaccharide-Induced Leukocyte Migration by a Platelet-Dependent Mechanism
Yanira Riffo Vasquez, Richard Amison, Simon Pitchford, Clive P. Page. King's Col. London, UK

B289 *(Sunday)*
Comprehensive Analysis of Ricin Binding In Vivo and Cellular Damage upon Pulmonary Exposure
Anita Sapoznikov, Reut Falach, Ron Alcalay, Nehama Seliger, Yoav Gal, Tamar Sabo, Chanoch Kronman. Israel Institute for Biol. Research, Ness Ziona, Israel

B290 *(Monday)*
Does Hydrogen Sulfide Influence Apoptosis Process in Lungs from Allergic Mice?
Heloisa Helena A. Ferreira, Jackeline A. Mendes, Matheus C. Ribeiro, Gislaine Cristina P. Moreira, Mateus S. Silva, Natalia H. Dias, Bruna T. Albaladejo, José A. Pereira, Thalita Rocha. São Leopoldo Mandic Institute and Research Ctr., Campinas, São Paulo; State Univ. of Campinas/Unicamp; São Francisco Univ., Brazil

B291 *(Tuesday)*
Moderate Physical Exercise Decreases Airway Inflammation in a Murine Model of Asthma
Paula Fernandes, Thayse R. Brüggemann, Clarice R. Olivo, Fernanda M. Bruni, Mílton A. Martins, Fernanda M. Arantes-Costa. Sch. of Med. of Univ. of São Paulo; Institute for Investigation in Immunology, INCT, São Paulo, Brazil

B292 *(Sunday)*
Proteinase-Activated Receptor 2 Plays a Pivotal Role in Allergen-Induced Leukocyte Recruitment in Experimental Lung Inflammation
Natalia A. Matos, Raphael G. Ferreira, Annie R.P. Alvarez, Karine A. Damasceno, Geovanni D. Cassali, José C. Alves-Filho, André Klein. Federal Univ. of Minas Gerais, Belo Horizonte, Brazil; Ribeirão Preto Med. Sch., Univ. of São Paulo, Ribeirão Preto, Brazil

B293 *(Monday)* **Abstract Withdrawn**
Protective Role of Surfactant Protein-D in Nitrogen Mustard Induced Lung Toxicity
Vasanthi R. Sunil, Kinal P. Vayas, Jessica Cervelli, Michael Goedken, Rama Malaviya, Jeffrey D. Laskin, Debra L. Laskin. Rutgers Univ. Ernest Mario Sch. of Pharmacy, Piscataway, NJ; Robert Wood Johnson Med. Sch., Piscataway, NJ

B294 *(Tuesday)*
Transcriptomic and Proteomic Profiling of Sputum Reveals Inflammasome-Associated Signatures in Severe Asthma
Ian M. Adcock, Christos Rossios, Stelios Pavlides, Matthew Loza, Fred Baribaud, Scott Kuo, Anthony Rowe, Uraj Hoda, Ratko Djukanovic, Peter J. Sterk. NHLI, Imperial Col. London; U-BIOPRED Consortia

B295 *(Sunday)*
A Gene Signature from the CFA/HDM Model of Asthma Preferentially Maps to Human Severe Asthma
Ian M. Adcock, Kirsty Russell, Stelios Pavlides, Christos Rossios, Navin Rao, Kian F. Chung. NHLI, Imperial Col. London; U-BIOPRED Consortia

B296 *(Monday)*
Endogenous Cholinergic System Is Involved in Sexual Dimorphism on Pulmonary Inflammation in an Asthma Experimental Model
Nathalia M. Pinheiro, Fernanda P.R. Santana, Francine M. Almeida, Adenir Perini, Iolanda F.L.C Tibério, Milton A. Martins, Marco Antônio M. Prado, Vânia F. Prado, Ana Cristina B. Faloppa, Wothan T. Lima, Carla M. Prado. Univ. of São Paulo; Univ. Federal of São Paulo, Brazil; Univ. of Western Ontario, London, ON, Canada

B297 *(Tuesday)*
Sodium Metabisulfite Challenge: Little Evidence of Inflammatory Potential
Daniel E. Maddox, Sharon M. Flynn. Mayo Clinic, Rochester, MN

B298 *(Sunday)*
A Corticosteroid-Resistant Allergic Mouse Model of Severe Asthma with Clinically Relevant Endpoints: Correlating Inflammatory Responses to Alterations in Lung Mechanics
Paulette W. Andreotta, Dominic R. Beal, Martina Rosado, Samantha Rogers, Stephen T. Sonis, Gregory D. Lyng. Biomodels, LLC, Watertown, MA

B299 *(Monday)*
Effects of Cholinergic Hypofunction in Lung Mechanics and Histopathology in an Experimental Model of Lung Inflammation Induced by Air Pollution in Mice
Fernanda P.R. Santana, Nathalia M. Pinheiro, Márcis M.B. Mernak, Perini Adenir, Kelly Yoshizaki, Mariângela Macchione, Paulo H. Saldiva, Luciana C. Caperuto, Milton A. Martins, Iolanda F.L.C. Tibério, Marco Antônio M. Prado, Vânia F. Prado, Carla M. Prado. Sch. of Med., Univ. de São Paulo; Brazil; Univ. Federal de São Paulo, Brazil; Univ. of Western Ontario, London,, ON, Canada

B300 *(Tuesday)* **Abstract Withdrawn**

MicroRNA-21 Drives Severe, Steroid-Insensitive Experimental Asthma by Amplifying PI3K-Mediated Suppression of HDAC2

Philip M. Hansbro, Richard Y. Kim, James W. Pinkerton, Malcolm R. Starkey, Ama T. Essilfie, Jemma R. Mayall, Bernadette Jones, Tatt Jhong Haw, Simon Keely, Joerg Mattes, Ian M. Adcock, Paul S. Foster, Jay C. Horvat. The Univ. of Newcastle, Australia; Natl. Heart & Lung Institute, Imperial Col. London, UK

B301 *(Sunday)* **Abstract Withdrawn**

Tumour Necrosis Factor-Related Apoptosis Inducing Ligand Promotes the Development of Experimental Chronic Obstructive Pulmonary Disease

Philip M. Hansbro, Tatt J. Haw, Malcolm R. Starkey, Prema M. Nair, Irwan Hanish, Duc H. Nguyen, Gang Liu, Mark D. Inman, Richard Y. Kim, Adam M. Collison, Darryl A. Knight, Hideo Yagita, Joerg Mattes, Jay C Horvat. Hunter Med. Research Institute, The Univ. of Newcastle, New South Wales, Australia; Faculty of Biotechnology and Biomolecular Science, Univ. Putra Malaysia, Selangor, Malaysia; St. Joseph's Healthcare, McMaster Univ., Hamilton, ON, Canada; Juntendo Univ. Sch. of Med., Tokyo, Japan

B302 *(Monday)* **Abstract Withdrawn**

RelB-Deficient Dendritic Cells Promote the Development of Spontaneous Allergic Airway Inflammation in Mice

Philip M. Hansbro, Prema M. Nair, Malcolm R. Starkey, Tatt J. Haw, Roland Ruscher, Muralidhara R. Maradana, Ranjeny Thomas, Brendan O'Sullivan. Sch. of Biomed. Science and Pharmacy, Faculty of Health and Hunter Med. Research Institute, The Univ. of Newcastle, NSW, Australia; Univ. of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hosp., Woolloongabba, QLD, Australia

B303 *(Tuesday)* **Abstract Withdrawn**

The Role of PD-1 in Viral Predisposition to Secondary Bacterial Pneumonia

Philip Hansbro, Alexandra Brown, Ama-Tawiah Essilfie, Emma Beckett, Alison Thorburn, Hideo Yagita, Hideo Yagita, Paul Foster, Jay Horvat. Univ. of Newcastle, Callaghan, NSW, Australia; Jutendo Univ., Tokyo, Japan; Monash Univ., Clayton, VIC, Australia

B304 *(Sunday)*

Antifibrogenic Effect of Dominant-Negative Inhibitor of Soluble TNF Xpro 1595 on Experimental Silicosis in Mice

Patricia M.R. Silva, Bianca T. Ciambarella, Ana Carolina S. Arantes, Yago A.J.S.A. David E. Szymkowski, Marco Aurelio Martns. Oswaldo Cruz Fndn., Rio de Janeiro, Brazil; Xencor, Monrovia, CA

B305 *(Monday)*

Role of the Atypical Chemokine Receptor ACKR2 on Cigarette Smoking-Induced COPD in Mice

Diego S. Coutinho, Tatiana Paula T. Ferreira, Davidson F. Dias, Ana Carolina S. Arantes, Bianca Ciambarella, Magda F. Serra, Andrey J. Fernandes, Antonio Gabriel S. Silva, Patricia M R Silva, Massimo Locati, Marco Aurélio Martins. Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil; Univ. of Milan, Italy

B306 *(Tuesday)*

Comparative Proteomic Analysis of Survival and Non-survival Sepsis Patients Using iTRAQ-Based Absolute Quantitation

Narendra K. Sharma, Alexandre K. Tashima, Milena K.C. Brunialti, Flavia R. Machado, Eliezer Silva, Otelo Rigato, Reinaldo Salomao. Escola Paulista de Med., Federal Univ. of São Pãulo; Brazil; ICU, Hosp. São Paulo; ICU, Hosp. Israelita Albert Einstein, Brazil; ICU, Hosp. Sirio Libanes, Brazil

B307 *(Sunday)*

Modulation of Inflammatory Response during *Streptococcus pneumoniae* Infection Prevents Lung Injury and Improves Bacteria Clearance in Mice

Luciana P. Tavares, Cristiana C. Garcia, Juliana P. Vago, Celso M. Queiroz-Junior, Bruna A. David, Milene A. Rachid, Remo C. Russo, Patrícia R. Martins, Lirlândia P. Sousa, Mauro M. Teixeira. Univ. Federal de Minas Gerais, Belo Horizonte, Brazil; Institute Oswaldo Cruz, Rio de Janeiro, Brazil

B308 *(Monday)*

Phototherapy: Attenuation of Cholinergic Hyperreactivity, β2-Adrenergic Hyporresponsiveness and Mitochondrial mRNA Expression in Rat Bronchi Segments and Pulmonary Tissue in *E. coli* Lipopolysaccharide-Induced Airway Inflammation by an NF-κB, AP-1 and Mitochondrial Dependent Mechanism

Flávia Mafra de Lima, Renata Kelly Palma, Niels Olsen Saraiva Camara. Univ. of São Paulo, São Paulo, Brazil; Centro Universitário Nove de Julho - Uninove, São Paulo, Brazil

Small Molecule Therapeutics for Inflammatory Diseases

B309 *(Tuesday)*
Gedunin Binds to MD-2 and Impairs LPS-Induced TLR4 Signaling in Macrophages
Perla V. Borges, Katelim H. Moret, Clarissa M. Monteiro, Franklin S. Silva, Carlos R. Alves, Ernesto Caffarena, Paulo R. Batista, Maria das Graças Henriques, Patrícia Pacheco, Carmen Penido. Oswaldo Cruz Fndn., Rio de Janeiro, Brazil

B310 *(Sunday)*
Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, Is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan In Vitro
Stephen Clarke, Stuart Perper, Kristie Grebe, Annette Schwartz, Christian Goess, Liz O'Connor, Dawna Hartman, Susan Westmorland, Candace Graff, Andrew Souers, Joel Leverson, Steven Elmore, Lisa Olson, Li Chun Wang. AbbVie Bioresearch Ctr., Worcester, MA; AbbVie Inc., North Chicago, IL

B311 *(Monday)*
Characterization of a Small Molecule IRAK4 Kinase Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases
Chrystelle Lamagna, Meagan Chan, Sothy Yi, Chi Young, Roy Frances, Stacey Siu, Sylvia Braselmann, Don Payan, Darren McMurtrie, Ryan Kelley, Thilo Heckrodt, Rose Yen, Yan Chen, Hui Li, Rajinder Singh, Gary Park, Esteban Masuda, Vanessa Taylor. Rigel Pharmaceuticals, South San Francisco, CA

B312 *(Tuesday)*
ß-Caryophyllene Modulates Neutrophil Migration in Inflammatory Reaction Induced by *Mycobacterium bovis*-BCG
Magaiver Andrade-Silva, Luana B. Correa, André Candéa, Simone C. Cavalher-Machado, Elaine C. Rosas, Maria das Graças Henriques. Fndn. Oswaldo Cruz, Rio de Janeiro, Brazil

B313 *(Sunday)*
Discovery of Selective RORγ Inverse Agonists and Demonstration of Efficacy in Inflammatory Disease Models
Ravi K. Ujjinamatada, Ravi D. Krishna Babu, Kavitha Nellore, Samiulla S. Dodheri, Charamanna K B, Subhendu Mukherjee, Kancharla BabuRao, Wesley Roy Balasubramanian, Sanjay B. Rathod, Anirudha Lakshminarasimhan, Narasimha K. Rao, Anuradha Ramanathan, Natar. Aurigene Discovery Technologies Limited, Bangalore, India

T Regulatory Cells

B314 *(Monday)*
The FOXP3 T Regulatory Cells in Obstructive and Non-obstructive Smokers: A Descriptive Study in Airways and Lymphoid Follicles
Davi S. Sales, Ivy A. Zanchetta, Juliana T. Ito, Raquel Annoni, Thais Mauad, Milton A. Martins, Fernanda D.T.Q.S. Lopes. Univ. of São Paulo, Brazil

B315 *(Tuesday)*
Impact of Regulatory T Cells on Chemokine Response in Tuberculosis
Divya Kamboj, Dipendra Kumar Mitra, Anant Mohan. All India Institute of Med. Science, New Delhi, India

B316 *(Sunday)*
Restoration of Treg Cell Function with PD-L1 Fc Protein in Rheumatoid Arthritis
Kaustav Chowdhury, Dipendra Kumar Mitra, Uma Kumar, Soumabha Das, Prabin Kumar, Uma Kanga, Jaydeep Chaudhuri, Santu Bandyopadhaya, Parasar Ghosh, Ravi Kiran Basyal, Maumita Kanjilal. All India Institute of Med. Science, New Delhi; Indian Institute of Chemical Biology, Kolkata; IPGMER, Kolkata, India

Tissue Damage/Repair

B317 *(Monday)*
Critical Role of CXCR7 in Modulating Inflammation, Angiogenesis and Fibrogenesis in Skin Injury in Mice
Alan S. Barbosa, Leandro C. Freitas-Limas, Camila P. Almeida, Luiza D.C. Lima, Maria C.C. Canesso, Angélica T. Vieira, Robson A.S. Santos, Daniela V. Rosa, Erika K. Sacramento, Marco A. Romano-Silva, Mauro M. Teixeira, Charles C. Mackay, Lucíola S. Barcel. Federal Univ. of Minas Gerais; Sch. of Med., Federal Univ. of Minas Gerais, Brazil; Faculty of Med., Nursing and Health Sciences, Monash Univ., Australia

B318 *(Tuesday)*
The Development of New Therapy Facial Nerve Injury Using the M2 Macrophage Induction Factors
Fumiya Kano, Kohki Matsubara, Akihito Yamamoto. Nagoya Univ. Grad. Sch. of Med., Nagoya, Japan

B319 *(Sunday)*
Assessment of Porcine Dermis Scaffolds and Their Biocompatibility Using a Model of Xenogeneic Implantation
Sonia M. Oliani, Kallyne K.O. Mimura, Andreia R. Moraes, Tahera Ansari, Karin V. Greco. Univ. of São Paulo State, Brazil; University Col. London, UK

B320 *(Monday)*
The Worsening Asthma Process Driven by Bronchoalveolar Epithelium with Co-exposition to Cigarette Smoke
Thayse R. Brüggemann, Paula Fernandes, Fernanda M. Bruni, Mílton A. Martins, Fernanda M. Arantes-Costa. Sch. of Med. of Univ. of São Paulo; Institute for Investigation in Immunol., INCT, São Paulo, Brazil

B321 *(Tuesday)*
Nerve Regeneration in Injured Tooth Is Mediated by the Interaction between the Complement Fragment C5a and Pulp Fibroblasts
Fanny Chmilewsky, Imad About, Warda Ayaz, Seung H. Chung. Univ. of Illinois at Chicago; Aix-Marseille Univ., Provence, France

B322 *(Sunday)*
Molecular Imaging Techniques to Evaluate Nitrogen Mustard Induced Lung Injury
Edward J. Yurkow, Justin Schumacher, Alessandro Venosa, Derek Adler, Jeffrey Laskin, Debra Laskin. Rutgers Univ., Piscataway, NJ

Toll Receptors

B323 *(Monday)*
A Novel Cell Surface Protein That Imparts Cytokine Specificity to TLR4 Signalling
Nilesh J. Bokil, Lin Luo, Jennifer L. Stow, Matthew J. Sweet. The Univ. of Queensland, Brisbane, Australia

B324 *(Tuesday)*
Altered Toll-Like Receptor Signaling in Individuals with Type 1 Bipolar Disorder
Andrea Wieck, Carine Hartmann do Prado, Laura Petersen, Bárbara Nery Porto, Rodrigo Grassi-Oliveira, Moisés Evandro Bauer. Pontifical Catholic Univ. of Rio Grande do Sul, Porto Alegre, Brazil

B325 *(Sunday)*
Neuronal TLR Signaling Controls Neuronal Excitability, Neuroinflammation, Pain, and Itch
Ru-Rong Ji, Chul-Kyu Park, Tong Liu, Zhen-Zhong Xu, Qingjian Han, Yong Ho Kim, Temugin Berta. Duke Univ. Med. Ctr., Durham, NC

Translational Medicine and Biomarkers

B326 *(Monday)* **Abstract Withdrawn**
Molecular Detection of Inflammation in Cell and Animal Models Using Hyperpolarized 13C-Pyruvate
Julia Nguyen, Jeffrey T. Gu, Linda Nguyen, Renuka Sriram, Dave Korenchan, John Kurhanewicz, John D. MacKenzie. UCSF, San Francisco, CA

B327 *(Tuesday)*
Omega-3 Nutritional Supplementation Improves Amyloid-Beta Immunity through Specialized Pro-resolving Mediators
Milan Fiala, Sam Famenini, Rachel Rubattino, Bien Sagong, Jessica Leung, Ramesh Halder. UCLA Sch. of Med., Los Angeles, CA

B328 *(Sunday)*
Translational Properties of a Folate-Aminopterin Small Molecule Drug Conjugate with a Metabolically Activated Linker System
Yingjuan Lu, Satish Rao, Paul Kleindl, Fei You, Michael Pugh, Vicky Cross, Elaine Westrick, Alex Lloyd, Leroy Wheeler II, Patrick Klein, Iontcho P. Vlahov, Philip S. Low, Christopher P. Leamon. Endocyte Inc., West Lafayette, IN; Purdue Univ., West Lafayette, IN

B329 *(Monday)*
New Electrochemiluminescence-Based ELISA for High-Throughput Analysis of Serum Oxidative Damage Associated with Inflammation
Annie Knight, Emma Taylor, Jane E. Carré, Yuktee Dogra, Jo Tarr, Roman Lukaszewski, Paul G. Winyard. Univ. of Exeter Med. Sch., Exeter, UK; Dstl, Porton Down, Salisbury, UK

B330 *(Tuesday)*
Measurement of Serum Nitrate Concentration for the Diagnosis of Infective Gastroenteritis
Miranda J. Smallwood, Kyle Stewart, Thalia Groom, Jessica Cross, Nigel Benjamin, Paul G. Winyard. Univ. of Exeter Med. Sch., UK; Torbay Hosp., Torquay, UK

B331 *(Sunday)*
Mechanisms of Drug-Induced Skin Rash Using Biomap® Human Primary Cell-Based Systems
Jason Ptacek, Karen Matta, Sylvie Privat, Dat Nguyen, Ellen Berg, Alison O'Mahony. BioSeek, a division of DiscoveRx Corp, South San Francisco, CA

B332 *(Monday)*
CRP and 14-3-3 Eta Are Each Associated with Joint Damage Progression, Their Titres Do Not Correlate and Are Better Predictors of Progression Together Than Alone
Anthony Marotta, Nathalie Carrier, Artur J. Fernandes, Patrick Liang, Ariel Masetto, Yuan Gui, Jane Savill, Sara Michienzi, Henri A. Menard, Walter P. Maksymowych, Gilles Boire. Augurex Life Science Corp., North Vancouver, BC; Univ. of Sherbrooke, QC; McGill Univ. Health Ctr. Research Institute; Ctr. hospitalier Univ. de Sherbrooke, QC; Univ. of Alberta; MSK Research Axis, Montreal, QC, Canada

B333 *(Tuesday)*
suPAR: A Novel Inflammatory Biomarker in Clinical Routine Associated with Readmission and Mortality
Line J.H. Rasmussen, Steen Ladelund, Thomas H. Haupt, Jørgen H. Poulsen, Gertrude Ellekilde, Ove Andersen. Copenhagen Univ. Hosp. Hvidovre, Denmark

B334 *(Sunday)*
Serum Interleukin-18 and S100A8/A9 as Prediction Markers for Disease Activity in Patients Adult Onset Still's Disease
Dae Hyun Yoo, Jinju Kim, Seung Taek Song. Hanyang Univ. Hosp. for Rheumatic Diseases, Seoul, South Korea

B335 *(Monday)*
Clinical and Biologic Characterization of Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey, Simon Lacey, Pamela A. Shaw, Jos Melenhorst, Noelle Frey, David Barrett, Fang Chen, Julie Fitzgerald, Vanessa Gonzalez, Shannon Maude, Edward Pequignot, Scott Weiss, Carl June, David Porter, Stephan A. Grupp. Children's Hosp. of Philadelphia; Univ. of Pennsylvania, Philadelphia, PA

Seaport World Trade Center



Exhibitor List

DISCLAIMER

Participation in the Exhibits Program does not constitute an endorsement by the World Congress on Inflammation (WCI) of the claims, products or services offered.

Company Name **Booth Number**

AMBIOTIS 551
3 Rue des Satellites
Toulouse 31400
France
Phone: 33 562244157
Email: contact@ambiotis.com
Web: www.ambiotis.com

Aragen Bioscience, Inc. 640
380 Woodview Avenue
Morgan Hill, CA 95037
Phone: 408-779-1700
Fax: 408-779-1711
Email: info@aragenbio.com
Web: www.aragenbio.com

Biomodels LLC 567
313 Pleasant Street
Watertown, MA 02472
Phone: 857-228-1100
Email: acoyne@biomodels.com
Web: www.biomodels.com

Biomodels LLC, a preclinical drug research organization, conducts predictive and highly translational studies for biotechnology and pharmaceutical companies in several different indications including Inflammatory and Pulmonary Diseases, Fibrosis, Oncology, Cancer Supportive Care and Radiation Countermeasures. Biomodels specializes in (non-GLP) efficacy studies that optimize dose, schedule, and define mechanism of action.

Bio-Techne 662
614 McKinley Place NE
Minneapolis, MN 55413
Phone: 612-379-2956
Fax: 612-379-6580
Email: info@rndsystems.com
Web: www.rndsystems.com

Bio-Techne brings together the world class brands of R&D Systems, Novus Biologicals, Tocris Bioscience and ProteinSimple to better serve our customers and the community. R&D Systems reagents have been trusted for immunology research for over 30 years. We are now adding innovative instruments to our portfolio in a way that allows us to leverage our gold standard reagents into complete solutions for you. Visit booth #662 to learn more about the entire Bio-Techne portfolio.

Bolder BioPATH Inc.. 656
5541 Central Avenue Suite 160
Boulder, CO 80303
Phone: 303 633-5400
Email: phillip@bolderbiopath.com
Web: www.boulderbiopath.com

Bolder BioPATH, Inc. is a contract pharmacology, toxicology and pathology company specializing in In Vivo models of Rheumatoid Arthritis, Osteoarthritis, Inflammatory Bowel Disease, Cancer, as well as other autoimmune and inflammation models. Our goals are to provide preclinical (efficacy and toxicity) data to support advancing proteins and small molecules to IND/NDA stage.

Cayman Chemical Company 652
1180 East Ellsworth Road
Ann Arbor, MI 48108
Phone: 800-364-9897
Fax: 734-971-3420
Email: sales@CaymanChem.com
Web: www.caymanchem.com

Cayman Chemical specializes in the production and distribution of assay kits, high purity biochemicals, antibodies, and enzymes for drug discovery and basic research. Products for research in inflammation, oxidative stress, metabolism, free radical biomarkers, and other areas are readily available. Cayman also offers custom biochemical synthesis and assays services.

DiscoveRx Corporation 739
42501 Albrae Street, Suite 100
Fremont, CA 94538
Phone: 510-979-1415
Fax: 510-979-1650
Email: info@discoverx.com
Web: www.discoverx.com

EMD Millipore Corporation 565
290 Concord Road
Billerica, MA 01821
Phone: 978-715-1338
Email: jessica.masotta@emdmillipore.com
Web: www.emdmillipore.com

EMD Millipore is the Life Science division of Merck KGaA of Germany, supporting discovery, development and production of biotech and pharmaceutical drug therapies. Offering comprehensive solutions through premium reagents, tools, and instrumentation, in turn, facilitating life science research on cellular analysis, network elucidation, functional genomics, target validation, as well as lead optimization and bioanalysis. We provide the tools necessary for our customer's success.

Epistem Ltd. 553
The Incubator Building 48 Grafton Street
Manchester M13 9XX
United Kingdom
Phone: 44 0161 603 7713
Email: l.brain@epistem.co.uk
Web: www.epistem.co.uk

Epistem is headquartered in Manchester UK with additional facilities in the US. Founded on ground-breaking research in epithelial stem cell biology. For 15 years Epistem has been providing reliable, innovative pre-clinical models and services to customers worldwide in the areas of oncology, mucositis, inflammatory bowel disease and dermatology. All of our models are complemented by Luminex, FACS and ELISA readouts, as well as our histology, IHC and gene expression. Our inflammation models including IBD, RA and Psoriasis.

Essential Pharmaceutical, LLC 543
100 Princeton South Corporate Center, Suite 140
Ewing, NJ 08628
Phone: 609-323-7838
Email: dgferneyhough@essentialpharma.com
Web: www.essentialpharma.com

Essential Pharmaceuticals provides next generation products to culture and preserve cells without serum. Now basic research or scaled protein production can be conducted with all the benefits and none of the negative consequences of serum use. Cell-Ess is a serum replacement providing a new level of performance, convenience and experiment control over FBS. Save time. Be in control. Be certain.

Focus Biomolecules 533
400 Davis Drive, Suite 600
Plymouth Meeting, PA 19462
Phone: 610-994-1134
Fax: 610-465-9100
Email: sales@focusbiomolecules.com
Web: www.focusbiomolecules.com

Focus Biomolecules is a primary supplier of cutting edge small molecule reagents for life sciences research started by former BIOMOL employees. We also offer custom synthesis in our laboratories in Philadelphia and custom targeted libraries. Focus Biomolecules prides itself on superior customer and technical support backed by extensive experience.

HistoTox Labs, Inc.. 658
2108 55th St. Suite 110
Boulder, CO 80301
Phone: 303-633-5401
Web: www.histotoxlabs.com

HistoTox Labs is a GLP contract laboratory performing pre-clinical Histology, Immunohistochemistry and Pathology services. Additional services include decalcified bone techniques, antibody optimization, full slide scanning, digital image analysis, special stains and frozen techniques. Our commitment to outstanding customer service, high quality sections, competitive pricing and quick turnaround times, have made us the ideal source for reliable histology preparation services for over 11 years.

Hycult Biotech Inc.. 557
600 W. Germantown Pike, Ste. 110
Plymouth Meeting, PA 19462
Phone: 484-534-4566
Fax: 484-368-3558
Email: orders-us@hycultbiotech.com
Web: www.hycultbiotech.com

Hycult Biotech designs, develops, produces and markets antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields, with an emphasis on complement, neutrophil proteins, TLR, scavenger receptors and acute phase proteins. Hycult Biotech has a strong interest in progressing research in the area of inflammation and cell damage caused by pathogens or oxidation factors.

MD Biosciences 545
2575 University Ave W #100
St. Paul, MN 55114
Phone: 651-641-1770
Fax: 651-641-1773
Email: info-us@mdbiosciences.com
Web: www.mdbiosciences.com

MD Biosciences is an AAALC accredited preclinical contract research organization focused in inflammation/ autoimmune, metabolic, pain/CNS, oncology and wound healing. Services: - Efficacy studies in rodents - Pig translational models to bridge the preclinical-clinical gap - In vivo Phenotypic Screening - In vitro ImmuneProfiler for mechanism of action and pathway studies - Biomarker studies for preclinical, animal health and clinical trials - Histology/IHC

Miltenyi Biotec. 563
Friedrich-Ebert-Str. 68
51429 Bergisch Gladbach
Germany
Phone: 49 2204 83060
Email: sabinek@miltenyibiotech.de
Web: www.miltenyibiotech.de

Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 1,500 employees in 25 countries.

Myriad RBM. 561
3300 Duval Road
Austin, TX 78759
Phone: 512-835-8026
Email: info@myriadrbm.com
Web: www.myriadrbm.com

Myriad RBM, Inc. is a leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on our Multi-Analyte Profiling (MAP) platform. Our platform provides researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner. All services are performed in our CLIA certified laboratory. Myriad RBM also offers companion diagnostic services, custom assay development, and innovative cell culture products.

Research Diets, Inc. 757
20 Jules Lane
New Brunswick, NJ 08901
Phone: 732-247-2390
Fax: 732-247-2340
Email: info@researchdiets.com
Web: www.researchdiets.com

Research Diets, Inc. formulates and produces purified OpenSource® Diets for laboratory animals. Our open formulas allow scientists to report, repeat, and revise their work. Custom diets shipped in 5-7 days. The BioDAQ® Food and Liquid Intake Monitor features spill-reducing hoppers, mounts to home cage, records the time, duration, amount of each meal automatically. Automated gate is programmable by time or amount consumed. Data is interpreted using powerful analysis software.

SB Drug Discovery. 737
West of Scotland Science Park
Glasgow G2O OXA
United Kingdom
Phone: 44 131 587 6100
Fax: 44 141 587 6110
Email: david.dalrymple@sbdrugdiscovery.com
Web: www.sbdrugdiscovery.com

SB Drug Discovery is a contract research services company offering expertise in high throughput screening, selectivity profiling and cell-based / in vivo assay services against a broad range of drug discovery targets including PDEs, nuclear receptors and ion channels. With a core knowledge in inflammation and pain and over 20 years' experience servicing a worldwide client base, SB holds the potential to rapidly enhance your drug discovery programs.

Sinclair Research Center 555
562 State Road DD
Auxvasse, MO 65231
Phone: 573-387-4400
Fax: 573 387-4404
Email: chorton@sinclairresearch.com
Web: www.sinclairresearch.com

Springer Basel AG 755
Picassoplatz 4
Basel CH-4052
Switzerland
Phone: 41 61 205 07 03
Email: detlef.klueber@springer.com
Web: www.springer.com

Studylog Systems 539
101-A Hickey Blvd., Suite 301
S. San Francisco, CA 94080
Phone: 650-516-4360
Fax: 650-745-3388
Email: info@studylog.com
Web: www.studylog.com

Because an animal study is much more than just a spreadsheet, Study Director Animal Study Management Software manages the entire work-flow of an animal study, allowing users to cut their study-related time in half. It's comprehensive functionality, ease-of-use and flexibility make animal researchers' lives easier, more organized and productive.

Washington Biotechnology Inc. 751
6200 Seaforth Street
Baltimore, MD 21224
Phone: 410-633-9210
Fax: 410-633-9213
Email: wbio@washingtonbiotech.com
Web: www.washingtonbiotech.com

With 27 years' experience, WBI provides drug efficacy studies in animal models of human disease including inflammation, cancer, bacterial infection and pain. Inflammation models include arthritis, gout, multiple sclerosis, inflammatory bowel disease, psoriasis, delayed-type hypersensitivity (contact dermatitis), lupus, pancreatitis, hepatitis and diabetes. Complementary services: histopathology, clinical chemistries, cytokine analysis, compound quantitation, gross necropsy observations, organ & tumor collections/ analysis.

Author Index

The numbers following the letter "B" signify the poster board number/location. All numbers, including those without the preceding letter"B," reference the corresponding number of the author's abstract in the "Abstract Issue."

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

PRIMARY CELLS
Human and Animal Cells

- Endothelial Cells
- Epithelial Cells
- Bone Marrow Cells
- Tumor Cells
- Stem Cells

Genetically Modified & Wild-Type

Mouse & Rat Cells

Rabbit Cells
Monkey Cells
Porcine Cells
Human Cells

Featured Products

Mouse and Rat Endothelial Cells

Mouse and Rat Epithelial Cells

Tumor Endothelial Cells

CUSTOM CELL ISOLATION

CELL CULTURE MEDIA



(312) 226-8198
(312) 226-8958
info@cellbiologics.com

2201 West Campbell Park Drive
Chicago, IL 60612 USA
www.cellbiologics.com